var title_f41_10_42144="Supraspinatus abduction exercise with resistance";
var content_f41_10_42144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/86058/Suprasp_abduct_resist_video.mp4?title=Supraspinatus+abduction+exercise+with+resistance\" style=\"width:496px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Supraspinatus abduction exercise with resistance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shoulder abduction against resistance is used to strengthen the supraspinatus muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42144=[""].join("\n");
var outline_f41_10_42144=null;
var title_f41_10_42145="Patient information: Taking care of bruises (The Basics)";
var content_f41_10_42145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16584\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/7/3187\">",
"         How bruises heal",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/11/43185\">",
"         Patient information: Taking care of cuts and scrapes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/44/2755\">",
"         Patient information: Warfarin (Coumadin) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/32/39425\">",
"         Patient information: von Willebrand disease (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/15/21747\">",
"         Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/55/6002\">",
"         Patient information: von Willebrand disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Taking care of bruises (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/taking-care-of-bruises-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9403413\">",
"      <span class=\"h1\">",
"       What are bruises?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bruises happen when blood vessels under the skin break, but the skin isn&rsquo;t cut. Blood leaks into the tissues under the skin. Bruises start off red in color, and then turn blue or purple. As they heal, bruises can turn green and yellow (",
"      <a class=\"graphic graphic_figure graphicRef54079 \" href=\"mobipreview.htm?3/7/3187\">",
"       figure 1",
"      </a>",
"      ). Most bruises heal in 1 to 2 weeks, but some take longer.",
"     </p>",
"     <p>",
"      Bruises can happen when people get hurt, fall, or bump themselves. People usually have pain and swelling in the area of the bruise. Sometimes, the swelling happens right away. Other times, the swelling starts 1 or 2 days later.",
"     </p>",
"     <p>",
"      Some people bruise more easily and get worse bruises. These include people who have conditions that keep the blood from clotting normally and people who take medicines to prevent blood clots.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9403428\">",
"      <span class=\"h1\">",
"       How are bruises treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A bruise will get better on its own. But to feel better and help your bruise heal, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Put a cold gel pack, bag of ice, or bag of frozen vegetables on the injured area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin. Use the ice (or other cold object) for at least 6 hours after your injury. Some people find it helpful to ice longer, even up to 2 days after their injury.",
"       </li>",
"       <li>",
"        Raise the area, if possible &ndash; Raising the area above the level of your heart helps to reduce swelling.",
"       </li>",
"       <li>",
"        Take medicine to reduce the pain and swelling &ndash; To treat pain, you can take",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (brand name: Tylenol&reg;). To treat pain and swelling, you can take",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;). But people who have certain conditions or take certain medicines should not take ibuprofen. If you are unsure, ask your doctor or nurse if you can take ibuprofen.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should NOT:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Put a warm pack or heating pad on your bruise",
"       </li>",
"       <li>",
"        Stick a needle or other object in your bruise to drain it",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9403443\">",
"      <span class=\"h1\">",
"       When should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You get a fever",
"       </li>",
"       <li>",
"        Your bruise causes your joints to swell",
"       </li>",
"       <li>",
"        You can&rsquo;t move or walk because of your bruise",
"       </li>",
"       <li>",
"        You get bruises for no reason or have unusual bleeding, such as from your gums or in your urine",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9403458\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/11/43185?source=see_link\">",
"       Patient information: Taking care of cuts and scrapes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2755?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/32/39425?source=see_link\">",
"       Patient information: von Willebrand disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/55/6002?source=see_link\">",
"       Patient information: von Willebrand disease (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/10/42145?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16584 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-042A3B073A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42145=[""].join("\n");
var outline_f41_10_42145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9403413\">",
"      What are bruises?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9403428\">",
"      How are bruises treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9403443\">",
"      When should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9403458\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16584\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/7/3187\">",
"      How bruises heal",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/11/43185?source=related_link\">",
"      Patient information: Taking care of cuts and scrapes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2755?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/55/6002?source=related_link\">",
"      Patient information: von Willebrand disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/32/39425?source=related_link\">",
"      Patient information: von Willebrand disease (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_10_42146="Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)";
var content_f41_10_42146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16161\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/13/18647\">",
"         Foods and drinks with calcium and vitamin D",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/57/12179\">",
"         Patient information: Depression (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/32/32257\">",
"         Patient information: Generalized anxiety disorder (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/17/18707\">",
"         Patient information: Hormonal birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/6/24675\">",
"         Patient information: Medicines for depression (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/41/20116\">",
"         Patient information: Depression in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/24/21894\">",
"         Patient information: Depression treatment options for adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/42/7844\">",
"         Patient information: Exercise (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/32/22021\">",
"         Patient information: Hormonal methods of birth control (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/12/13510\">",
"         Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/premenstrual-syndrome-pms-and-premenstrual-dysphoric-disorder-pmdd-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29093563\">",
"      <span class=\"h1\">",
"       What are premenstrual syndrome and premenstrual dysphoric disorder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Premenstrual syndrome (PMS) is a group of symptoms that happens right before a woman gets her monthly period. Many women get PMS, especially mild PMS.",
"     </p>",
"     <p>",
"      When the symptoms are severe, doctors call it premenstrual dysphoric disorder (PMDD). PMDD is not as common.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29093570\">",
"      <span class=\"h1\">",
"       What are the symptoms of PMS and PMDD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;PMS and PMDD cause body symptoms as well as changes in mood. The most common symptoms are bloating and feeling tired, angry, or worried.",
"     </p>",
"     <p>",
"      Other symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling sad or hopeless, or crying a lot",
"       </li>",
"       <li>",
"        Mood swings",
"       </li>",
"       <li>",
"        Trouble concentrating",
"       </li>",
"       <li>",
"        Eating more than usual or craving certain foods",
"       </li>",
"       <li>",
"        Sleeping too much or having trouble sleeping",
"       </li>",
"       <li>",
"        Breast soreness or swelling",
"       </li>",
"       <li>",
"        Headaches",
"       </li>",
"       <li>",
"        Joint or muscle pain",
"       </li>",
"       <li>",
"        Weight gain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If symptoms are severe, women can have trouble at work, school, or getting along with family and friends.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29093577\">",
"      <span class=\"h1\">",
"       Is there a test for PMS or PMDD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you have it by talking with you. He or she will want to know which symptoms you have and when you have them. To get this information, he or she might ask you to write down your symptoms each day for 2 monthly cycles.",
"     </p>",
"     <p>",
"      To have PMS or PMDD, you must have symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Only 1 to 2 weeks before your period starts, and not during or right after your period",
"       </li>",
"       <li>",
"        That affect both your body and mood",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29093584\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help feel better, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Get regular exercise &mdash; Exercise usually helps people feel less sad and worried.",
"       </li>",
"       <li>",
"        Find a way to relax &mdash; For example, you can try yoga or relaxation exercises.",
"       </li>",
"       <li>",
"        Get enough calcium &mdash; Calcium can help improve symptoms. Try to eat foods with calcium each day (",
"        <a class=\"graphic graphic_figure graphicRef79375 \" href=\"mobipreview.htm?18/13/18647\">",
"         figure 1",
"        </a>",
"        ). If you can&rsquo;t, ask your doctor or nurse about taking a pill or tablet with calcium.",
"       </li>",
"       <li>",
"        Avoid salty foods and eating large meals, if you have bloating",
"       </li>",
"       <li>",
"        Take an &ldquo;NSAID&rdquo; medicine to treat pain or headaches &mdash; NSAIDs are a group of medicines that includes",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You might hear or read about herbs or other vitamins that can help improve PMS and PMDD. It&rsquo;s a good idea to ask your doctor or nurse before you try them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29093591\">",
"      <span class=\"h1\">",
"       Can doctors treat PMS and PMDD with medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can treat PMS and PMDD with different kinds of medicines. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A group of medicines called &ldquo;SSRIs&rdquo; &mdash; SSRIs include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/58/30630?source=see_link\">",
"         fluoxetine",
"        </a>",
"        (sample brand names: Prozac&reg; and Sarafem&reg;) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/43/23222?source=see_link\">",
"         sertraline",
"        </a>",
"        (brand name: Zoloft&reg;). These medicines are also used to treat depression and anxiety (when people worry too much).",
"       </li>",
"       <li>",
"        Birth control pills &mdash; Some women find that their PMS and PMDD improve after they start taking birth control pills. There are different types of birth control pills. Your doctor will help you choose the one that&rsquo;s right for you.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29093598\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/57/12179?source=see_link\">",
"       Patient information: Depression (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/32/32257?source=see_link\">",
"       Patient information: Generalized anxiety disorder (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/17/18707?source=see_link\">",
"       Patient information: Hormonal birth control (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/6/24675?source=see_link\">",
"       Patient information: Medicines for depression (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/12/13510?source=see_link\">",
"       Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=see_link\">",
"       Patient information: Depression in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=see_link\">",
"       Patient information: Hormonal methods of birth control (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/42/7844?source=see_link\">",
"       Patient information: Exercise (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/24/21894?source=see_link\">",
"       Patient information: Depression treatment options for adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/10/42146?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16161 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-49CB555465-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42146=[""].join("\n");
var outline_f41_10_42146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29093563\">",
"      What are premenstrual syndrome and premenstrual dysphoric disorder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29093570\">",
"      What are the symptoms of PMS and PMDD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29093577\">",
"      Is there a test for PMS or PMDD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29093584\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29093591\">",
"      Can doctors treat PMS and PMDD with medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29093598\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16161\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/13/18647\">",
"      Foods and drinks with calcium and vitamin D",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/42/7844?source=related_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/32/32257?source=related_link\">",
"      Patient information: Generalized anxiety disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/17/18707?source=related_link\">",
"      Patient information: Hormonal birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=related_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/6/24675?source=related_link\">",
"      Patient information: Medicines for depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/12/13510?source=related_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_10_42147="Adult atopic dermatitis 2";
var content_f41_10_42147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Adult chronic atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lichenified, hyperpigmented plaque in the elbow flexure of a 35-year-old woman with atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Yusoff Saifuzzaman, MD, Dermatlas;",
"     <a href=\"file://www.dermatlas.org\" target=\"_blank\">",
"      file://www.dermatlas.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42147=[""].join("\n");
var outline_f41_10_42147=null;
var title_f41_10_42148="Transperineal fistula repair5";
var content_f41_10_42148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The second layer of closure is placed into the muscularis of the rectum in the same direction as the first layer, thus imbricating the first layer and reinforcing the closure",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42148=[""].join("\n");
var outline_f41_10_42148=null;
var title_f41_10_42149="Dividing apple extraction";
var content_f41_10_42149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rectal foreign body",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An apple has been divided so that it can be removed using a transanal approach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Steele, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42149=[""].join("\n");
var outline_f41_10_42149=null;
var title_f41_10_42150="Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone";
var content_f41_10_42150=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/10/42150/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/10/42150/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/10/42150/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/10/42150/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/10/42150/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/10/42150/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/10/42150/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of benign soft tissue masses are usually non-neoplastic and of little clinical consequence. However, some locally aggressive fibromatoses (desmoid tumors), infiltrating lipomas, neurofibromas, and vertebral hemangiomas may cause significant morbidity and, in some cases, mortality.",
"   </p>",
"   <p>",
"    Radiation therapy for a variety of benign diseases affecting soft tissue and bone will be reviewed here. These include Gorham's disease, desmoplastic fibroma of bone, pigmented villonodular synovitis, and symptomatic vertebral hemangiomas. Radiation therapy for other conditions affecting soft tissue, such as desmoid tumors, keloid, ganglia, and Dupuytren&rsquo;s contracture, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1847?source=see_link\">",
"     \"Keloids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41223?source=see_link\">",
"     \"Ganglia and nodules\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39783?source=see_link&amp;anchor=H13#H13\">",
"     \"Dupuytren's contracture\", section on 'Other interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GORHAM'S DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gorham's disease (also known as Gorham-Stout disease, disappearing bone disease, or essential osteolysis) is a rare disorder characterized by relatively painless bone destruction with massive osteolysis due to progression of lymphangiomatous tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/1\">",
"     1",
"    </a>",
"    ]. There may also be significant osteoclast activation. Why this occurs is not clear, but increased levels of interleukin-6 may contribute to the osteolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pattern is that of lytic destruction of cortical bone and extension across joints to the adjacent bone. There is usually little or no soft tissue mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment consists of resection when this is feasible from the standpoints of the medical condition of the patient, the technical aspects of the procedure, and the likelihood of retained function. There is anecdotal evidence that radiation therapy also may be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, two patients with disease involving C1 and the occiput were managed by 45 to 50 Gy alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/4\">",
"       4",
"      </a>",
"      ]. Both patients experienced cessation of progression and were otherwise well at follow-up exceeding 12 years. There has been no remodeling of bone in either of these patients.",
"     </li>",
"     <li>",
"      Others have demonstrated benefit from radiation therapy in treating chylothorax related to chest wall involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/6\">",
"       6",
"      </a>",
"      ] and a lesion in the mandible [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A patterns of care study from Germany with literature review concluded that RT (30 to 45 Gy) may prevent disease progression in 77 to 80 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of systemic therapy has not been systematically evaluated. One patient with progressive disease appeared to respond to a combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    and bisphosphonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. There are also reports of benefit from bisphosphonates alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DESMOPLASTIC FIBROMA OF BONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoplastic fibroma of bone, known as collagenous fibroma, is a benign tumor of bone that has a histological appearance similar to that of desmoid tumor. This is an uncommon tumor that represents less than 0.1 percent of bone tumors. These lesions appear in young adults, with approximately equal frequency in males and females. Affected patients typically present with a history of a painless, slowly growing mass, often of relatively long duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These lesions can also appear as soft tissue tumors; in these cases, the lesions are predominantly subcutaneous, but fascial involvement is common and approximately one-quarter involve skeletal muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/11\">",
"     11",
"    </a>",
"    ]. When they arise in bone, the most frequently involved sites are the pelvic and other flat bones, the jawbones, and for the long bones, the diaphyseal regions. The tumors are often large, ranging in size from 1 to 20 cm. They are firm and pearl-gray in color on gross examination. The lesional cells are bland, stellate and spindle-shaped fibroblasts separated by a collagenous matrix; there is typically no mitotic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/11\">",
"     11",
"    </a>",
"    ]. A characteristic (2;11)(q31;q12) translocation has been reported in several affected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/12\">",
"     12",
"    </a>",
"    ]. The beta-catenin pathway does not seem to have the same essential role in the tumorigenesis of desmoplastic fibroma as it has in desmoid-type fibromatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Desmoplastic fibroma of bone is managed by surgical resection with extremely few exceptions. One patient with a 7.6 cm lesion in the iliac crest responded well to a course of fractionated radiation of 60 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/14\">",
"     14",
"    </a>",
"    ], as did a patient with a mandibular lesion who refused surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent disease appears to be rare. In one study, none of 39 patients developed a recurrence at a median follow-up of 11 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PIGMENTED VILLONODULAR SYNOVITIS/TENOSYNOVIAL GIANT CELL TUMOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pigmented villonodular",
"    <span class=\"nowrap\">",
"     synovitis/tenosynovial",
"    </span>",
"    giant cell tumor",
"    <span class=\"nowrap\">",
"     (PVNS/TGCT)",
"    </span>",
"    is a rare but well recognized proliferative lesion of synovial tissue. It is characterized by hypervascular proliferative synovium containing multinucleated giant cells, macrophages and hemosiderin. The multinucleated cells express features of osteoclasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/16\">",
"     16",
"    </a>",
"    ]. Progressive nodular disease near or in the joints limits function and may destroy adjacent bone. Although most believe PVNS to be an inflammatory process, others consider it a benign neoplasm.",
"   </p>",
"   <p>",
"    PVNS occurs in two forms: a diffuse form that involves the entire synovium and accounts for in the majority of cases, and a localized form that involves a discrete section of the synovium. PVNS almost always involves a single joint; the knee and foot synovial structures are most commonly affected, while involvement of the shoulder, hand, and hip is less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plain radiographs may reveal well circumscribed areas of bone erosion. MRI shows a characteristic lack of signal on both T1 and T2 images which has been attributed to the presence of large amounts of hemosiderin in the synovium (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54059 \" href=\"mobipreview.htm?42/37/43602\">",
"     image 1",
"    </a>",
"    ). This MRI signature is an important key to correct diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principal treatment modality is resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Although marginal excision represents the optimal treatment for localized PVNS, diffuse PVNS is more difficult to eradicate and is optimally treated with total or near total synovectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28565?source=see_link\">",
"     \"Synovectomy for inflammatory arthritis of the knee\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The local recurrence rate among patients with localized PVNS is low, but patients with diffuse disease can have multiple recurrences and bulky disease, resulting in significant bone destruction. In this setting, radiation therapy to a dose of 35 to 50 Gy has been effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/23-29\">",
"     23-29",
"    </a>",
"    ]. In a preliminary report of the largest series of 41 patients, 40 of whom had microscopic or gross residual disease prior to radiation, 40 maintained local control at an average 77 months follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/23\">",
"     23",
"    </a>",
"    ]. These data have been corroborated by published experience from at least two other centers as well as a National Patterns of Care study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/24,28,29\">",
"     24,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postoperative intraarticular administration of radioactive isotopes has been advocated in the past for patients thought to be at high risk for recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/27,30,31\">",
"     27,30,31",
"    </a>",
"    ], but this approach has fallen out of favor.",
"   </p>",
"   <p>",
"    Other novel therapies for PVNS are suggested by the biology of the tumor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Particularly in view of the documented presence of macrophages and related proinflammatory cytokines such as tumor necrosis factor alpha (TNFa) in PVNS, an intriguing report suggests control of signs and symptoms in a patient with refractory PVNS using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , a monoclonal antibody targeting TNFa at a dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/32\">",
"       32",
"      </a>",
"      ]. Additional experience with this agent is needed.",
"     </li>",
"     <li>",
"      A translocation has been identified, CSF1-COL6A3, t(1;2)(p13;q35), which causes overexpression of the CSF1 (also called macrophage colony stimulating factor 1) gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/33\">",
"       33",
"      </a>",
"      ]. The receptor for CSF1 is also overexpressed in these tumors, implying the participation of an autocrine loop between overexpressed CSF1 and its receptor in the pathogenesis or progression of these tumors.",
"      <br/>",
"      <br/>",
"      This basic biology is analogous to dermatofibrosarcoma protuberans (DFSP), a typically low-grade soft tissue sarcoma in which a translocation causes overexpression of a ligand (platelet-derived growth factor, PDGF) in the setting of receptor expression in the same tumor. The PDGF receptor is a receptor tyrosine kinase, and DFSP is sensitive to the tyrosine kinase inhibitor,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=see_link&amp;anchor=H3#H3\">",
"       \"Dermatofibrosarcoma protuberans\", section on 'Molecular pathogenesis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=see_link&amp;anchor=H23#H23\">",
"       \"Dermatofibrosarcoma protuberans\", section on 'Imatinib'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Imatinib and other multitargeted TK inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      , inhibit the CSF1 receptor (also a receptor tyrosine kinase), suggesting that these drugs represent a logical therapeutic approach for recurrent PVNS as well. At least one report documents a brief complete response with imatinib in a patient with relapsed PVNS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/34\">",
"       34",
"      </a>",
"      ], and a preliminary report of a phase II study of 33 patients with progressive disease documents disease stabilization in a large proportion of patients with nilotinib [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC VERTEBRAL HEMANGIOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangiomas are benign neoplasms consisting of blood vessels. Autopsy series suggest a prevalence of 10 to 12 percent for vertebral body hemangiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/36\">",
"     36",
"    </a>",
"    ], but the vast majority remain asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About one-half of vertebral body hemangiomas are associated with painful symptoms and, in a few cases, they cause neurological emergencies like acute spinal cord compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/37\">",
"     37",
"    </a>",
"    ]. The diagnosis is usually confirmed by CT or MRI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61148 \" href=\"mobipreview.htm?29/30/30183\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\", section on 'Other'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Options for treatment include surgical procedures such as decompressive laminectomy, vertebrectomy, or ligation of the segmental arteries, and conservative methods such as embolization, vertebroplasty,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intralesional alcohol injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/36\">",
"     36",
"    </a>",
"    ]. Radiation therapy may be applied as a treatment for painful vertebral hemangiomas, both a single modality, and for postsurgical prevention of local relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report, a total of 84 patients with 96 symptomatic lesions were irradiated for a symptomatic vertebral hemangioma (98 percent for pain; 29 percent had additional neurologic symptoms) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42150/abstract/41\">",
"     41",
"    </a>",
"    ]. Prior to undergoing RT, 31 patients had been treated with resection, embolization, or vertebroplasty. The median total dose was 34 Gy. At a median 68 month follow-up, 62 percent had complete symptom relief, 29 percent had partial pain relief, and 10 percent had no pain relief. Total doses &ge;34 Gy resulted in significantly greater symptom relief and a lower recurrence rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of nonmalignant proliferative soft tissue and bone lesions are of modest clinical consequence. However, some locally aggressive proliferative lesions, despite their non-malignant nature, can cause significant morbidity, and in some cases, mortality. These include desmoid tumors (aggressive fibromatosis), desmoplastic fibroma of bone, pigmented villonodular synovitis, and vertebral hemangiomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation therapy may be indicated for the treatment of several of these conditions, either as an alternative to surgery, or as an adjunct to resection in order to decrease local recurrence rates.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/1\">",
"      Manisali M, Ozaksoy D. Gorham disease: correlation of MR findings with histopathologic changes. Eur Radiol 1998; 8:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/2\">",
"      Devlin RD, Bone HG 3rd, Roodman GD. Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab 1996; 81:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/3\">",
"      Mawk JR, Obukhov SK, Nichols WD, et al. Successful conservative management of Gorham disease of the skull base and cervical spine. Childs Nerv Syst 1997; 13:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/4\">",
"      Dunbar SF, Rosenberg A, Mankin H, et al. Gorham's massive osteolysis: the role of radiation therapy and a review of the literature. Int J Radiat Oncol Biol Phys 1993; 26:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/5\">",
"      Heyd R, Micke O, Surholt C, et al. Radiation therapy for Gorham-Stout syndrome: results of a national patterns-of-care study and literature review. Int J Radiat Oncol Biol Phys 2011; 81:e179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/6\">",
"      Duffy BM, Manon R, Patel RR, Welsh JS. A case of Gorham's disease with chylothorax treated curatively with radiation therapy. Clin Med Res 2005; 3:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/7\">",
"      Ebert CS Jr, Zdanski C, Ardeshirpour F, et al. Recurrent infantile myofibromatosis: a report of conservative management and discussion of treatment strategies. Ear Nose Throat J 2008; 87:E4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/8\">",
"      Hagberg H, Lamberg K, Astr&ouml;m G. Alpha-2b interferon and oral clodronate for Gorham's disease. Lancet 1997; 350:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/9\">",
"      Kuriyama DK, McElligott SC, Glaser DW, Thompson KS. Treatment of Gorham-Stout disease with zoledronic acid and interferon-&alpha;: a case report and literature review. J Pediatr Hematol Oncol 2010; 32:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/10\">",
"      Hammer F, Kenn W, Wesselmann U, et al. Gorham-Stout disease--stabilization during bisphosphonate treatment. J Bone Miner Res 2005; 20:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/11\">",
"      Miettinen M, Fetsch JF. Collagenous fibroma (desmoplastic fibroblastoma): a clinicopathologic analysis of 63 cases of a distinctive soft tissue lesion with stellate-shaped fibroblasts. Hum Pathol 1998; 29:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/12\">",
"      Bernal K, Nelson M, Neff JR, et al. Translocation (2;11)(q31;q12) is recurrent in collagenous fibroma (desmoplastic fibroblastoma). Cancer Genet Cytogenet 2004; 149:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/13\">",
"      Hauben EI, Jundt G, Cleton-Jansen AM, et al. Desmoplastic fibroma of bone: an immunohistochemical study including beta-catenin expression and mutational analysis for beta-catenin. Hum Pathol 2005; 36:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/14\">",
"      Sanfilippo NJ, Wang GJ, Larner JM. Desmoplastic fibroma: a role for radiotherapy? South Med J 1995; 88:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/15\">",
"      Nag HL, Kumar R, Bhan S, et al. Radiotherapy for desmoplastic fibroma of bone: a case report. J Orthop Surg (Hong Kong) 2003; 11:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/16\">",
"      Darling JM, Goldring SR, Harada Y, et al. Multinucleated cells in pigmented villonodular synovitis and giant cell tumor of tendon sheath express features of osteoclasts. Am J Pathol 1997; 150:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/17\">",
"      M&uuml;ller LP, Bitzer M, Degreif J, Rommens PM. Pigmented villonodular synovitis of the shoulder: review and case report. Knee Surg Sports Traumatol Arthrosc 1999; 7:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/18\">",
"      Mankin H, Trahan C, Hornicek F. Pigmented villonodular synovitis of joints. J Surg Oncol 2011; 103:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/19\">",
"      Bhimani MA, Wenz JF, Frassica FJ. Pigmented villonodular synovitis: keys to early diagnosis. Clin Orthop Relat Res 2001; :197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/20\">",
"      D&uuml;rr HR, St&auml;bler A, Maier M, Refior HJ. Pigmented villonodular synovitis. Review of 20 cases. J Rheumatol 2001; 28:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/21\">",
"      Hamlin BR, Duffy GP, Trousdale RT, Morrey BF. Total knee arthroplasty in patients who have pigmented villonodular synovitis. J Bone Joint Surg Am 1998; 80:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/22\">",
"      Ogilvie-Harris DJ, Weisleder L. Arthroscopic synovectomy of the knee: is it helpful? Arthroscopy 1995; 11:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/23\">",
"      O'Sullivan B, Grifin A, Wunder J, et al. Sustained remission following radiation treatment for high-risk pigmented villonodular synovitis (abstract). Int J Radiat Oncol Biol Phys 2005; 63:S50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/24\">",
"      Horoschak M, Tran PT, Bachireddy P, et al. External beam radiation therapy enhances local control in pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys 2009; 75:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/25\">",
"      Blanco CE, Leon HO, Guthrie TB. Combined partial arthroscopic synovectomy and radiation therapy for diffuse pigmented villonodular synovitis of the knee. Arthroscopy 2001; 17:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/26\">",
"      Bisbinas I, De Silva U, Grimer RJ. Pigmented villonodular synovitis of the foot and ankle: a 12-year experience from a tertiary orthopedic Oncology Unit. J Foot Ankle Surg 2004; 43:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/27\">",
"      Chin KR, Barr SJ, Winalski C, et al. Treatment of advanced primary and recurrent diffuse pigmented villonodular synovitis of the knee. J Bone Joint Surg Am 2002; 84-A:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/28\">",
"      Berger B, Ganswindt U, Bamberg M, Hehr T. External beam radiotherapy as postoperative treatment of diffuse pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys 2007; 67:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/29\">",
"      Heyd R, Micke O, Berger B, et al. Radiation therapy for treatment of pigmented villonodular synovitis: results of a national patterns of care study. Int J Radiat Oncol Biol Phys 2010; 78:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/30\">",
"      Shabat S, Kollender Y, Merimsky O, et al. The use of surgery and yttrium 90 in the management of extensive and diffuse pigmented villonodular synovitis of large joints. Rheumatology (Oxford) 2002; 41:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/31\">",
"      Franssen MJ, Boerbooms AM, Karthaus RP, et al. Treatment of pigmented villonodular synovitis of the knee with yttrium-90 silicate: prospective evaluations by arthroscopy, histology, and 99mTc pertechnetate uptake measurements. Ann Rheum Dis 1989; 48:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/32\">",
"      Kroot EJ, Kraan MC, Smeets TJ, et al. Tumour necrosis factor alpha blockade in treatment resistant pigmented villonodular synovitis. Ann Rheum Dis 2005; 64:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/33\">",
"      West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 2006; 103:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/34\">",
"      Blay JY, El Sayadi H, Thiesse P, et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008; 19:821.",
"     </a>",
"    </li>",
"    <li>",
"     Ray-Coquard I, Gelderblom H, Chevreau C, et al. An open-label international multicentric phase II study of nilotinib in progressive, pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment. J Clin Oncol 30, 2012 (suppl; abstr 10006). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=98976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/36\">",
"      Acosta FL Jr, Dowd CF, Chin C, et al. Current treatment strategies and outcomes in the management of symptomatic vertebral hemangiomas. Neurosurgery 2006; 58:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/37\">",
"      Pastushyn AI, Slin'ko EI, Mirzoyeva GM. Vertebral hemangiomas: diagnosis, management, natural history and clinicopathological correlates in 86 patients. Surg Neurol 1998; 50:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/38\">",
"      Bartels RH, Grotenhuis JA, Van Der Spek JA. Symptomatic vertebral hemangiomas. J Neurosurg Sci 1991; 35:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/39\">",
"      Brunot S, Berge J, Barreau X, et al. [Long term clinical follow up of vertebral hemangiomas treated by percutaneous vertebroplasty]. J Radiol 2005; 86:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/40\">",
"      Persaud T. The polka-dot sign. Radiology 2008; 246:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/41\">",
"      Heyd R, Seegenschmiedt MH, Rades D, et al. Radiotherapy for symptomatic vertebral hemangiomas: results of a multicenter study and literature review. Int J Radiat Oncol Biol Phys 2010; 77:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/42\">",
"      Rades D, Bajrovic A, Alberti W, Rudat V. Is there a dose-effect relationship for the treatment of symptomatic vertebral hemangioma? Int J Radiat Oncol Biol Phys 2003; 55:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42150/abstract/43\">",
"      Miszczyk L, Tukiendorf A. Radiotherapy of painful vertebral hemangiomas: the single center retrospective analysis of 137 cases. Int J Radiat Oncol Biol Phys 2012; 82:e173.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7733 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42150=[""].join("\n");
var outline_f41_10_42150=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GORHAM'S DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DESMOPLASTIC FIBROMA OF BONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PIGMENTED VILLONODULAR SYNOVITIS/TENOSYNOVIAL GIANT CELL TUMOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SYMPTOMATIC VERTEBRAL HEMANGIOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7733\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7733|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/37/43602\" title=\"diagnostic image 1\">",
"      PVNS knee MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/30/30183\" title=\"diagnostic image 2\">",
"      MRI vertebral body hemangioma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=related_link\">",
"      Dermatofibrosarcoma protuberans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39783?source=related_link\">",
"      Dupuytren's contracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41223?source=related_link\">",
"      Ganglia and nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1847?source=related_link\">",
"      Keloids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28565?source=related_link\">",
"      Synovectomy for inflammatory arthritis of the knee",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_10_42151="HSTCL CD3 staining";
var content_f41_10_42151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F59379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F59379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Hepatosplenic T-cell lymphoma CD3 expression",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Liver biopsy reveals positive staining of the tumor cells with CD3 antibody. Immunoperoxidase, 40x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry and Immunochemistry for Hematologic Neoplasms, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42151=[""].join("\n");
var outline_f41_10_42151=null;
var title_f41_10_42152="Amoxicillin: Drug information";
var content_f41_10_42152=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amoxicillin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/2/39972?source=see_link\">",
"    see \"Amoxicillin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"    see \"Amoxicillin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Moxatag&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Amoxi&reg;;",
"     </li>",
"     <li>",
"      Mylan-Amoxicillin;",
"     </li>",
"     <li>",
"      Novamoxin&reg;;",
"     </li>",
"     <li>",
"      NTP-Amoxicillin;",
"     </li>",
"     <li>",
"      Nu-Amoxi;",
"     </li>",
"     <li>",
"      PHL-Amoxicillin;",
"     </li>",
"     <li>",
"      PMS-Amoxicillin;",
"     </li>",
"     <li>",
"      Pro-Amox-250;",
"     </li>",
"     <li>",
"      Pro-Amox-500",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F134562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Penicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F134516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Oral:  250-500 mg every 8 hours or 500-875 mg twice daily",
"     <b>",
"      or",
"     </b>",
"     extended-release tablet 775 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chlamydial infection during pregnancy (unlabeled use):",
"     </b>",
"     Oral: 500 mg 3 times/day for 7 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ear, nose, throat, genitourinary tract, or skin/skin structure infections:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Amoxicillin-clavulanate is preferred for first-line treatment of acute bacterial rhinosinusitis (Chow, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Mild-to-moderate:",
"     </i>",
"     Oral: 500 mg every 12 hours",
"     <b>",
"      or",
"     </b>",
"     250 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Severe:",
"     </i>",
"     Oral: 875 mg every 12 hours",
"     <b>",
"      or",
"     </b>",
"     500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Tonsillitis and/or pharyngitis:",
"     </i>",
"     Oral: Extended release tablet: 775 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"     </b>",
"     <b>",
"      eradication:",
"     </b>",
"     Oral: 1000 mg twice daily; requires combination therapy with at least one other antibiotic and an acid-suppressing agent (proton pump inhibitor or H",
"     <sub>",
"      2",
"     </sub>",
"     blocker)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lower respiratory tract infections:",
"     </b>",
"     Oral: 875 mg every 12 hours",
"     <b>",
"      or",
"     </b>",
"     500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Lyme disease:",
"     </b>",
"     Oral: 500 mg every 6-8 hours (depending on size of patient) for 21-30 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Periodontitis (aggressive) (in combination with metronidazole) associated with presense of",
"     </b>",
"     <b>",
"      <i>",
"       Actinobacillus actinomycetemcomitans",
"      </i>",
"     </b>",
"     <b>",
"      (AA):",
"     </b>",
"     Oral: 500 mg every 8 hours for 10 days used in addition to scaling and root planing (Varela, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pharyngitis, group A streptococci (IDSA guidelines):",
"     </b>",
"     1000 mg once daily or 500 mg twice daily (maximum daily dose: 1000 mg) for 10 days (Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Postexposure inhalational anthrax prophylaxis (ACIP recommendations):",
"     </b>",
"     Oral: 500 mg every 8 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Use",
"     <b>",
"      only",
"     </b>",
"     if isolates of the specific",
"     <i>",
"      B. anthracis",
"     </i>",
"     are sensitive to amoxicillin (MIC &le;0.125 mcg/mL); may be administered to pregnant and breast-feeding women.  Duration of antibiotic postexposure prophylaxis (PEP) is &ge;60 days in a previously unvaccinated exposed person. Antimicrobial therapy should continue for 14 days after the third dose of PEP vaccine. Those who are partially or fully vaccinated should receive at least a 30-day course of antimicrobial PEP and continue with licensed vaccination regimen. Unvaccinated workers, even those wearing personal protective equipment with adequate respiratory protection, should receive antimicrobial PEP. Antimicrobial PEP is not required for fully vaccinated people (five-dose I.M. vaccination series with a yearly booster) who enter an anthrax area clothed in personal protective equipment. If respiratory protection is disrupted, a 30-day course of antimicrobial therapy is recommended (ACIP, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against infective endocarditis:",
"     </b>",
"     Oral: 2 g 30-60 minutes before procedure.",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prophylaxis in total joint replacement patients undergoing dental procedures which produce bacteremia:",
"     </b>",
"     Oral: 2 g 1 hour prior to procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prosthetic joint infection, chronic antimicrobial suppression of prosthetic joint infection associated with beta-hemolytic streptococci, penicillin-susceptible",
"      <b>",
"       <i>",
"        Enterococcus",
"       </i>",
"      </b>",
"      spp, or",
"      <b>",
"       <i>",
"        Propionibacterium",
"       </i>",
"      </b>",
"      spp (unlabeled use):",
"     </b>",
"     Oral: 500 mg 3 times daily (Osmon, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F134538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"      see \"Amoxicillin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &le;3 months: Oral: 20-30 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;3 months and &lt;40 kg: Oral: 20-100 mg/kg/day in divided doses every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;3 months and &ge;40 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Oral: Extended-release tablet: 775 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute otitis media:",
"     </b>",
"     Children &gt;3 months and &lt;40 kg: Oral: 80-90 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011): Note:",
"     </b>",
"     In children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Empiric treatment or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (MICs to penicillin &le;2.0 mcg/mL) (preferred): 90 mg/kg/day in 2-3 divided doses (maximum: 4 g/day).",
"     <b>",
"      Note:",
"     </b>",
"     Dividing in 3 doses is recommended for MIC = 2 mcg/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Group A",
"     <i>",
"      Streptococcus",
"     </i>",
"     (moderate-to-severe) (preferred): 50-75 mg/kg/day in 2 divided doses (maximum: 4 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      H. influenzae",
"     </i>",
"     (beta-lactamase negative) mild infection (preferred): 75-100 mg/kg/day in 3 divided doses (maximum: 4 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ear, nose, throat, genitourinary tract, or skin/skin structure infections:",
"     </b>",
"     Children &gt;3 months and &lt;40 kg: Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Amoxicillin-clavulanate is preferred for first-line treatment of acute bacterial rhinosinusitis (Chow, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Mild-to-moderate:",
"     </i>",
"     25 mg/kg/day in divided doses every 12 hours",
"     <b>",
"      or",
"     </b>",
"     20 mg/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Severe:",
"     </i>",
"     45 mg/kg/day in divided doses every 12 hours",
"     <b>",
"      or",
"     </b>",
"     40 mg/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Tonsillitis and/or pharyngitis:",
"     </i>",
"     Children &ge;12 years: Extended release tablet: 775 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lower respiratory tract infections:",
"     </b>",
"     Children &gt;3 months and &lt;40 kg: Oral: 45 mg/kg/day in divided doses every 12 hours",
"     <b>",
"      or",
"     </b>",
"     40 mg/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Lyme disease:",
"     </b>",
"     Children &gt;3 months and &lt;40 kg: Oral:  25-50 mg/kg/day divided every 8 hours (maximum: 500 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pharyngitis, group A streptococci (IDSA guidelines):",
"     </b>",
"     50 mg/kg once daily or alternatively, 25 mg/kg twice daily  (maximum total daily dose: 1000 mg) for 10 days (Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Postexposure inhalational anthrax prophylaxis (ACIP recommendations):",
"     </b>",
"     Children &lt;40 kg: Oral: 45 mg/kg/day divided into 3 daily doses (maximum: 500 mg/dose) (ACIP, 2010).",
"     <b>",
"      Note:",
"     </b>",
"     The AAP recommends a higher dose (80 mg/kg/day divided into 3 daily doses [maximum: 500 mg/dose]) due to the lack of data on amoxicillin dosages for treating anthrax and the high mortality rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use",
"     <b>",
"      only",
"     </b>",
"     if isolates of the specific",
"     <i>",
"      B. anthracis",
"     </i>",
"     are sensitive to amoxicillin (MIC &le;0.125 mcg/mL).  Duration of antibiotic postexposure prophylaxis (PEP) is &ge;60 days in a previously-unvaccinated exposed person. Antimicrobial therapy should continue for 14 days after the third dose of PEP vaccine. Those who are partially or fully vaccinated should receive at least a 30-day course of antimicrobial PEP and continue with licensed vaccination regimen. Unvaccinated workers, even those wearing personal protective equipment with adequate respiratory protection, should receive antimicrobial PEP. Antimicrobial PEP is not required for fully-vaccinated people (five-dose I.M. vaccination series with a yearly booster) who enter an anthrax area clothed in personal protective equipment. If respiratory protection is disrupted, a 30-day course of antimicrobial therapy is recommended (ACIP, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against infective endocarditis:",
"     </b>",
"     Children &gt;3 months and &lt;40 kg: Oral: 50 mg/kg 1 hour before procedure.",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F134517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F134518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Use of certain dosage forms (eg, extended-release 775 mg tablet and immediate-release 875 mg tablet) should be avoided in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or patients requiring hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: 250-500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 250-500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderately dialyzable (20% to 50%) by hemodialysis or peritoneal dialysis; approximately 50 mg of amoxicillin per liter of filtrate is removed by continuous arteriovenous or venovenous hemofiltration. Dose as per Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute guidelines.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 125 mg/5 mL (80 mL, 100 mL, 150 mL); 200 mg/5 mL (50 mL, 75 mL, 100 mL); 250 mg/5 mL (80 mL, 100 mL, 150 mL); 400 mg/5 mL (50 mL, 75 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg, 875 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 125 mg, 200 mg, 250 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moxatag&trade;: 775 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended-release formulation",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F134492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer around-the-clock to promote less variation in peak and trough serum levels. The appropriate amount of suspension may be mixed with formula, milk, fruit juice, water, ginger ale, or cold drinks; administer dose immediately after mixing.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Moxatag&trade; extended release tablet: Administer within 1 hour of finishing a meal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy",
"     <i>",
"      in vivo",
"     </i>",
"     , particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F134491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of otitis media, sinusitis, and infections caused by susceptible organisms involving the upper and lower respiratory tract, skin, and urinary tract; prophylaxis of infective endocarditis in patients undergoing surgical or dental procedures; as part of a multidrug regimen for",
"     <i>",
"      H. pylori",
"     </i>",
"     eradication; periodontitis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F134559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Postexposure prophylaxis for anthrax exposure with documented susceptible organisms; chronic oral antimicrobial suppression of prosthetic joint infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F134569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amoxicillin may be confused with amoxapine, Augmentin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amoxil may be confused with amoxapine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fisamox [Australia] may be confused with Fosamax brand name for alendronate [U.S., Canada, and multiple international markets] and Vigamox brand name for moxifloxacin [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Limoxin [Mexico] may be confused with Lanoxin brand name for digoxin [U.S., Canada, and multiple international markets]; Lincocin brand name for lincomycin [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zimox: Brand name for amoxicillin [Italy], but also the brand name for carbidopa/levodopa [Greece]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zimox [Italy] may be confused with Diamox which is the brand name for acetazolamide [Canada and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F134560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, behavioral changes, confusion, dizziness, headache, hyperactivity (reversible), insomnia,  seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acute exanthematous pustulosis, erythematous maculopapular rash, erythema multiforme, exfoliative dermatitis, hypersensitivity vasculitis, mucocutaneous candidiasis, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Black hairy tongue, diarrhea, hemorrhagic colitis, nausea, pseudomembranous colitis, tooth discoloration (brown, yellow, or gray; rare), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, eosinophilia, hemolytic anemia, leukopenia,thrombocytopenia, thrombocytopenia purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Acute cytolytic hepatitis, ALT increased, AST increased, cholestatic jaundice, hepatic cholestasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Crystalluria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, serum sickness-like reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F134495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amoxicillin, penicillin, other beta-lactams, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F134476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infectious mononucleosis: A high percentage of patients with infectious mononucleosis have developed rash during therapy; ampicillin-class antibiotics not recommended in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended. In addition, use of certain dosage forms (eg, extended release 775 mg tablet and immediate release 875 mg tablet) should be avoided in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or patients requiring hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Chewable tablets contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Amoxicillin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Maternal use of amoxicillin has generally not resulted in an increased risk of adverse fetal effects; however, an increased risk of cleft lip with cleft palate has been observed in some studies. It is the drug of choice for the treatment of chlamydial infections in pregnancy and for anthrax prophylaxis when penicillin susceptibility is documented. Amoxicillin may be used in certain situations prior to vaginal delivery in women at high risk for endocarditis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, oral amoxicillin clearance is increased during pregnancy resulting in lower concentrations and smaller AUCs. Oral ampicillin-class antibiotics are poorly absorbed during labor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F134522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5695240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Very small amounts of amoxicillin are excreted in breast milk. The manufacturer recommends that caution be exercised when administering amoxicillin to nursing women. Nondose-related effects could include modification of bowel flora and allergic sensitization of the infant.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F134498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food. Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moxatag&trade;: Take within 1 hour of finishing a meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F134497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Amoxicillin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $24.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $44.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Amoxicillin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (100): $26.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $53.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (Amoxicillin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg/5 mL (150 mL): $4.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/5 mL (75 mL): $6.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (100 mL): $6.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg/5 mL (75 mL): $7.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Moxatag Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     775 mg (30): $524.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amoxicillin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $49.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     875 mg (100): $87.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F134486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With prolonged therapy, monitor renal, hepatic, and hematologic function periodically; assess patient at beginning and throughout therapy for infection; monitor for signs of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F134499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acilina (PY);",
"     </li>",
"     <li>",
"      Acimox (MX);",
"     </li>",
"     <li>",
"      Adbiotin (CO);",
"     </li>",
"     <li>",
"      Alfamox (IT);",
"     </li>",
"     <li>",
"      Almodan (GB);",
"     </li>",
"     <li>",
"      Almorsan (AR);",
"     </li>",
"     <li>",
"      Alphamox (AU);",
"     </li>",
"     <li>",
"      Amagesen Solutab (DE);",
"     </li>",
"     <li>",
"      Amicil (MX);",
"     </li>",
"     <li>",
"      Amimox (SE);",
"     </li>",
"     <li>",
"      Amobay (MX);",
"     </li>",
"     <li>",
"      Amoclave (ES);",
"     </li>",
"     <li>",
"      Amoclen (CZ);",
"     </li>",
"     <li>",
"      Amodex (FR);",
"     </li>",
"     <li>",
"      Amoflux (BR);",
"     </li>",
"     <li>",
"      Amolin (TW);",
"     </li>",
"     <li>",
"      Amotaks (PL);",
"     </li>",
"     <li>",
"      Amoval (PE);",
"     </li>",
"     <li>",
"      Amox (AE, BH, CY, EG, IQ, IR, IT, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Amoxal (VE);",
"     </li>",
"     <li>",
"      Amoxcil (CL);",
"     </li>",
"     <li>",
"      Amoxcillin (TH);",
"     </li>",
"     <li>",
"      Amoxcin (TW);",
"     </li>",
"     <li>",
"      Amoxi (IL);",
"     </li>",
"     <li>",
"      Amoxi TO (TH);",
"     </li>",
"     <li>",
"      Amoxi-basan (DE);",
"     </li>",
"     <li>",
"      Amoxicap (PK);",
"     </li>",
"     <li>",
"      Amoxicilina (CO, EC);",
"     </li>",
"     <li>",
"      Amoxiclin (PE);",
"     </li>",
"     <li>",
"      Amoxico (PH);",
"     </li>",
"     <li>",
"      Amoxidal (AR, UY);",
"     </li>",
"     <li>",
"      Amoxidin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Amoxidin 7 (PE);",
"     </li>",
"     <li>",
"      Amoxifur (MX);",
"     </li>",
"     <li>",
"      Amoxiga (CO);",
"     </li>",
"     <li>",
"      Amoxihexal (DE);",
"     </li>",
"     <li>",
"      Amoxil (AE, AU, BF, BH, BJ, BR, CI, CY, EC, EG, ET, GB, GH, GM, GN, GR, ID, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NZ, OM, PE, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Amoxillin (IL, IT);",
"     </li>",
"     <li>",
"      Amoxin (FI);",
"     </li>",
"     <li>",
"      Amoxinova (MX);",
"     </li>",
"     <li>",
"      Amoxipenil (CN);",
"     </li>",
"     <li>",
"      Amoxisol (MX);",
"     </li>",
"     <li>",
"      Amoxivan (IN);",
"     </li>",
"     <li>",
"      Amoxivet (MX);",
"     </li>",
"     <li>",
"      Amoxsan (ID);",
"     </li>",
"     <li>",
"      Amoxsan Forte (ID);",
"     </li>",
"     <li>",
"      Amoxy (CL);",
"     </li>",
"     <li>",
"      Amoxy-diolan (DE);",
"     </li>",
"     <li>",
"      Amoxypen (DE, PE);",
"     </li>",
"     <li>",
"      Apo-Amoxi (MY);",
"     </li>",
"     <li>",
"      Aroxin (SG);",
"     </li>",
"     <li>",
"      Azillin (CH);",
"     </li>",
"     <li>",
"      Bacihexal (PH);",
"     </li>",
"     <li>",
"      Bactamox (VE);",
"     </li>",
"     <li>",
"      Bactox (EE);",
"     </li>",
"     <li>",
"      Bactox Ge (FR);",
"     </li>",
"     <li>",
"      Beamoxy (MY);",
"     </li>",
"     <li>",
"      Betamox (MY);",
"     </li>",
"     <li>",
"      Bimxan (MX);",
"     </li>",
"     <li>",
"      Biotamoxal (AR);",
"     </li>",
"     <li>",
"      Bomox (TH);",
"     </li>",
"     <li>",
"      Bristamox (EC, FR);",
"     </li>",
"     <li>",
"      Bufamoxy (ID);",
"     </li>",
"     <li>",
"      Cilamox (AU, PH);",
"     </li>",
"     <li>",
"      Clamoxyl (AT, AU, BB, BE, BM, BS, BZ, CH, FR, GY, JM, NL, NZ, PE, PR, PT, SR, TT);",
"     </li>",
"     <li>",
"      Coamox (TH);",
"     </li>",
"     <li>",
"      Dimopen (MX);",
"     </li>",
"     <li>",
"      Duomox (BG, HN);",
"     </li>",
"     <li>",
"      Dymoxin (TH);",
"     </li>",
"     <li>",
"      Edamox (HK);",
"     </li>",
"     <li>",
"      Ethimox (ID);",
"     </li>",
"     <li>",
"      Farconcil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Fisamox (AU);",
"     </li>",
"     <li>",
"      Flemoxin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Flubiotic (ES);",
"     </li>",
"     <li>",
"      Foxolin (KP);",
"     </li>",
"     <li>",
"      Fullcilina (AR);",
"     </li>",
"     <li>",
"      Gexcil (PH);",
"     </li>",
"     <li>",
"      Gimalxina (MX);",
"     </li>",
"     <li>",
"      Gomcillin (KP);",
"     </li>",
"     <li>",
"      Grinsul (AR);",
"     </li>",
"     <li>",
"      Grunamox (EC);",
"     </li>",
"     <li>",
"      Hiconcil (BE, FR);",
"     </li>",
"     <li>",
"      Hidramox (MX);",
"     </li>",
"     <li>",
"      Hipen (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Hypher (CL);",
"     </li>",
"     <li>",
"      Ibiamox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TH, YE);",
"     </li>",
"     <li>",
"      Ikamoxil (ID);",
"     </li>",
"     <li>",
"      Imacillin (DK, NO, SE);",
"     </li>",
"     <li>",
"      Imadrax (DK);",
"     </li>",
"     <li>",
"      Izoltil (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Jutamox (DE);",
"     </li>",
"     <li>",
"      Lamoxy (IN);",
"     </li>",
"     <li>",
"      Magnimox (PE);",
"     </li>",
"     <li>",
"      Manmox (TH);",
"     </li>",
"     <li>",
"      Maxamox (AU);",
"     </li>",
"     <li>",
"      Maxcil (ZA);",
"     </li>",
"     <li>",
"      Meixil (TH);",
"     </li>",
"     <li>",
"      Mexylin (ID);",
"     </li>",
"     <li>",
"      Milamox-BIG (TH);",
"     </li>",
"     <li>",
"      Mopen (IT);",
"     </li>",
"     <li>",
"      Mox (IN);",
"     </li>",
"     <li>",
"      Moxarin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Moxilen (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SG, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Moxylin (EC);",
"     </li>",
"     <li>",
"      Moxypen (IL, ZA);",
"     </li>",
"     <li>",
"      Moxyvit (IL);",
"     </li>",
"     <li>",
"      Novabritine (BE);",
"     </li>",
"     <li>",
"      Novamox (PH);",
"     </li>",
"     <li>",
"      Novax (ID);",
"     </li>",
"     <li>",
"      Novoxil (BR);",
"     </li>",
"     <li>",
"      Ospamox (AE, AT, BG, BH, CR, CY, DE, DO, EG, GT, HK, ID, IQ, IR, JO, KW, LB, LY, MY, NI, NZ, OM, PA, PL, PT, QA, RU, SA, SV, SY, UY, YE);",
"     </li>",
"     <li>",
"      Pamocil (IT);",
"     </li>",
"     <li>",
"      Pamoxicillin (TW);",
"     </li>",
"     <li>",
"      Pamoxin (KP);",
"     </li>",
"     <li>",
"      Pasetocin (JP);",
"     </li>",
"     <li>",
"      Penamox (MX);",
"     </li>",
"     <li>",
"      Penbiosyn (PH);",
"     </li>",
"     <li>",
"      Piramox (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Polymox (MX);",
"     </li>",
"     <li>",
"      Pondnoxcill (TH);",
"     </li>",
"     <li>",
"      Pyramox (TH);",
"     </li>",
"     <li>",
"      Rancil (TH);",
"     </li>",
"     <li>",
"      Ranmoxy (AU, ZA);",
"     </li>",
"     <li>",
"      Ranoxyl (TH);",
"     </li>",
"     <li>",
"      Shamoxil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Sia-mox (TH);",
"     </li>",
"     <li>",
"      Solciclina (MX);",
"     </li>",
"     <li>",
"      Solpenox (ID);",
"     </li>",
"     <li>",
"      Sterimox (PH);",
"     </li>",
"     <li>",
"      Strimox (SG);",
"     </li>",
"     <li>",
"      Supercillin (TW);",
"     </li>",
"     <li>",
"      Teramoxyl (PH);",
"     </li>",
"     <li>",
"      Trifamox (AR, PY);",
"     </li>",
"     <li>",
"      Trimox (TH);",
"     </li>",
"     <li>",
"      Velamox (PE);",
"     </li>",
"     <li>",
"      Widecillin (ID);",
"     </li>",
"     <li>",
"      Winpen (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Xalyn-Or (MX);",
"     </li>",
"     <li>",
"      Zai Lin (CL);",
"     </li>",
"     <li>",
"      Zerrsox (PH);",
"     </li>",
"     <li>",
"      Zimox (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F134475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F134494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid and nearly complete; food does not interfere",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended-release tablet: Rate of absorption is slower compared to immediate-release formulations; food decreases the rate but not extent of absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely to most body fluids and bone; poor penetration into cells, eyes, and across normal meninges",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pleural fluids, lungs, and peritoneal fluid; high urine concentrations are attained; also into synovial fluid, liver, prostate, muscle, and gallbladder; penetrates into middle ear effusions, maxillary sinus secretions, tonsils, sputum, and bronchial secretions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CSF:blood level ratio: Normal meninges: &lt;1%; Inflamed meninges: 8% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 17% to 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates, full-term: 3.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Normal renal function: 0.7-1.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 7-21 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Capsule: 2 hours; Extended-release tablet: 3.1 hours; Suspension: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% as unchanged drug); lower in neonates",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Extended-release tablets: In healthy volunteers, serum drug concentrations were below 0.25 mcg/mL and undetectable at 16 hours following dosing.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media, &ldquo;Diagnosis and Management of Acute Otitis Media,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 113(5):1451-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/15121972/pubmed\" id=\"15121972\" target=\"_blank\">",
"        15121972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boguniewicz M and Leung DY, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(3):221-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/7761188/pubmed\" id=\"7761188\" target=\"_blank\">",
"        7761188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, &ldquo;Management of Community-Acquired Pediatric Pneumonia in an Era of Increasing Antibiotic Resistance and Conjugate Vaccines,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2002, 21:592-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/12182396/pubmed\" id=\"12182396\" target=\"_blank\">",
"        12182396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canafax DM, Yuan Z, Chonmaitree T, et al, &ldquo;Amoxicillin Middle Ear Fluid Penetration and Pharmacokinetics in Children With Acute Otitis Media,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1998, 17(2):149-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/9493813/pubmed\" id=\"9493813\" target=\"_blank\">",
"        9493813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Use of Anthrax Vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-6):1-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/20651644/pubmed\" id=\"20651644\" target=\"_blank\">",
"        20651644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(8):e72-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/22438350/pubmed\" id=\"22438350\" target=\"_blank\">",
"        22438350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow MS, Quintiliani R, and Nightingale CH, &ldquo;",
"      <i>",
"       In Vivo",
"      </i>",
"      Inactivation of Tobramycin by Ticarcillin. A Case Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1982, 247(5):658-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/6798229/pubmed\" id=\"6798229\" target=\"_blank\">",
"        6798229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dajani AS, Taubert KA, Wilson WW, et al, &ldquo;Prevention of Bacterial Endocarditis. Recommendations by the American Heart Association,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 277(22):1794-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/9178793/pubmed\" id=\"9178793\" target=\"_blank\">",
"        9178793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daly JS, Dodge RA, Glew RH, et al, &ldquo;Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 1997, 17(1):42-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/9069064/pubmed\" id=\"9069064\" target=\"_blank\">",
"        9069064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dougall HT, Smith L, Duncan C, et al, &ldquo;The Effect of Amoxicillin on Salivary Nitrite Concentrations: An Important Mechanism of Adverse Reactions?&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1995, 39(4):460-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/7640157/pubmed\" id=\"7640157\" target=\"_blank\">",
"        7640157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dowell JA, Korth-Bradley J, Milisci M, et al, &ldquo;Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2001, 41:979-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/11549103/pubmed\" id=\"11549103\" target=\"_blank\">",
"        11549103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farchione LA, &ldquo;Inactivation of Aminoglycosides by Penicillins,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1982, 8(Suppl A):27-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/7263563/pubmed\" id=\"7263563\" target=\"_blank\">",
"        7263563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuchs PC, Stickel S, Anderson PH, et al, &ldquo;",
"      <i>",
"       In Vitro",
"      </i>",
"      Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(1):182-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/2014975/pubmed\" id=\"2014975\" target=\"_blank\">",
"        2014975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Halstenson CE, Wong MO, Herman CS, et al, &ldquo;Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1992, 36(9):1832-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/1416875/pubmed\" id=\"1416875\" target=\"_blank\">",
"        1416875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hautekeete ML, Brenard R, Horsmans Y, et al, &ldquo;Liver Injury Related to Amoxycillin-Clavulanic Acid: Interlobular Bile-Duct Lesions and Extrahepatic Manifestations,&rdquo;",
"      <i>",
"       J Hepatol",
"      </i>",
"      , 1995, 22(1):71-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/7751590/pubmed\" id=\"7751590\" target=\"_blank\">",
"        7751590",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hill S, Yeates M, Pathy J, et al, &ldquo;A Controlled Trial of Norfloxacin and Amoxicillin in the Treatment of Uncomplicated Urinary Tract Infection in the Elderly,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1985, 15(4):505-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/3159711/pubmed\" id=\"3159711\" target=\"_blank\">",
"        3159711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hitt CM, Patel KB, Nicolau DP, et al, &ldquo;Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(23):2704-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/9408514/pubmed\" id=\"9408514\" target=\"_blank\">",
"        9408514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones KH and Hill SA, &ldquo;The Toxicology, Absorption and Pharmacokinetics of Amoxicillin,&rdquo;",
"      <i>",
"       Adv Clin Pharmacol",
"      </i>",
"      , 1974, 7:20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/4619748/pubmed\" id=\"4619748\" target=\"_blank\">",
"        4619748",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konishi H, Goto M, Nakamoto Y, et al, &ldquo;Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 23(5):653-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/6223576/pubmed\" id=\"6223576\" target=\"_blank\">",
"        6223576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Korppi M, &ldquo;Community-Acquired Pneumonia in Children. Issues in Optimizing Antibacterial Treatment,&rdquo;",
"      <i>",
"       Pediatr Drugs",
"      </i>",
"      , 2003, 5(12):821-32.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau A, Lee M, Flascha S, et al, &ldquo;Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients With Normal Renal Function,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 24(4):533-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/6651279/pubmed\" id=\"6651279\" target=\"_blank\">",
"        6651279",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McIntosh K, &ldquo;Community-Acquired Pneumonia in Children,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(6):429-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/11832532/pubmed\" id=\"11832532\" target=\"_blank\">",
"        11832532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oe PL, Simonian S, Verhoef J, &ldquo;Pharmacokinetics of the New Penicillins, Amoxicillin and Flucloxacillin in Patients With Terminal Renal Failure Undergoing Hemodialysis,&rdquo;",
"      <i>",
"       Chemotherapy",
"      </i>",
"      , 1973, 19:279.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/4787741/pubmed\" id=\"4787741\" target=\"_blank\">",
"        4787741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parry MF, &ldquo;The Penicillins,&rdquo;",
"      <i>",
"       Med Clin North Am",
"      </i>",
"      , 1987, 71(6):1093-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/3320613/pubmed\" id=\"3320613\" target=\"_blank\">",
"        3320613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prignet JM, Galzin M, Duval JL, et al, &ldquo;Amoxicillin-Induced Esophageal Ulcer With Intractable Hiccups as the Presenting Manifestation,&rdquo;",
"      <i>",
"       Sem Hop",
"      </i>",
"      , 1995, 71:186-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russoe ME and Atkins-Thor E, &ldquo;Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,&rdquo;",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1981, 15(4):175-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/7237864/pubmed\" id=\"7237864\" target=\"_blank\">",
"        7237864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 55(10):e86-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swanson-Biearman B, Dean DS, Lopez G, et al, &ldquo;The Effects of Penicillin and Cephalosporin Ingestions in Children Less Than Six Years of Age,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1988, 30(1):66-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/3354190/pubmed\" id=\"3354190\" target=\"_blank\">",
"        3354190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2005, 100(10):2324-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/16181387/pubmed\" id=\"16181387\" target=\"_blank\">",
"        16181387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thompson MIB, Russo ME, Saxon BJ, et al, &ldquo;Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1982, 21(2):268-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/6462107/pubmed\" id=\"6462107\" target=\"_blank\">",
"        6462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tu YH, Stiles ML, Allen LV Jr, et al, \"Stability of Amoxicillin Trihydrate-Potassium Clavulanate in Original Containers and Unit Dose Oral Syringes,\"",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1988, 45(5):1092-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/3400652 /pubmed\" id=\"3400652 \" target=\"_blank\">",
"        3400652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, Center for Drug Evaluation and Research, &ldquo;Commentary on Nonlabeled Dosing of Oral Amoxicillin in Adults and Pediatrics for Post-Exposure Inhalational Anthrax,&rdquo; December 10, 2001. Available at",
"      <a href=\"file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072106.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072106.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Varela VM, Heller D, Silva-Senem MX, et al, \"Systemic Antimicrobials Adjunctive to a Repeated Mechanical and Antiseptic Therapy for Aggressive Periodontitis: A 6-Month Randomized Controlled Trial,\"",
"      <i>",
"       J Periodontol",
"      </i>",
"      , 2011, 82(8):1121-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/21235333/pubmed\" id=\"21235333\" target=\"_blank\">",
"        21235333",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Viollier AF, Standiford HC, Drusano GL, et al, &ldquo;Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1985, 15(5):597-606.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/4008387/pubmed\" id=\"4008387\" target=\"_blank\">",
"        4008387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walterspiel JN, Feldman S, Van R, et al, &ldquo;Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(9):1875-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/1952861/pubmed\" id=\"1952861\" target=\"_blank\">",
"        1952861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westphal JF, Jehl F, Brogard JM, et al, &ldquo;Amoxicillin Intestinal Absorption Reduction by Amiloride: Possible Role of the Na",
"      <sup>",
"       +",
"      </sup>",
"      -H",
"      <sup>",
"       +",
"      </sup>",
"      Exchanger,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57(3):257-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/7697943/pubmed\" id=\"7697943\" target=\"_blank\">",
"        7697943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright AJ, &ldquo;The Penicillins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(3):290-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/10090000/pubmed\" id=\"10090000\" target=\"_blank\">",
"        10090000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Amoxicillin Update,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1991, 39(5):322,4,6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/10/42152/abstract-text/1812049/pubmed\" id=\"1812049\" target=\"_blank\">",
"        1812049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8673 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42152=[""].join("\n");
var outline_f41_10_42152=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134511\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134512\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134562\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134516\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134538\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134517\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134518\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673165\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134488\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134472\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134492\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134491\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134559\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134569\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134560\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134495\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134476\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298741\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134481\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134484\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720643\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134522\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5695240\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134498\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134497\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134486\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134499\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134475\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134494\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8673\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8673|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/2/39972?source=related_link\">",
"      Amoxicillin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=related_link\">",
"      Amoxicillin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_10_42153="Genetic factors in the amyloid diseases";
var content_f41_10_42153=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetic factors in the amyloid diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/10/42153/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/10/42153/contributors\">",
"     Peter D Gorevic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/10/42153/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/10/42153/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/10/42153/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/10/42153/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/10/42153/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/10/42153/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis is a generic term that refers to the extracellular tissue deposition of fibrils composed of low molecular weight subunits (5 to 25 kD) of proteins, many of which are normal constituents of serum. The fibrils are insoluble polymers comprised of these low molecular weight subunit proteins. These subunits are derived, in turn, from soluble precursors, which undergo conformational changes that lead to the adoption of a predominantly antiparallel beta-pleated sheet configuration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amyloid deposits appear as amorphous hyaline material on light microscopy (",
"    <a class=\"graphic graphic_picture graphicRef63840 graphicRef78183 graphicRef54148 graphicRef75254 \" href=\"mobipreview.htm?43/14/44266\">",
"     picture 1A-D",
"    </a>",
"    ). The fibrils bind Congo red (leading to green birefringence under polarized light) and thioflavine T (producing an intense yellow-green fluorescence). Electron microscopic examination of the ultrastructure of amyloid deposits generally demonstrates straight and unbranching fibrils, which may be composed of protofilaments at higher resolution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/3\">",
"     3",
"    </a>",
"    ]. Immunohistochemical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/4\">",
"     4",
"    </a>",
"    ] and biochemical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/5\">",
"     5",
"    </a>",
"    ] techniques can be used to identify the type of protein subunit.",
"   </p>",
"   <p>",
"    Routes to fibrillogenesis include partial folding or unfolding of the precursor protein that may be facilitated by acidification or proteolysis and that may be accelerated by nucleation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Fibril formation is also associated with co-deposition of other substances, notably including glycosaminoglycans (GAGs, particularly heparan sulfate), serum amyloid P-component (SAP, a member of the pentraxin family that includes C-reactive protein), and specific apolipoproteins (E and J) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Cofactors may significantly modulate fibrillogenesis at any of several steps involved in the conversion of soluble precursors to fibrils and may potentially influence the deposition phase of amyloid in tissue, as well as resorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of heredity in the expression of amyloid diseases has been recognized for many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/12\">",
"     12",
"    </a>",
"    ]. Some amyloid disorders appear to be entirely due to heritable abnormalities in precursor proteins. In addition, the expression of acquired amyloidoses may be affected by genetically determined factors.",
"   </p>",
"   <p>",
"    The genetic contributions to various types of amyloidosis will be reviewed here. Three types of genetic abnormalities have been identified in amyloidogenic proteins: polymorphisms, variant molecules (eg, due to missense mutations, deletions, or premature stop codons), and genetically determined posttranslational modifications (",
"    <a class=\"graphic graphic_table graphicRef70058 graphicRef81283 \" href=\"mobipreview.htm?15/20/15694\">",
"     table 1A-B",
"    </a>",
"    ). In addition, mutations in genes for non-amyloidogenic proteins can play a permissive role in amyloid development. Examples include pyrin mutations in familial Mediterranean fever and presenilin mutations in early-onset Alzheimer disease.",
"   </p>",
"   <p>",
"    An overview of the amyloidoses is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=see_link\">",
"     \"An overview of amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETIC AMYLOIDOSES REFLECTED IN SUBUNIT PROTEIN MUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the familial diseases associated with missense mutations, the point mutation that correlates with clinical disease usually occurs in the part of the precursor molecule that actually forms the fibril subunit protein; other precursor domains may be eliminated by metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/13\">",
"     13",
"    </a>",
"    ] or may be digested away prior to or after fibril formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/6\">",
"     6",
"    </a>",
"    ]. Amino acid substitutions resulting from missense mutations may be found in subunit protein subsequences that adopt a fibrillar configuration in vitro. This has been demonstrated by examining the fibrillogenic potential of recombinant proteins or synthetic peptides corresponding to these sub-sequences. In some instances, the mutant is intrinsically more fibrillogenic in vitro than the wild-type peptide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amyloid precursor protein (APP) mutations that have been associated with early-onset or familial cases of Alzheimer disease (AD) also include substitutions that occur contiguous to, but not within, the amyloidogenic Alzheimer beta protein (A&szlig;) sequence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. In these cases, it is assumed that diversion of APP processing to an amyloid-producing pathway is the primary mechanism leading to accumulation of fibrillogenic A&szlig; peptides at the sites of pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/18\">",
"     18",
"    </a>",
"    ]. In two forms of hereditary amyloid disease",
"    <span class=\"nowrap\">",
"     (British/Danish",
"    </span>",
"    dementia and apolipoprotein A-II nephropathy), mutations at the site of stop codons lead to carboxyterminal extensions that are not expressed by the wild-type protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/2,19,20\">",
"     2,19,20",
"    </a>",
"    ]. Fibril subunit protein may include an amino-terminal portion of the precursor (eg, apolipoprotein A1), a carboxyterminal fragment (eg, fibrinogen A&alpha;-chain), or the entire molecule (transthyretin).",
"   </p>",
"   <p>",
"    Mutant forms of amyloidogenic proteins can be defined serologically or by",
"    <span class=\"nowrap\">",
"     immunoblot/immunoelectrophoresis,",
"    </span>",
"    looking for abnormal precursors or metabolic products in blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Genetic testing for the single base substitution characteristic for the particular amyloid disease is usually carried out by directly sequencing the amplified exon of the relevant gene of interest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A resource for the tabulation of mutations associated with the systemic hereditary amyloidoses is",
"    <a class=\"external\" href=\"file://www.amyloidosismutations.com/\">",
"     www.amyloidosismutations.com",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transthyretin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transthyretin (TTR or prealbumin) gene is located on chromosome 18, and more than 100 TTR mutations have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/25\">",
"     25",
"    </a>",
"    ]. Nearly all mutant TTR gene products are amyloidogenic. Mutations have been identified in approximately 40 percent of the amino acids of this 127 residue single chain molecule. Twenty-two residues have more than one substitution associated with disease; these tend to occur at mutational hot spots in the DNA sequence and along portions of the molecule known to adopt a beta-pleated sheet configuration from x-ray crystallography of wild-type TTR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different variants of the TTR gene present predominantly as neuropathic, cardiomyopathic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ocular (vitreous) disease, which may be familial or sporadic. Certain populations have an increased prevalence of particular mutations. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In endemic areas of Portugal, 1 of every 600 people carries a TTR gene that leads to a methionine substitution for valine at position 30 and that may result in familial amyloidotic polyneuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/27\">",
"       27",
"      </a>",
"      ]. The same mutation is seen in some other countries such as Sweden and Japan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. In northern Sweden, the carrier frequency is 8.3-fold higher than in Portugal, but with a lower incidence and prevalence due to a much lower penetrance (5 versus 87 percent) before age 40 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/30\">",
"       30",
"      </a>",
"      ]. Although haplotype analysis of contiguous TTR gene regions in Swedish, French, Portuguese, and Japanese carriers indicates common founders, these phenotypic differences suggest the importance of additional genetic and epigenetic factors in disease expression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Isolated cardiac amyloidosis presenting virtually exclusively as late-onset (age &gt;65) disease is more common in African-Americans than Caucasians, and nearly 1 to 1.5 million persons are carriers for an amyloidogenic substitution of isoleucine for valine at position 122 (V122I), including 13,000 homozygotes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/32\">",
"       32",
"      </a>",
"      ]. In addition, the carrier rate is &gt;5 percent in some areas of West Africa. Approximately one-quarter of those with senile cardiac amyloid detected at autopsy are heterozygous for the V122I TTR mutation. This form of amyloid has been estimated to account for approximately 25 percent of all cases of cardiac amyloid in African-Americans and to be a significant cause of the 28 percent death rate due to cardiovascular disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Overall, 14 TTR mutations manifest as cardiac-predominant familial disease, and some (Ile20, Gly42, Lys92) have also been associated with late-onset expression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Five TTR mutations (Gly30, Arg 53, Ser64, His69, Cys 114) have been associated with clinically significant central nervous system involvement, manifesting as leptomeningeal involvement, dementia, cerebellar dysfunction with ataxia, or cerebral hemorrhage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/2,35\">",
"       2,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alzheimer amyloid precursor protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Alzheimer amyloid precursor protein (APP) gene is located on chromosome 21; 32 mutations have been identified within APP from 76 families with early-onset disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/2,17,18\">",
"     2,17,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'APP gene'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prion protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prion protein (PrP) gene is located on chromosome 20. Over 20 mutations, including several deletion mutants, have been described; atypical phenotypes are seen in association with Gerstmann-Str&auml;ussler-Scheinker disease and fatal familial insomnia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7017?source=see_link\">",
"     \"Biology and genetics of prions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/28/31176?source=see_link\">",
"     \"Diseases of the central nervous system caused by prions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gerstmann-Str&auml;ussler-Scheinker (GSS) disease (most commonly associated with a mutation at codon 102) is characterized by severe cerebellar ataxia and often spastic paraparesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fatal familial insomnia is determined by a mutation at codon 178 associated with a specific polymorphism at codon 129 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gelsolin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gelsolin gene is located on chromosome nine. Two mutations have been described, both at codon 654 (residue 187, called the Meretoja substitution) within the amyloidogenic fragment of gelsolin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/13,16,21,41\">",
"     13,16,21,41",
"    </a>",
"    ]. These mutations are associated with a characteristic triad of lattice corneal dystrophy, cranial neuropathy, and cutis laxa that is called familial amyloidosis, Finnish type (FAF), because of the striking clustering of the disease in the southern part of this country.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Apolipoprotein A-I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The apolipoprotein A-I (apo A-I) gene is located on chromosome one. It is the second most common hereditary systemic amyloidosis. Nineteen mutations have been described, most of which are single amino acid substitutions resulting from point mutations; deletions and insertions may also be associated with amyloid deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations of apo A-I amyloidogenic gene mutations vary with the location of mutation in the approximately 93 residue fragments found in the subunit protein. Mutations in the 75 amino-terminal residues manifest as an interstitial and medullary nephropathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    as hepatic involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/42\">",
"     42",
"    </a>",
"    ]. Cutaneous amyloid deposits, cardiomyopathy, neuropathy, or laryngeal dysfunction are more characteristic of mutations beyond residue 90 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/24,43\">",
"     24,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Apolipoprotein A-II",
"    </span>",
"    &nbsp;&mdash;&nbsp;The apo A-II gene is also located on chromosome one. Five stop-codon mutations have been described at residue 78 in exon four, leading to a 21 residue extension at the C-terminus of the molecule. The clinical phenotype is a slowly progressive renal (glomerular and interstitial amyloid) disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/19,24,44,45\">",
"     19,24,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lysozyme",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lysozyme gene is located on chromosome 12. Six mutations have been associated with prominent renal and gastrointestinal amyloid disease of variable onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/14,46,47\">",
"     14,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fibrinogen A&alpha;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fibrinogen alpha chain gene is located on chromosome four; nine mutations have been described, all associated with renal amyloidosis that is strikingly glomerular, without interstitial or vascular involvement; it is the most common cause of hereditary amyloidosis in the United Kingdom. One patient with a valine substitution for glutamic acid at position 526 of the fibrinogen alpha chain survived for several years following renal transplantation but subsequently developed amyloidosis in her renal allograft and hepatic failure due to amyloid deposits in her liver; liver and repeat kidney transplantation was successful and eliminated the source of the amyloidogenic protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cystatin C",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cystatin gene is located on chromosome 20. One mutation has been described; it is associated with massive amyloid angiopathy, cerebral hemorrhage (Icelandic type), and a fatal outcome in the third to fourth decades of life in approximately 50 percent of the cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/2,15,50\">",
"     2,15,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2895908\">",
"    <span class=\"h2\">",
"     Beta-2 microglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The &beta;2-microglobulin (&beta;2m) gene is located on chromosome 15; this protein is the major subunit of the amyloid complicating chronic hemo- or peritoneal dialysis, in which it occurs as the wild-type protein which accumulates in blood due to defective clearance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .) By contrast, a novel dominantly inherited Asp76Asn variant of &beta;2m has been described associated with systemic amyloidosis in a French family, in whom it was manifested as gastrointestinal disease, autonomic neuropathy, and sicca syndrome. In these patients, &beta;2m levels in blood were normal, and the variant molecule was found to have striking intrinsic amyloidogenicity in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Confusion with AL amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic cases due to hereditary amyloidoses may be confused with AL (primary) amyloidosis, a plasma cell dyscrasia. This was illustrated in a study of 350 patients suspected of having AL amyloidosis by clinical and laboratory findings and the absence of a family history; 34 (9.7 percent) had a mutant gene for an &ldquo;amyloidogenic&rdquo; protein, most often involving fibrinogen Aa or transthyretin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/52\">",
"     52",
"    </a>",
"    ]. The presence of low concentrations of monoclonal immunoglobulins (less than 0.2",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    in 8 of these 34 patients may have contributed to the misdiagnosis. A thorough family history and exclusion of these heritable disorders is important, since treatment for AL amyloidosis (eg, chemotherapy) has no role in the treatment of the hereditary disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35994?source=see_link\">",
"     \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     VARIABLE PENETRANCE AND LATE-ONSET HEREDITARY AMYLOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features, age at onset, and progression of disease may be uniform among members of the same kindred carrying specific amyloidogenic mutations. As an example, in a large kindred of persons with Finnish type of familial amyloidosis caused by a mutation in the gelsolin gene, early signs of corneal lattice dystrophy were apparent by the third or fourth decade of life. The characteristic facies, due to cranial neuropathy and cutis laxa, most apparent around the eyes, developed progressively in the fifth and sixth decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a uniform course is not universal. Rarely, individuals with an amyloidogenic mutation (homozygous or heterozygous) may remain relatively asymptomatic or may have late-onset or more severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/28,33,34,54,55\">",
"     28,33,34,54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variations in clinical manifestations of disease between different kindreds carrying the same mutations suggest an important role for modifier genes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    possibly environmental factors in disease expression. Thus, the TTR Met(30) substitution, which accounts for approximately 60 percent of cases of familial amyloidotic polyneuropathy due to TTR, may present at different ages or with varying clinical presentations when sampled among large groups of affected patients in Portugal, Sweden, or Japan. Haplotype analysis indicates multiple founders responsible for disease in different geographic areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/27,30\">",
"     27,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasional kindreds have been described in which the onset of neuropathy or cardiomyopathy associated with TTR mutations occurs late in life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/30,32,34,54\">",
"     30,32,34,54",
"    </a>",
"    ]. Of particular interest has been TTR Ile (122), associated with late onset senile amyloid cardiomyopathy, which is a common polymorphism virtually unique to the African-American population. It has been estimated that 3.9 percent of African-Americans (ie, 1.3 million people) are carriers for this variant TTR molecule and are, therefore, at risk for the development of cardiac amyloid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5026739\">",
"    <span class=\"h1\">",
"     GENETIC DETERMINANTS OF AA AMYLOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple genetic factors may influence the expression of AA amyloid, although it is defined as amyloidosis that is &ldquo;secondary&rdquo; to chronic inflammatory diseases. In early studies, the frequency of amyloid complicating disorders such as leprosy was noted to sometimes vary strikingly between leprosaria. Additionally, the frequency of AA amyloid complicating juvenile and adult rheumatoid arthritis (RA) and tuberculosis varied between populations. As an example, surveys indicated a higher incidence of AA amyloidosis among RA patients in Japan and Finland than in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased prevalence of AA amyloidosis in specific ethnic populations may reflect the significant (eg, up to 1:5 for specific pyrin mutations) carrier rate of genes predisposing to autoinflammatory diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/57\">",
"     57",
"    </a>",
"    ]. (See below.) These diseases may present as what has been termed &ldquo;phenotype 2,&rdquo; in which (usually) renal amyloid is found without any indication of symptoms of periodic fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/58\">",
"     58",
"    </a>",
"    ]. In a large database of patients with AA amyloidosis evaluated in the UK Amyloidosis referral center, approximately 9 percent were associated with known autoinflammatory disease, and approximately 6 percent were found to have &ldquo;idiopathic&rdquo; AA, occurring in the absence of any apparent underlying inflammatory disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/59\">",
"     59",
"    </a>",
"    ]. These observations may also have relevance to the greatly increased incidence of AA as a cause of renal amyloid in Turkey, where surveys have validated the prevalence of pyrin mutations, as well as autoinflammatory diseases such as familial Mediterranean fever (FMF) and Beh&ccedil;et&rsquo;s disease versus biopsy series from other countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AA forms by proteolysis from either one of two human acute-phase SAA proteins (SAA1 and SAA2), encoded by members of a gene family on chromosome 11. The SAA1 gene has five alleles (1.1 to 1.5), and the SAA2 gene has two (2.1 to 2.2), based on amino acid substitutions at positions 52, 57, and 60 of the molecule for SAA1 and at position 71 for SAA2. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30086?source=see_link\">",
"     \"Pathogenesis of secondary (AA) amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among Europeans, the incidence of AA amyloid appears to be increased in persons homozygous for the 1.1 allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/61\">",
"     61",
"    </a>",
"    ]. In contrast, the 1.1 allele appears to have an inhibitory effect on the development of AA amyloidosis in Japan and East Asia, where homozygosity of the 1.3 allele correlates positively with renal AA, and an additional single-nucleotide polymorphism at the 5' flanking region of SAA1 also confers increased risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/62\">",
"     62",
"    </a>",
"    ]. Studies from Turkey have shown that the 1.1 allele is a significant risk factor for AA amyloid complicating Beh&ccedil;et&rsquo;s disease, and an association between the SAA",
"    <span class=\"nowrap\">",
"     1-13T/C",
"    </span>",
"    polymorphism and amyloidosis in FMF patients has been found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Additional studies are necessary to reconcile these observations and to establish the significance of SAA polymorphisms as predictive risk factors for the development of AA amyloid.",
"   </p>",
"   <p>",
"    Genetic factors may have relevance to reports of a declining incidence of AA amyloidosis complicating RA in some populations (eg, Finland) and not others (eg, Japan), as well as varying incidences of subclinical versus clinical disease, and time to develop overt amyloid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     AA AMYLOID AND THE HEREDOFAMILIAL AMYLOIDOSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;AA amyloid complicates four hereditary diseases with varying frequencies: familial Mediterranean fever; the TRAPS syndrome, Muckle-Wells syndrome, and (rarely) hyperimmunoglobulinemia IgD with periodic fever syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15494?source=see_link\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Familial Mediterranean fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial Mediterranean fever (FMF) is characterized by recurrent febrile episodes associated with serositis and arthritis, typically lasting two to four days. Amyloid presents as nephropathy, which may follow a period of active disease (phenotype I) or which may be the presenting manifestation (phenotype II). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25078?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of familial Mediterranean fever\", section on 'Long-term complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32261?source=see_link\">",
"     \"Pathophysiology of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of amyloidosis in inadequately treated patients with FMF varies with the population group. It occurs in approximately 37 percent of Sephardic Jews, 21 percent of Iraqis, 8 percent of Turks, and 8 percent of Armenians but has not been seen among an American population of Armenian ancestry living in California; amyloidosis is rare in Ashkenazi Jews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/67\">",
"     67",
"    </a>",
"    ]. Similarly, among FMF patients living in Turkey, the disease score was much higher than that in Turkish FMF patients living in Germany [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FMF was historically thought to be transmitted as an autosomal recessive disease, and most affected individuals are indeed homozygous. However, the availability of genetic testing has also revealed disease in compound heterozygotes and in some heterozygous individuals, the latter usually presenting with milder disease of later onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The responsible molecule is pyrin, a neutrophil and mononuclear cell-specific protein that has an important role in regulation of apoptosis and inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/70\">",
"     70",
"    </a>",
"    ]. Pyrin is encoded by a single (MEFV) gene on chromosome 16p. Over 60 mutations (almost all missense mutations) have been identified associated with the FMF phenotype; however, five mutations (M680I, M694V, M694I, and V726A on exon 10, and E148Q on exon two) account for &gt;85 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32261?source=see_link\">",
"     \"Pathophysiology of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of specific pyrin mutations (eg, M694V, E148Q-V726A double mutation) correlates positively with the incidence and severity of disease and AA amyloid in some populations. M680 and M694 mutations are associated with early-onset of FMF, with more severe disease, and with an increased incidence of AA amyloidosis in all ethnic groups; homozygosity for the M694V mutation is significantly associated with phenotype II presentation of AA amyloidosis. Nevertheless, variability in expression of the same mutation between populations, and even within families, suggests a significant effect for environment and other genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/67\">",
"     67",
"    </a>",
"    ]. Several modifying genetic factors influence disease expression, including male sex, SAA1 polymorphisms, and major histocompatibility complex class 1-related gene A; by contrast, the development of AA amyloid appears to be more selectively influenced by MEFV genotype and SAA1 alleles",
"    <span class=\"nowrap\">",
"     (SAA1&alpha;/&alpha;)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/68,71\">",
"     68,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32261?source=see_link\">",
"     \"Pathophysiology of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     TRAPS syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor necrosis factor receptor-1 (TNFR1)-associated periodic syndrome (TRAPS), also referred to as Hibernian fever, produces recurrent febrile episodes lasting one or more weeks, serositis, myalgia, rash, and periorbital edema. Muscle and fascia may be inflamed. The disease is dominantly inherited, and the relevant gene (TNFR1) has been mapped to chromosome 12. Disease manifestations are responsive to treatment with the soluble TNF receptor-immunoglobulin heavy chain fusion protein,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28551?source=see_link\">",
"     \"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over 60 distinct disease-associated mutations of TNFR1 have been identified, some of which are functional polymorphisms. Dominantly inherited missense mutations in TNFR1 that cause TRAPS affect almost every cysteine residue within the first two cysteine-rich domains (CRD1 and CRD2) of the extracellular region of the protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/70\">",
"     70",
"    </a>",
"    ]. AA amyloid may complicate TRAPS with an estimated prevalence of 14 to 25 percent, with considerable variability between families. Mutations affecting cysteine residues are accompanied by a higher risk for amyloid than non-cysteine mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/66\">",
"     66",
"    </a>",
"    ]. Fourteen to 25 percent of patients with TRAPS develop AA amyloidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28551?source=see_link\">",
"     \"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Muckle-Wells syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Muckle-Wells syndrome (MWS) consists of periodic fever, urticaria, arthralgia, and deafness. It has a similar phenotype to the familial cold urticaria syndrome except for lack of cold sensitivity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=see_link&amp;anchor=H6#H6\">",
"     \"Cryopyrin-associated periodic syndromes and related disorders\", section on 'Muckle-Wells syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MWS is transmitted as an autosomal dominant trait. The disease is due to mutations in the cryopyrin gene (CIAS1) on chromosome 1q44 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/72\">",
"     72",
"    </a>",
"    ]. Mutations in this gene are also associated with the phenotypes of Neonatal Multisystem Inflammatory Disease",
"    <span class=\"nowrap\">",
"     (NOMID)/Chronic",
"    </span>",
"    Infantile Neurologic, Cutaneous, and Articular (CINCA) syndromes, Autosomal Dominant Periodic Fever Syndrome, and Familial Cold Autoinflammatory Syndrome (FCAS). Eleven mutations of C1AS1 have been associated with MWS, 39 with",
"    <span class=\"nowrap\">",
"     NOMID/CINCA,",
"    </span>",
"    11 with FCAS, and an additional four with more than one of these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/70\">",
"     70",
"    </a>",
"    ]. The incidence of AA amyloid has been reported to be approximately 25 percent in MWS, approximately 20 percent in",
"    <span class=\"nowrap\">",
"     CINCA/NOMID,",
"    </span>",
"    and approximately 2 percent in FCAS. Cryopyrinopathies are responsive to treatment with Interleukin-1 receptor antagonist (IL-1ra) and other IL-1&beta; antagonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=see_link&amp;anchor=H2#H2\">",
"     \"Cryopyrin-associated periodic syndromes and related disorders\", section on 'Cryopyrin-associated periodic syndromes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=see_link&amp;anchor=H8#H8\">",
"     \"Cryopyrin-associated periodic syndromes and related disorders\", section on 'Treatment of cryopyrinopathies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hyperimmunoglobulin D syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyper-IgD syndrome is a hereditary disease associated with mutations in the mevalonate kinase gene on chromosome 12 and may be rarely (2 to 4 percent) associated with AA amyloidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/74\">",
"     74",
"    </a>",
"    ]. Over 75 different mutations of mevalonate kinase have been associated with the HIDS phenotype; HIDS mutations are recessively inherited and often include one mild coupled with a severe mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15494?source=see_link&amp;anchor=H5#H5\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\", section on 'Hyper-IgD syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A resource for the tabulation of mutations associated with the periodic fever syndromes is",
"    <a class=\"external\" href=\"file://fmf.igh.cnrs.fr/ISSAID/infevers/\">",
"     file://fmf.igh.cnrs.fr/ISSAID/infevers/",
"    </a>",
"    (accessed February 7, 2011). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3768?source=see_link&amp;anchor=H9#H9\">",
"     \"Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis\", section on 'Other manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ALZHEIMER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous mutations have been found to affect the Alzheimer amyloid precursor protein (APP) gene and the presenilin genes. A resource for the tabulation of APP, PSEN1, and PSEN2 mutations associated with AD is",
"    <a class=\"external\" href=\"file://www.molgen.ua.ac.be/ADMutations\">",
"     www.molgen.ua.ac.be/ADMutations",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     APP gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Alzheimer amyloid precursor protein (APP) gene is located on chromosome 21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/75\">",
"     75",
"    </a>",
"    ]. Thirty-two mutations in this gene have been described in association with neurodegeneration. All pathogenic mutations so far have identified cluster around the three major processing sites of APP sequence that are relevant to the generation of the amyloidogenic A&szlig; sequence (ie, sites of cleavage by the alpha- [N-terminal], beta- [C-terminal], and gamma- [position 17 to 18 of the A&szlig; sequence] secretases).",
"   </p>",
"   <p>",
"    The Swedish double mutation at positions 670 to 673 is the only mutation close to the beta-secretase site, and several mutations occur at positions 713 to 723, near the gamma-secretase cleavage site. These mutations alter processing and lead to the accumulation (up to 18-fold) of A&szlig; peptides ending at position 42 rather than 40, which are longer and more fibrillogenic.",
"   </p>",
"   <p>",
"    The region comprising residues 21 to 23 of the A&beta; sequence is a &ldquo;hot spot&rdquo; in which six variants have been reported, all manifesting vascular disease significantly associated with cerebral amyloid angiopathy (CAA), hemorrhagic strokes, and dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/2\">",
"     2",
"    </a>",
"    ]. The Arctic mutation at position 22 renders APP less accessible to the alpha-secretase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/18\">",
"     18",
"    </a>",
"    ]. These vasculopathic mutations significantly influence fibrillogenesis and resistance to proteolytic digestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Presenilins and autosomal dominant early-onset AD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Missense mutations in the presenilin genes are the most common cause of autosomal dominant Alzheimer disease (AD), accounting for approximately 80 percent of cases of early-onset familial AD. One hundred eighty-five mutations in presenilin 1 (PS1), encoded by a single gene (PSEN1) on chromosome 14, and 13 mutations of presenilin 2 (PS2), on chromosome one (PSEN2), have been associated with familial AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Although broadly distributed through the coding sequence, most disease-associated PSEN1 mutations occur in the highly-conserved transmembrane domains of the molecule. Whereas PS1 mutations most often correlate with early-onset specific disease, PS2 mutations may be associated with a phenotype resembling sporadic AD as to onset and severity. Also, specific mutations of PS2 have also been correlated with differences in the phenotypic expression of amyloid angiopathy and in the level of Alzheimer beta protein (A&szlig;) sequence deposition in the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/2,79\">",
"     2,79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37001?source=see_link\">",
"     \"Cerebral amyloid angiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Presenilin is the catalytic subunit of the membrane gamma-secretase activity that is responsible for cleaving the A&szlig; peptide at its carboxyterminus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Apo E polymorphisms and late-onset AD",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that 60 to 80 percent of late-onset AD may also be genetically determined. The epsilon 4 (E4) allele of apolipoprotein E (apo E4) is overrepresented among patients with late-onset sporadic AD and is a significant dose-dependent risk factor (threefold risk with one allele, ninefold for two alleles); by contrast, the E2 allele may be protective against AD. Both candidate gene and genome wide association studies have been used to confirm the overrepresentation (approximately fourfold) of apo E polymorphisms and to identify a number of other genes (eg Clusterin, Complement receptor 1), which appear to confer low-level susceptibility to late-onset AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=see_link&amp;anchor=H4#H4\">",
"     \"Risk factors for dementia\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Bri2 gene-related Dementias-Two mutations in the Bri2 gene on chromosome 13 are responsible for an early-onset AD-like dementia, as well as features of GSS and CAA that have been described in British and Danish kindreds. Mutations (one a single nucleotide substitution and the other a 10 nucleotide insertion) occurring at or near the stop codon of the gene result in production of longer-than-normal protein products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/2\">",
"     2",
"    </a>",
"    ]. (See above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OCULAR AMYLOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis of the eye may be an organ-specific manifestation of a systemic disease or may be localized to this organ. Examples of the former include lattice dystrophy type II in familial amyloidosis, Finnish type, due to mutant gelsolin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/16,21,41\">",
"     16,21,41",
"    </a>",
"    ] and vitreous amyloidosis, which may be a prominent feature among some kindred associated with mutant TTR molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various phenotypes of corneal amyloidosis have been related to mutations of gelsolin in lattice corneal dystrophy, type 3, as seen in FAF (see above), to 21 mutations of the tumor-associated calcium signal transducer 2 (TACSTD2) gene in gelatinous drop dystrophy, and to &gt;40 mutations of a gene product variously called keratoepithelin, transforming growth factor beta-induced protein (TGFB1), or BIGH3 in lattice corneal type 1 and granular corneal dystrophies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/82-84\">",
"     82-84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5027229\">",
"    <span class=\"h1\">",
"     LOCALIZED AMYLOIDS ASSOCIATED WITH GENETIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic diseases manifesting organic-specific or localized amyloids include AD, prionoses, hereditary cerebral hemorrhage with amyloidosis (HCHWA) syndromes (cystatin C, Bri2), and the lattice corneal dystrophies. (See above.) Additional examples include amyloid due to calcitonin associated with medullary carcinoma of the thyroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/85\">",
"     85",
"    </a>",
"    ] and lichen amyloidosis, which has been reported to be due to galectin-7, associated with familial medullary carcinoma of the thyroid and multiple endocrine neoplasia syndrome 2A (MEN2A) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42153/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over 500 mutations and polymorphisms have been associated with heritable and acquired forms of amyloidosis, affecting genes for amyloid subunit proteins and their precursors, proteins affected in autoinflammatory diseases in which AA amyloid may occur, presenilins, and apolipoprotein E (",
"    <a class=\"graphic graphic_table graphicRef85771 \" href=\"mobipreview.htm?4/39/4733\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26879016\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amyloidosis is a generic term that refers to the extracellular tissue deposition of fibrils that are insoluble polymers comprised of low molecular weight subunit proteins. These subunits are derived from soluble precursors, which undergo conformational changes that lead to the adoption of a predominantly antiparallel beta-pleated sheet configuration. Some amyloid disorders appear to be entirely due to heritable abnormalities in precursor proteins, and the expression of acquired amyloidoses may be affected by genetically determined factors (",
"      <a class=\"graphic graphic_table graphicRef85771 \" href=\"mobipreview.htm?4/39/4733\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three types of genetic abnormalities have been identified in amyloidogenic proteins: polymorphisms; variant molecules (eg, due to missense mutations, deletions, and premature stop codons); and genetically determined posttranslational modifications. In addition, mutations in genes for non-amyloidogenic proteins can play a permissive role in amyloid development. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among the familial diseases associated with missense mutations, the point mutation that correlates with clinical disease usually occurs in the part of the precursor molecule that actually forms the fibril subunit protein; other precursor domains may be eliminated by metabolism or may be digested away prior to or after fibril formation. Subunit protein mutations associated with genetic amyloidoses may occur in genes for transthyretin, Alzheimer amyloid precursor protein, prion protein, gelsolin, apolipoprotein A-I (apo A-I), apo A-II, fibrinogen alpha chain, and cystatin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetic amyloidoses reflected in subunit protein mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical features, age at onset, and progression of disease may be uniform among members of the same kindred carrying specific amyloidogenic mutations. However, a uniform course is not universal. Rarely, individuals with an amyloidogenic mutation (homozygous or heterozygous) may remain relatively asymptomatic, may have late-onset disease, or may have more severe disease. Variations in clinical manifestations between different kindreds carrying the same mutations suggest an important role for modifier genes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      possibly environmental factors in disease expression. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Variable penetrance and late-onset hereditary amyloidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The frequency of AA (secondary) amyloid complicating disorders such as leprosy, juvenile and adult rheumatoid arthritis (RA), and tuberculosis varies considerably between populations. Additional studies are necessary to reconcile these observations and to establish the significance of SAA polymorphisms as predictive risk factors for the development of AA amyloid. (See",
"      <a class=\"local\" href=\"#H5026739\">",
"       'Genetic determinants of AA amyloidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AA amyloid complicates four hereditary diseases with varying frequencies: familial Mediterranean fever; the TRAPS syndrome, Muckle-Wells syndrome, and, rarely, hyperimmunoglobulinemia IgD syndrome. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'AA amyloid and the heredofamilial amyloidoses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More than 20 mutations in the Alzheimer amyloid precursor protein (APP) gene located on chromosome 21 have been described in association with neurodegeneration. All pathogenic mutations so far have identified cluster around the three major processing sites of APP sequence that are relevant to the generation of the amyloidogenic A&szlig; sequence. However, the severity of dementia does not correlate well with the amount of amyloid deposited in the brain, and other mechanisms of neurotoxicity of the variant APP gene products have been proposed. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'APP gene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Missense mutations in the presenilin genes are the most common cause of autosomal dominant Alzheimer disease (AD), accounting for approximately 50 percent of cases of early-onset familial AD. The epsilon 4 (E4) allele of apolipoprotein E (apo E4) is overrepresented among patients with late-onset sporadic AD and is a significant dose-dependent risk factor; by contrast, the E2 allele may be protective against AD. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Presenilins and autosomal dominant early-onset AD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Apo E polymorphisms and late-onset AD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amyloidosis of the eye may be an organ-specific manifestation of a systemic disease may be or localized to this organ. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Ocular amyloids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/1\">",
"      Sideras K, Gertz MA. Amyloidosis. Adv Clin Chem 2009; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/2\">",
"      Rostagno A, Holton JL, Lashley T, et al. Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. Cell Mol Life Sci 2010; 67:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/3\">",
"      Jahn TR, Makin OS, Morris KL, et al. The common architecture of cross-beta amyloid. J Mol Biol 2010; 395:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/4\">",
"      Picken MM. Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med 2010; 134:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/5\">",
"      Lavatelli F, Vrana JA. Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid 2011; 18:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/6\">",
"      Rochet JC, Lansbury PT Jr. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 2000; 10:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/7\">",
"      Chiti F, Dobson CM. Amyloid formation by globular proteins under native conditions. Nat Chem Biol 2009; 5:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/8\">",
"      Zhang X, Li JP. Heparan sulfate proteoglycans in amyloidosis. Prog Mol Biol Transl Sci 2010; 93:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/9\">",
"      Pepys MB. Amyloidosis. Annu Rev Med 2006; 57:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/10\">",
"      Dergunov AD. Role of ApoE in conformation-prone diseases and atherosclerosis. Biochemistry (Mosc) 2006; 71:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/11\">",
"      McLaurin J, Yang D, Yip CM, Fraser PE. Review: modulating factors in amyloid-beta fibril formation. J Struct Biol 2000; 130:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/12\">",
"      Thomas PK. Genetic factors in amyloidosis. J Med Genet 1975; 12:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/13\">",
"      Huff ME, Balch WE, Kelly JW. Pathological and functional amyloid formation orchestrated by the secretory pathway. Curr Opin Struct Biol 2003; 13:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/14\">",
"      Moraitakis G, Goodfellow JM. Simulations of human lysozyme: probing the conformations triggering amyloidosis. Biophys J 2003; 84:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/15\">",
"      Calero M, Pawlik M, Soto C, et al. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J Neurochem 2001; 77:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/16\">",
"      Maury CP, Nurmiaho-Lassila EL, Boysen G, Liljestr&ouml;m M. Fibrillogenesis in gelsolin-related familial amyloidosis. Amyloid 2003; 10 Suppl 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/17\">",
"      Levy E, Prelli F, Frangione B. Studies on the first described Alzheimer's disease amyloid beta mutant, the Dutch variant. J Alzheimers Dis 2006; 9:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/18\">",
"      Sahlin C, Lord A, Magnusson K, et al. The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. J Neurochem 2007; 101:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/19\">",
"      Yazaki M, Liepnieks JJ, Barats MS, et al. Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg. Kidney Int 2003; 64:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/20\">",
"      Ghiso J, Vidal R, Rostagno A, et al. A newly formed amyloidogenic fragment due to a stop codon mutation causes familial British dementia. Ann N Y Acad Sci 2000; 903:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/21\">",
"      Maury CP, Sletten K, Totty N, et al. Identification of the circulating amyloid precursor and other gelsolin metabolites in patients with G654A mutation in the gelsolin gene (Finnish familial amyloidosis): pathogenetic and diagnostic implications. Lab Invest 1997; 77:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/22\">",
"      Nepomuceno AI, Mason CJ, Muddiman DC, et al. Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization fourier-transform ion-cyclotron-resonance mass spectrometry. Clin Chem 2004; 50:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/23\">",
"      Altland K, Benson MD, Costello CE, et al. Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis 2007; 28:2053.",
"     </a>",
"    </li>",
"    <li>",
"     Benson MD. The hereditary amyloidoses. In: Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations, Springer, 2012. p.53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/25\">",
"      Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003; 10:160.",
"     </a>",
"    </li>",
"    <li>",
"     Sekijima, Y, Yoshida, K, Tokuda, T, Ikeda, S. Familial Transthyretin Amyloidosis. In: Gene Reviews, Pagon, RA, Bird, TC, Dolan, CR, Stephens, K (Eds), University of Washington, Seattle 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/27\">",
"      Zaros C, Genin E, Hellman U, et al. On the origin of the transthyretin Val30Met familial amyloid polyneuropathy. Ann Hum Genet 2008; 72:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/28\">",
"      Holmgren G, Hellman U, Lundgren HE, et al. Impact of homozygosity for an amyloidogenic transthyretin mutation on phenotype and long term outcome. J Med Genet 2005; 42:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/29\">",
"      Kato-Motozaki Y, Ono K, Shima K, et al. Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus. J Neurol Sci 2008; 270:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/30\">",
"      Hellman U, Alarcon F, Lundgren HE, et al. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008; 15:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/31\">",
"      Olsson M, Norgren N, Obayashi K, et al. A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers. BMC Med Genet 2010; 11:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/32\">",
"      Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997; 336:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/33\">",
"      Augustin S, Llige D, Andreu A, et al. Familial amyloidosis in a large Spanish kindred resulting from a D38V mutation in the transthyretin gene. Eur J Clin Invest 2007; 37:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/34\">",
"      Kristen AV, Ehlermann P, Helmke B, et al. Transthyretin valine-94-alanine, a novel variant associated with late-onset systemic amyloidosis with cardiac involvement. Amyloid 2007; 14:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/35\">",
"      Liepnieks JJ, Dickson DW, Benson MD. A new transthyretin mutation associated with leptomeningeal amyloidosis. Amyloid 2011; 18 Suppl 1:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/36\">",
"      Mastrianni JA. The genetics of prion diseases. Genet Med 2010; 12:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/37\">",
"      Hsiao K, Baker HF, Crow TJ, et al. Linkage of a prion protein missense variant to Gerstmann-Str&auml;ussler syndrome. Nature 1989; 338:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/38\">",
"      Liberski PP. Gerstmann-Str&auml;ussler-Scheinker disease. Adv Exp Med Biol 2012; 724:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/39\">",
"      Medori R, Tritschler HJ, LeBlanc A, et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med 1992; 326:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/40\">",
"      Gambetti P, Parchi P, Chen SG. Hereditary Creutzfeldt-Jakob disease and fatal familial insomnia. Clin Lab Med 2003; 23:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/41\">",
"      Kiuru S. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid 1998; 5:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/42\">",
"      Obici L, Palladini G, Giorgetti S, et al. Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology 2004; 126:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/43\">",
"      Rowczenio D, Dogan A, Theis JD, et al. Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol 2011; 179:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/44\">",
"      Magy N, Liepnieks JJ, Yazaki M, et al. Renal transplantation for apolipoprotein AII amyloidosis. Amyloid 2003; 10:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/45\">",
"      Benson MD. Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid 2005; 12:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/46\">",
"      R&ouml;cken C, Becker K, F&auml;ndrich M, et al. ALys amyloidosis caused by compound heterozygosity in exon 2 (Thr70Asn) and exon 4 (Trp112Arg) of the lysozyme gene. Hum Mutat 2006; 27:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/47\">",
"      Sattianayagam PT, Gibbs SD, Rowczenio D, et al. Hereditary lysozyme amyloidosis -- phenotypic heterogeneity and the role of solid organ transplantation. J Intern Med 2012; 272:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/48\">",
"      Gillmore JD, Lachmann HJ, Wechalekar A, Hawkins PN. Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation. Blood 2010; 115:4313; author reply 4314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/49\">",
"      Mousson C, Heyd B, Justrabo E, et al. Successful hepatorenal transplantation in hereditary amyloidosis caused by a frame-shift mutation in fibrinogen Aalpha-chain gene. Am J Transplant 2006; 6:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/50\">",
"      Palsdottir A, Snorradottir AO, Thorsteinsson L. Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects. Brain Pathol 2006; 16:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/51\">",
"      Valleix S, Gillmore JD, Bridoux F, et al. Hereditary systemic amyloidosis due to Asp76Asn variant &beta;2-microglobulin. N Engl J Med 2012; 366:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/52\">",
"      Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002; 346:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/53\">",
"      Comenzo RL, Zhou P, Fleisher M, et al. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006; 107:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/54\">",
"      Sequeiros J, Saraiva MJ. Onset in the seventh decade and lack of symptoms in heterozygotes for the TTRMet30 mutation in hereditary amyloid neuropathy-type I (Portuguese, Andrade). Am J Med Genet 1987; 27:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/55\">",
"      Koike H, Sobue G. Late-onset familial amyloid polyneuropathy in Japan. Amyloid 2012; 19 Suppl 1:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/56\">",
"      Obici L, Raimondi S, Lavatelli F, et al. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009; 61:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/57\">",
"      Papadopoulos VP, Giaglis S, Mitroulis I, Ritis K. The population genetics of familial mediterranean fever: a meta-analysis study. Ann Hum Genet 2008; 72:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/58\">",
"      Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005; 84:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/59\">",
"      Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/60\">",
"      Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007; 56:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/61\">",
"      Booth DR, Booth SE, Gillmore JD, et al. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 1998; 5:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/62\">",
"      Ajiro J, Narita I, Sato F, et al. SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2006; 16:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/63\">",
"      Utku U, Dilek M, Akpolat I, et al. SAA1 alpha/alpha alleles in Beh&ccedil;et's disease related amyloidosis. Clin Rheumatol 2007; 26:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/64\">",
"      Akar N, Hasipek M, Ozt&uuml;rk A, et al. Serum amyloid A1 -13 T/C alleles in Turkish familial Mediterranean fever patients with and without amyloidosis. J Nephrol 2006; 19:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/65\">",
"      Pettersson T, Konttinen YT. Amyloidosis-recent developments. Semin Arthritis Rheum 2010; 39:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/66\">",
"      van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/67\">",
"      Pras M. Amyloidosis of familial mediterranean fever and the MEFV gene. Amyloid 2000; 7:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/68\">",
"      Ozen S, Aktay N, Lainka E, et al. Disease severity in children and adolescents with familial Mediterranean fever: a comparative study to explore environmental effects on a monogenic disease. Ann Rheum Dis 2009; 68:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/69\">",
"      Marek-Yagel D, Berkun Y, Padeh S, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum 2009; 60:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/70\">",
"      Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol 2009; 27:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/71\">",
"      Medlej-Hashim M, Delague V, Chouery E, et al. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet 2004; 5:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/72\">",
"      Kubota T, Koike R. Cryopyrin-associated periodic syndromes: background and therapeutics. Mod Rheumatol 2010; 20:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/73\">",
"      Toker O, Hashkes PJ. Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). Biologics 2010; 4:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/74\">",
"      Obici L, Manno C, Muda AO, et al. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2004; 50:2966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/75\">",
"      Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/76\">",
"      Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 2003; 361:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/77\">",
"      Lle&oacute; A, Berezovska O, Growdon JH, Hyman BT. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry 2004; 12:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/78\">",
"      Ryan NS, Rossor MN. Correlating familial Alzheimer's disease gene mutations with clinical phenotype. Biomark Med 2010; 4:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/79\">",
"      Mann DM, Pickering-Brown SM, Takeuchi A, et al. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am J Pathol 2001; 158:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/80\">",
"      De Strooper B, Annaert W. Novel research horizons for presenilins and &gamma;-secretases in cell biology and disease. Annu Rev Cell Dev Biol 2010; 26:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/81\">",
"      Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010; 68:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/82\">",
"      Klintworth GK. Corneal dystrophies. Orphanet J Rare Dis 2009; 4:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/83\">",
"      Kawasaki S, Kinoshita S. Clinical and basic aspects of gelatinous drop-like corneal dystrophy. Dev Ophthalmol 2011; 48:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/84\">",
"      Niel-Butschi F, Kantelip B, Iwaszkiewicz J, et al. Genotype-phenotype correlations of TGFBI p.Leu509Pro, p.Leu509Arg, p.Val613Gly, and the allelic association of p.Met502Val-p.Arg555Gln mutations. Mol Vis 2011; 17:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/85\">",
"      Khurana R, Agarwal A, Bajpai VK, et al. Unraveling the amyloid associated with human medullary thyroid carcinoma. Endocrinology 2004; 145:5465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/86\">",
"      Verga U, Fugazzola L, Cambiaghi S, et al. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol (Oxf) 2003; 59:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42153/abstract/87\">",
"      Westermark P, Murphy C, Eulitz M, et al. Galectin 7-associated cutaneous amyloidosis. Amyloid 2010; 17(Suppl 1):71.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5590 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42153=[""].join("\n");
var outline_f41_10_42153=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26879016\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETIC AMYLOIDOSES REFLECTED IN SUBUNIT PROTEIN MUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transthyretin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alzheimer amyloid precursor protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prion protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gelsolin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Apolipoprotein A-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Apolipoprotein A-II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lysozyme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fibrinogen A&alpha;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cystatin C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2895908\">",
"      Beta-2 microglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Confusion with AL amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      VARIABLE PENETRANCE AND LATE-ONSET HEREDITARY AMYLOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5026739\">",
"      GENETIC DETERMINANTS OF AA AMYLOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      AA AMYLOID AND THE HEREDOFAMILIAL AMYLOIDOSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TRAPS syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Muckle-Wells syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hyperimmunoglobulin D syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ALZHEIMER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      APP gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Presenilins and autosomal dominant early-onset AD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Apo E polymorphisms and late-onset AD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OCULAR AMYLOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5027229\">",
"      LOCALIZED AMYLOIDS ASSOCIATED WITH GENETIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26879016\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5590\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5590|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/25/33177\" title=\"picture 1A\">",
"      Amyloid light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/17/38162\" title=\"picture 1B\">",
"      Congo red amyloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/58/22441\" title=\"picture 1C\">",
"      Amyloid EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/29/36306\" title=\"picture 1D\">",
"      Amyloid AA IF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5590|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/1/4125\" title=\"table 1A\">",
"      Amyloid precursor proteins I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/9/10397\" title=\"table 1B\">",
"      Amyloid precursor proteins II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/39/4733\" title=\"table 2\">",
"      Amyloid mutations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7017?source=related_link\">",
"      Biology and genetics of prions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37001?source=related_link\">",
"      Cerebral amyloid angiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/28/31176?source=related_link\">",
"      Diseases of the central nervous system caused by prions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3768?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32261?source=related_link\">",
"      Pathophysiology of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35994?source=related_link\">",
"      Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28551?source=related_link\">",
"      Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_10_42154="Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis";
var content_f41_10_42154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/10/42154/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/10/42154/contributors\">",
"     Scott Sanoff, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/10/42154/contributors\">",
"     Mark D Okusa, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/10/42154/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/10/42154/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/10/42154/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/10/42154/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/10/42154/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renal failure phase in patients with postischemic (also called ischemic) acute tubular necrosis (ATN) typically lasts 7 to 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/1\">",
"     1",
"    </a>",
"    ], with most patients returning to or near their previous baseline level of renal function as the necrotic tubular cells regenerate. Regenerating tubular cells appear to be mostly derived from dedifferentiated cells (kidney-derived stem cells) that have survived the ischemic insult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Migrating bone marrow stem cells may contribute to this process but to a lesser extent.",
"   </p>",
"   <p>",
"    The following provides an overview of the different phases of ATN due to ischemia (",
"    <a class=\"graphic graphic_figure graphicRef67719 \" href=\"mobipreview.htm?26/53/27487\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiation phase &mdash; Postischemic ATN begins with an early phase of vasomotor nephropathy in which there are associated alterations in vascular reactivity and renal perfusion. These changes lead to cellular ATP depletion and oxidative injury.",
"     </li>",
"     <li>",
"      Extension phase &mdash; The changes in the initiation phase lead to activation of resident cells, such as dendritic cells, macrophages, endothelial cells and renal epithelial cells, leading to a pro-inflammatory state. Inflammatory cells adhere to activated endothelium in the peritubular capillaries of the outer medulla; this results in medullary congestion and further hypoxic injury to the S3 segment of the proximal tubule. Elaboration of inflammatory mediators leads to additional cellular injury.",
"     </li>",
"     <li>",
"      Maintenance phase &mdash; Restoration of tubule cells is accomplished via several potential mechanisms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Adjacent tubule cells redifferentiate and proliferate",
"     </li>",
"     <li>",
"      Kidney stem cells differentiate into tubule cells",
"     </li>",
"     <li>",
"      Hematopoietic cells engraft into areas of injury and differentiate into tubule cells or fuse with damaged cells, restoring vital cellular components necessary for cell survival",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repair phase &mdash; Polarity and function are ultimately reconstituted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible preventive and therapeutic measures for postischemic ATN will be reviewed here, considering experimental animal trials separately from human clinical trials. Pathogenesis and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4553?source=see_link\">",
"     \"Renal and patient outcomes after acute tubular necrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Except for a few isolated studies, the vast majority of animal studies have yet to conclusively demonstrate the benefit of pharmacological therapy in the prevention or treatment of postischemic ATN. Further, the applicability of animal studies to the prevention of post-ischemic ATN in humans is unproven. Attempts have been made to preserve renal function through the following general mechanisms: preserving cell viability, preventing or reversing intratubular obstruction, attenuating immunity and inflammation, and enhancing cell repair processes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a review of the many compounds",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    strategies for prevention that have been evaluated in animal models of ischemic ATN.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diuretics &mdash; In experimental models of acute kidney injury (AKI), loop diuretics and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      minimize the degree of renal injury and dysfunction if given at the time of the ischemic insult [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. These agents may have a variety of beneficial effects:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Both can induce a diuresis, potentially washing out obstructing cellular debris and casts.",
"     </li>",
"     <li>",
"      Loop diuretics diminish active NaCl transport in the thick ascending limb of the loop of Henle; the ensuing decrease in energy requirement (by as much as 45 percent) protects the cell in the face of a decrease in energy delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/7\">",
"       7",
"      </a>",
"      ]. The terminal (S3) segment of the proximal tubule, which ends in the outer medulla, may also be protected in this setting, since the decrease in loop transport increases oxygen availability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/8\">",
"       8",
"      </a>",
"      ]. This form of tubular protection appears to occur in vivo. In the presence of renal ischemia, the cells of the medullary thick ascending limb release several compounds &mdash; nonprostaglandin arachidonic acid metabolites and adenosine, a breakdown product of ATP &mdash; that inhibit local NaCl reabsorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       Mannitol",
"      </a>",
"      may preserve mitochondrial function by osmotically minimizing the degree of postischemic cell swelling or by scavenging free radicals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/6,10\">",
"       6,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       Dopamine",
"      </a>",
"      and ANP &mdash; Dopamine or atrial natriuretic peptide (ANP) alone appear to be without benefit, despite their ability to increase both renal blood flow and sodium excretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Despite the effect of dopamine to increase outer medullary blood flow in animals by 35 percent, it does not increase medullary pO2, an important measure of tissue oxygen delivery during ischemia-reperfusion injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/13\">",
"       13",
"      </a>",
"      ]. This may be one explanation for the lack of effectiveness of dopamine in human ATN. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Dopamine'",
"      </a>",
"      below.) In contrast, renal function can be preserved if: (1) ANP or urodilatin (a related peptide apparently produced within the kidney) is given either with dopamine (to prevent hypotension) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/14,15\">",
"       14,15",
"      </a>",
"      ] or with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      (to wash out obstructing casts) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/16\">",
"       16",
"      </a>",
"      ]; or (2) calcium channel blockers are administered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      ANP and urodilatin act in part by increasing the glomerular filtration rate (via changes in arteriolar resistance) and they may also be associated with a lesser degree of tubular necrosis and intratubular cast formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/11\">",
"       11",
"      </a>",
"      ]. The effects of dopamine in this setting are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/25/44435?source=see_link&amp;anchor=H6#H6\">",
"       \"Renal actions of dopamine\", section on 'Clinical utility'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link&amp;anchor=H48#H48\">",
"       \"Natriuretic peptide measurement in heart failure\", section on 'Atrial natriuretic peptide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35284?source=see_link\">",
"       Fenoldopam",
"      </a>",
"      mesylate &mdash; Fenoldopam is a potent dopaminergic agonist that exerts its pharmacological effects through",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      A-1 (DA-1) receptors without alpha- or beta- adrenergic effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. The use of fenoldopam is based upon experimental studies that demonstrate the ability of this drug to maintain renal blood flow and kidney tissue oxygenation:",
"      <br/>",
"      <br/>",
"      - In a rat model of ischemia-reperfusion, fenoldopam increased renal blood flow, renal cortical perfusion pressure, and corticomedullary tissue oxygen tension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/20\">",
"       20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      - In dogs, fenoldopam maintained renal blood flow, glomerular filtration rate and natriuresis in response to hypovolemic shock or following aortic cross-clamping [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The mechanism by which fenoldopam induces renal vasodilation is through its effect on dilating afferent and efferent arterioles with no apparent change in glomerular filtration rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Amino acids &mdash; In vitro studies suggested that the neutral amino acids glycine and, to a lesser degree, alanine (but not other amino acids) protected renal tubular cells against ischemic injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/24\">",
"       24",
"      </a>",
"      ]. However, the experimental technique induced the artifact of intracellular glycine depletion, which was corrected by the administration of glycine. No benefit of glycine has been found in in vivo models of postischemic AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Antiapoptotic/necrosis",
"      </span>",
"      agents &mdash; Nonselective and selective caspase inhibitors are effective in attenuating renal injury in ischemia- or endotoxemia-induced AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]:",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      is known to have anti-apoptotic and anti-inflammatory effects. It also reduces kidney inflammation and microvascular permeability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/29\">",
"       29",
"      </a>",
"      ], and has been associated with improved renal function in models of ischemic injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Guanosine reduced renal tubular cell apoptosis, an effect associated with inhibition of p53 expression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pifithrin-alpha, a novel p53 inhibitor, decreased tubule cell apoptosis and preserved renal function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/32\">",
"       32",
"      </a>",
"      ]. The importance of p53 in AKI was also suggested by a dose- and time-dependent attenuation of apoptosis and renal injury following the infusion of p53 siRNA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Poly ADP-ribose polymerase (PARP) is a nuclear enzyme that participates in DNA repair; however, excessive activation of PARP from cellular injury leads to intracellular NAD+, and ATP depletion, ultimately resulting in cell death. A water-soluble and potent PARP inhibitor, 5-aminoisoquinolinone (5-AIQ) may play a role in minimizing ischemia-reperfusion injury to kidney [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Free radical scavengers &mdash; The iron chelator,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      , is a well-known free radical scavenger. Deferoxamine has demonstrated a marked protective effect in different models of AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/35-38\">",
"       35-38",
"      </a>",
"      ]. Pyruvate is known as a potent endogenous antioxidant and free radical scavenger. Its derivative, ethyl pyruvate, reduced kidney injury in a cecal ligation puncture model of sepsis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/24\">",
"       24",
"      </a>",
"      ]. A mitochondrial-targeted tetrapeptide (SS31) that scavenges radical oxygen species and inhibits mitochondrial injury, reduces tubular injury in animal models of renal ischemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Growth factors &mdash; Exogenously administered erythropoietin before or at the time of reperfusion reduced kidney injury by decreasing tubular necrosis and apoptosis and enhancing tubular proliferation in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -induced AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/40-43\">",
"       40-43",
"      </a>",
"      ]. Erythropoietin also mediated mobilization and proliferation of endothelial progenitor cells (EPCs) from the bone marrow, which has been shown to participate in tissue repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Hepatocyte growth factor (HGF) can promote cell growth, motility and morphogenesis of various types of cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. Exogenous administration of HGF reduced apoptosis and acute renal injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/48\">",
"       48",
"      </a>",
"      ]. Similar results have been observed with insulin-like growth factor 1 (IGF-1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vasodilators &mdash; Endothelin-1 (ET-1), a potent vasoconstrictor, has been implicated in animal models of postischemic ATN or radiocontrast nephropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. ET-1 mediates its biological effects by binding to ETA or ETB receptors. Tezosentan, a dual ET-1 receptor antagonist, attenuated renal injury even when administered after ischemia in a rat model [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heme oxygenases (HOs) catalyze the rate-limiting step in degrading heme to form iron, carbon monoxide, and biliverdin. Biliverdin is converted to bilirubin by biliverdin reductase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/53\">",
"       53",
"      </a>",
"      ]. There are two major forms of HO, an inducible isoform, HO-1, and a constantly expressed isoform, HO-2. HO activation may provide protection via the enhanced production of carbon monoxide (CO) and the potent antioxidant bilirubin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. HO may reduce injury through its potent effect to induce vasodilation. The mechanism(s) responsible for HO induced vasodilation include CO activation of big-conductance KCa channels (BKCa) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/55\">",
"       55",
"      </a>",
"      ], or other ion channels,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nitric oxide dependent mechanisms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In ischemia",
"      <strong>",
"       -",
"      </strong>",
"      induced injury, the administration of CO donor compounds decreases the levels of plasma creatinine 24 hours after reperfusion as compared with vehicle-treated mice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bilirubin also reduces kidney reperfusion injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a rat model of renal ischemia, administration of the phosphodiesterase inhibitor,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"       milrinone",
"      </a>",
"      , was associated with a smaller rise in serum creatinine and less histologic evidence of tubular injury compared with control animals, possibly as a result of improved renal blood flow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-inflammatory drugs &mdash; A maladaptive immune response or inflammation has been recognized as an early event in post-ischemic ATN. Inflammatory cells, including polymorphonuclear cells, monocytes, macrophages and T cells, have received considerable attention as important contributors to ischemic AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/60-62\">",
"       60-62",
"      </a>",
"      ]. Several new compounds appear to be effective in reducing injury for ischemia-reperfusion through direct action on leukocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies suggest that the administration of anti-inflammatory mediators may prove effective in preventing or ameliorating ATN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of anti-ICAM-1 antibodies and synthetic RGD peptides (arginine-glycine-aspartic acid) that inhibit integrins have been found to lessen experimental ATN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/63-65\">",
"       63-65",
"      </a>",
"      ]. The RGD peptides are thought to act by diminishing intratubular obstruction via inhibition of cell-cell adhesion in the tubular lumen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/63,64\">",
"       63,64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The utility of the intravenous administration of alpha-melanocyte-stimulating hormone (an antiinflammatory neuropeptide) or its analog (AP214) was evaluated in murine and rat models of ATN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/66\">",
"       66",
"      </a>",
"      ]. Compared to placebo, active therapy prevented histologic damage and renal dysfunction, and remained effective even when administered six hours after induction of ischemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/66\">",
"       66",
"      </a>",
"      ] or sepsis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/67\">",
"       67",
"      </a>",
"      ]. This benefit was associated with inhibition of the induction of interleukin-8, intercellular adhesion molecule-1, and nitric oxide synthase. Both in vivo and in vitro studies point toward the important role of inducible nitric oxide synthase (iNOS) in mediating injury to proximal tubules, suggesting that iNOS inhibitors may be helpful [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adenosine binds to members of the G-protein coupled receptor family that includes four subtypes: A1, A2A, A2B, and A3R. Selective A2AR receptor agonists reduce kidney injury by 70 to 80 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/60,69-71\">",
"       60,69-71",
"      </a>",
"      ]. Dose-dependent studies in mice indicate that protection is due to reduced neutrophil",
"      <span class=\"nowrap\">",
"       adherence/recruitment",
"      </span>",
"      and release of reactive oxygen species and is independent of any change in systemic hemodynamic parameters [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sphingosine 1 phosphate (S1P) is a specific ligand for a family of G protein coupled endothelial differentiation gene (Edg) receptors (also referred to as S1PRs 1-5) that evoke diverse cellular signaling responses. An S1P analog, FTY720, leads to sequestration of lymphocytes in secondary lymphatic tissue and to direct epithelial cell cytoprotection to reduce injury from reperfusion injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/72-75\">",
"       72-75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peroxisome proliferator-activated receptors (PPARs) are transcription factors that regulate glucose and lipid metabolism. Pretreatment of animals with fibrates (PPARa ligand) ameliorated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      induced renal dysfunction. This was accompanied by suppression of NF-kB activation,",
"      <span class=\"nowrap\">",
"       cytokine/chemokine",
"      </span>",
"      expression and neutrophil infiltration, suggesting that the protective effect of fibrates is mediated through its anti-inflammatory effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/76\">",
"       76",
"      </a>",
"      ]. Infusion of bardoxolone methyl (BARD) appears to upregulate PPAR&gamma;, and has been shown to mitigate ischemic tubular injury in animal models [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      AKI was ameliorated by statins in a murine model of sepsis. Compared to mice treated with saline, simvastatin-treated mice had significantly less systemic anti-inflammatory effect, lower serum creatinine concentration and tubular damage scores, less tubular hypoxia, and less impaired intrarenal microcirculation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/78\">",
"       78",
"      </a>",
"      ]. A retrospective study has also suggested a benefit of statins in preventing AKI in patients undergoing elective surgery. (See",
"      <a class=\"local\" href=\"#H1884600\">",
"       'Statins'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Thrombomodulin and endothelial protein C receptors activate protein C and promote anticoagulation. Soluble thrombomodulin, independent of its ability to generate activated protein C reduced kidney ischemia reperfusion injury by improving microvascular flow dynamics, reducing endothelial leukocyte adhesion, and minimizing endothelial permeability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/79\">",
"       79",
"      </a>",
"      ]. APC has direct anti-inflammatory and anti-apoptotic activities and stabilizes endothelial barrier function via EPCRs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alkaline phosphatase is expressed abundantly in kidney tissue and in other cells and organs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]. In experimental studies alkaline phosphatase attenuated inflammation induced by sepsis and reduced mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/83-87\">",
"       83-87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Measures aimed at promoting bone marrow stem cell migration may help limit damage by promoting tubular cell regeneration. As demonstrated in a mouse model, adult bone marrow cells migrate to injured renal tubules, and differentiate into renal tubular epithelial cells to repopulate ischemia-damaged renal tubules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]. Experimental ATN has also been attenuated by the infusion of stem cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/88,90\">",
"       88,90",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, there is controversy concerning the capacity of these cells to repopulate the renal tubule [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/91\">",
"       91",
"      </a>",
"      ]. Studies demonstrate that tubule repair is through dedifferentiation (differentiation of adjacent cells) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/2,3\">",
"       2,3",
"      </a>",
"      ] or through kidney derived stem cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/4\">",
"       4",
"      </a>",
"      ]. In one study that used genetic fate-mapping techniques to label epithelial cells, tubular epithelial cells that survived ischemia-reperfusion injury were shown to proliferate and repopulate the tubule, providing strong evidence that the predominant mechanism of repair after ischemic tubular injury in the adult mammalian kidney is through proliferation of adjacent surviving epithelial cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/92\">",
"       92",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Several studies suggested that the reduction of injury observed with infusion of mesenchymal cells was due to paracrine effects of growth factors and cytokines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/93-95\">",
"       93-95",
"      </a>",
"      ]. A more recent study demonstrated that microvesicles derived from bone marrow mesenchymal stem cells accelerated recovery from glycerol-induced AKI by inducing tubule cell proliferation, an effect that was abolished by RNase.",
"      <br/>",
"      <br/>",
"      Microarray analysis determined that microvesicles shuttle mRNA associated with control of transcription, proliferation and immunoregulation. These results suggest that mesenchyme stem cells transfer via microvesicles mRNA that activate genes involved in proliferation and cell survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adipose tissue-derived stem cells have been used in the prevention of ischemic ATN. In a rat model of ischemia reperfusion injury, animals receiving stem cells intravenously at the time of reperfusion demonstrated less tubular injury, and down regulated inflammatory-related gene expression, including CXCL2 and IL-6 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antioxidants have been evaluated in postischemic ATN based upon the presumed role of reactive oxygen species in the generation of tubular injury. However, conflicting results have been obtained, perhaps due in part to the antiproliferative effect of these agents, which might slow tubular regeneration and mask any potential beneficial activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glucocorticoid administration during ischemia or with reperfusion reduces injury to proximal tubule cells by a mechanism independent of known anti-inflammatory effects or downstream transcription, appearing to be directly cytoprotective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other compounds &mdash; Neutrophil gelatinase-associated lipocalin, IL-6 and C5a antagonists, IL-10 and ghrelin (a compound with a growth hormone releasing effect) are other potential compounds that have multiple mechanisms of tissue protection and maybe beneficial in human ATN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/40-42,48,49,100-103\">",
"       40-42,48,49,100-103",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16758?source=see_link\">",
"       \"Ghrelin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ischemic preconditioning has been associated with less ischemic injury in the early phase of transplant reperfusion, with improved early function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/104,105\">",
"       104,105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Blockade of multiple signaling pathways involved in the inflammatory response have been shown the blunt ischemic injury to the kidneys. Fibroblast growth factor-inducible 14 (Fn14), a TWEAK receptor, has been found to be up-regulated in ischemic renal tissue. In an animal model of ischemia reperfusion injury, blockade of Fn14 reduced production of proinflammatory cytokines after injury, as well as the accumulation of inflammatory cells, tubular apoptosis, and development of chronic fibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/106\">",
"       106",
"      </a>",
"      ]. Similarly, blockade of high-mobility group box 1 (HMGB1) binding of toll-like receptor 4 (TLR4), reduces ischemic tubular injury in rodents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/107,108\">",
"       107,108",
"      </a>",
"      ]. Further, siRNA targeting NF-kB inflammatory pathway prevents ischemia reperfusion injury in rats [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental studies suggest that it may be possible to accelerate the rate of tubular regeneration and functional recovery in established post-ischemic ATN. These include the administration of growth factors or the combination of atrial natriuretic peptide and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth factors &mdash; Tubular recovery following ischemic injury is associated with the activation of growth response genes and the release of growth factors required for cell regeneration including insulin-like growth factor-I (IGF-I), epidermal growth factor (EGF), and hepatocyte growth factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/110-113\">",
"       110-113",
"      </a>",
"      ]. The recovery process involves two basic steps: tubular cell regeneration and differentiation into mature, functioning cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/112\">",
"       112",
"      </a>",
"      ]. In addition to growth factors, attachment of new cells to the extracellular matrix plays an important role in cell differentiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/112\">",
"       112",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      These observations may have potential utility. Although neither IGF-I nor EGF expression appears to be increased in the kidney during the recovery phase from experimental aminoglycoside-induced ATN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/114\">",
"       114",
"      </a>",
"      ], the exogenous administration of these growth factors can accelerate both tubular regeneration and the recovery of renal function in both postischemic and nephrotoxic AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/49,115-118\">",
"       49,115-118",
"      </a>",
"      ]. As an example, rats with postischemic ATN which were treated with IGF-1 had, when compared to a placebo-treated group, a lower peak plasma creatinine concentration (1.8 versus 3.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [158 versus 308",
"      <span class=\"nowrap\">",
"       micromol/L]),",
"      </span>",
"      a lower histologic score of tubular injury at day 7 (0.90 versus 2.35), and more complete recovery of glomerular filtration at day 7 (plasma creatinine concentration 0.6 versus 1.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [53 versus 97",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/49\">",
"       49",
"      </a>",
"      ]. IGF-I also decreases protein breakdown, a potentially important effect in patients with AKI who are often hypercatabolic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/117\">",
"       117",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although most of the above studies administered the growth factor before or soon after the ischemic episode, treatment delayed for 24 hours (which is more analogous to human disease) is still beneficial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/118\">",
"       118",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The administration of thyroid hormone has also appeared to enhance recovery of renal function in a number of animal models of AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/119,120\">",
"       119,120",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ANP plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      &mdash; In animal models, atrial natriuretic peptide (ANP) given with dopamine to prevent systemic hypotension can minimize the degree of renal failure if given concurrent with the ischemic insult [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BARRIERS TO CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The applicability of animal studies to the prevention of post-ischemic ATN in humans is unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. Several barriers to successful clinical trials persist. These include heterogeneous and complex patient factors (eg, co-morbidities and concurrent multi-organ failure in critically ill patients), lack of a standardized definition of and diagnostic criteria for post-ischemic ATN, and the lack of clear and specific endpoints for clinical trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AKI is characterized by a changing spectrum of illnesses with significant and extrarenal complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/124,125\">",
"       124,125",
"      </a>",
"      ]. These comorbid conditions are likely contributors to failed treatment regimens, particularly when mortality is used as an end point for the clinical trial.",
"     </li>",
"     <li>",
"      AKI is a multisystem disease and, in most studies, renal failure itself is not usually the cause of death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/126\">",
"       126",
"      </a>",
"      ]. In several studies, either heart failure or noncardiogenic acute respiratory distress syndrome was associated with AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/127-129\">",
"       127-129",
"      </a>",
"      ]. The potential systemic effects of AKI involve multiple organs, thereby leading to a high mortality.",
"     </li>",
"     <li>",
"      The lack of success of clinical trials of AKI is frequently due, in part, to low statistical power, lack of a consensus definition in previous trials, improper end points, difficulty in timely administration of the drug, adverse effects of the drug, and patient heterogeneity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/130\">",
"       130",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To begin to reduce the morbidity and mortality in AKI, there is a critical need to accurately define AKI, to identify those patients that are at risk for post-ischemic ATN, have early or established post-ischemic ATN and to identify novel biomarkers to diagnose the disorder early in the course. Identification of early versus late post-ischemic ATN may dictate the type of therapeutic intervention necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Definition of AKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;To better understand the difficulties associated with studying post-ischemic ATN, it is important to provide an overview of the evolving definition of acute kidney injury (AKI), independent of underlying cause. Clinical trials have used widely varying definitions of AKI. This has ranged from a 20 to 30 percent rise in the serum creatinine concentration to the need for renal replacement therapy.",
"   </p>",
"   <p>",
"    The absence of a consensus on a definition for AKI led to the Acute Dialysis Quality Initiative (ADQI) and the development of the Acute Kidney Injury Network (AKIN), which represents the efforts of workgroups that seek to develop consensus and evidence-based statements in the field of AKI. ADQI used a set of criteria called the RIFLE criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/131\">",
"     131",
"    </a>",
"    ]. A modification of the RIFLE criteria was subsequently proposed by the Acute Kidney Injury Network [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/132,133\">",
"     132,133",
"    </a>",
"    ] and further modified by KDIGO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of the RIFLE criteria and the AKIN and KDIGO modifications is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42773?source=see_link\">",
"     \"Definition of acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients at high risk for postischemic ATN include those with risk factors for AKI but who have a normal baseline glomerular filtration rate. They may include patients who have diabetes and hypertension or are taking medications such as nonsteroidal anti-inflammatory drugs. These individuals represent a population that needs to be identified to modify risk factors if possible and initiate preventive strategies when indicated.",
"   </p>",
"   <p>",
"    Early AKI due to ischemia represents a condition frequently referred to as \"prerenal azotemia\" and is characterized by a decreased glomerular filtration rate due to renal hypoperfusion. In this setting, the kidney is structurally normal and the condition is rapidly reversible when the underlying cause is corrected. It is vital to identify such patients as treatment to reverse the renal hypoperfusion may prevent established AKI. During this period, tubule injury may not be detectable or minimal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Established AKI due to ischemia represents a more severe reduction of glomerular filtration rate and may represent an extension of severe early AKI (prerenal azotemia). In some conditions, AKI may not be preceded by early AKI (eg, sepsis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An elevation in the serum creatinine concentration is a late marker and will detect AKI only after substantial injury is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/135\">",
"     135",
"    </a>",
"    ]. Many factors regulate the generation, volume of distribution, and excretion of creatinine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, it is imperative that new sensitive biomarkers are employed to detect a group that demonstrates a graded increase in tubular enzymuria (biomarker) and other biomarkers that suggest the earliest evidence of epithelial cell injury yet insufficient to cause frank necrosis and demonstrable rises in serum creatinine. The use and validation of sensitive biomarkers may permit identification of individuals with early tubular injury and identification of a subgroup of patients who might be the target for early intervention. Currently, several urinary biomarkers are being validated but have not been used clinically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/136-139\">",
"     136-139",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the controlled studies have involved patients with established ATN, not those prior to or early in the ischemic phase. Except for a few isolated studies, the vast majority of clinical studies have yet to conclusively demonstrate the benefit of pharmacological therapy in the prevention of post-ischemic ATN.",
"   </p>",
"   <p>",
"    The best approach to post-ischemic ATN is to prevent its development. Thus, the first step is to identify persons at high risk for AKI. In settings in which patients are subjected to procedures that may induce post-ischemic ATN (such as surgery), patients at increased risk should be identified and carefully assessed to determine the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    of such procedures.",
"   </p>",
"   <p>",
"    Postischemic ATN can result from prolonged hypotension due most commonly to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Major surgery (particularly cardiac surgery, abdominal aortic aneurysm surgery, and surgery to correct obstructive jaundice)",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"     <li>",
"      Marked hypovolemia",
"     </li>",
"     <li>",
"      Severe pancreatitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with underlying comorbidities, such as chronic kidney disease, atherosclerosis, diabetes mellitus, advanced malignancy, obesity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poor nutrition, are at particular risk for post-ischemic ATN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/140,141\">",
"     140,141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients undergoing cardiopulmonary bypass surgery, for example, risk factors for post-ischemic ATN may be patient-related (diabetes, obesity, heart failure) or procedure-related (length of cardiopulmonary bypass or nonpulsatile perfusion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/140-142\">",
"     140-142",
"    </a>",
"    ]. Different clinical scoring systems have been developed that help to predict the risk for ATN with cardiopulmonary bypass surgery.",
"   </p>",
"   <p>",
"    One scoring system analyzed 33,217 patients with a large validation sample [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/143\">",
"     143",
"    </a>",
"    ]. A score was given on the basis of 13 preoperative factors and ranged from 0 to 17 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/143\">",
"     143",
"    </a>",
"    ]. In the lowest risk group (score 0 to 2), the risk for ATN requiring dialysis was 0.4 percent, whereas in the highest risk group (score 9 to 13), the risk rose to 21.5 percent. Although this scoring system identifies a subset of high-risk patients, the majority of patients developing severe renal failure actually fell into lower-risk categories. This model was validated using an external cohort derived from a database of cardiac surgery performed between 2002 and 2006 at a University Hospital in Madrid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/144\">",
"     144",
"    </a>",
"    ]. Although the model accurately identified patients at risk for ATN, it generally underestimated the risk. Before this scoring system can be used clinically, further validation from other centers will be necessary. Nevertheless, the clinician should recognize factors that increase risk for ischemic ATN and intervene to change modifiable risk factors, such as nephrotoxins and hypovolemia.",
"   </p>",
"   <p>",
"    In patients at increased risk or early in the ischemic phase, we suggest non-pharmacologic interventions including optimizing volume status with intravenous fluids (if necessary), maintenance of adequate hemodynamic status to ensure renal perfusion and avoidance of further injury by removing or decreasing the effect of any nephrotoxins (eg, avoidance of aminoglycosides, amphotericin, and radiocontrast agents). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some pharmacological agents have shown promise in the prevention of postischemic ATN. However, conflicting results have been reported in different studies or their efficiency is yet to be confirmed. At present, we do NOT administer any pharmacologic agent for the prevention of postischemic ATN.",
"   </p>",
"   <p>",
"    Issues concerning the prevention of radiocontrast nephropathy and the prevention of non-ischemic causes of ATN are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Optimizing volume status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous well-designed studies have found that volume expansion or saline loading with intravenous saline prior to exposure to iodinated radiocontrast agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , hemoglobin, and myoglobin is effective in lowering the risk of ATN. Details concerning the studies that have examined this issue are available in separate topics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29833?source=see_link\">",
"     \"Cisplatin nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, a paucity of data exists concerning the efficacy of volume expansion with intravenous fluids to lower the risk of post-ischemic ATN. A common goal is to optimize volume status in order to maintain cardiac filling, cardiac output, and adequate renal perfusion, thus preventing ischemic kidney injury. These hemodynamic parameters are most often inferred from systolic, diastolic, and mean arterial pressures, or \"hemodynamic status.\" Although this approach has obvious clinical appeal, the impact upon clinical outcomes has not been well described and the exact regimen will vary based upon patient characteristics and the particular settings in which post-ischemic ATN is most likely to occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major surgery &mdash; The three surgical procedures that have the highest risk of post-ischemic ATN are cardiac surgery, abdominal aortic aneurysm surgery, and surgery to correct obstructive jaundice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, patients at high risk for post-ischemic ATN with surgery should be identified and attention should be given to altering modifiable risk factors (eg, volume status, and exposure to nephrotoxins). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A principal goal of the preoperative hydration strategy, as described above, is to optimize volume status, particularly among those at risk for postischemic ATN or early in the ischemic phase. This was best demonstrated by a meta-analysis of 20 randomized controlled trials that investigated the renoprotective effects of perioperative hemodynamic optimization among 4220 surgical patients who were undergoing elective or emergent procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/145\">",
"     145",
"    </a>",
"    ]. Postoperative AKI was reduced by perioperative hemodynamic optimization to achieve normal or supranormal values when compared with the control group who did not receive similar goal directed therapy (OR 0.64, 95% CI 0.50-0.83). This benefit was seen when optimization was initiated preoperatively, as well as intraoperatively and postoperatively, suggesting ischemic injury can be prevented or effectively treated with prompt reperfusion.",
"   </p>",
"   <p>",
"    In summary, hemodynamic optimization through volume expansion is a reasonable approach preoperatively, if not contraindicated, for those patients with evidence of hypovolemia (low blood pressure, central venous pressure, or pulmonary capillary wedge pressure). Volume expansion should be avoided in patients with high intraabdominal pressure, significant difficulties with oxygenation, or considerable peripheral edema that may hinder wound healing. Fluid administration should be assessed at regular intervals intraoperatively and postoperatively (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    ). Inotropes should be reserved for consideration in patients with remarkable hemodynamic instability despite adequate volume repletion, by those familiar with their risks.",
"   </p>",
"   <p>",
"    The preferred choice of intravenous hydration fluids, such as crystalloid (eg, isotonic saline, lactated ringer's, or bicarbonate solution) or synthetic colloid (eg, hydroxyl ethyl starch), is unclear, and depends on the clinical scenario [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/146-148\">",
"     146-148",
"    </a>",
"    ]. A small randomized single center study examined the effect of perioperative infusion of intravenous bicarbonate solution versus intravenous saline to 100 cardiac surgical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/149\">",
"     149",
"    </a>",
"    ]. Compared to those who received saline, fewer patients who received bicarbonate solution developed AKI, defined as a greater than 25 percent increase in creatinine over baseline (26 of 50 versus 16 of 50, respectively, OR 0.43, 95% CI 0.19-0.98). These findings need to be confirmed in larger multicenter randomized trials. Until such studies are performed, we continue to administer isotonic saline to achieve and maintain adequate preload.",
"   </p>",
"   <p>",
"    Numerous colloid products, including various hydroxyethyl starches, have been associated with renal failure in surgical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/150-152\">",
"     150-152",
"    </a>",
"    ], suggesting they should be avoided for routine volume repletion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sepsis &mdash; Issues surrounding measures aimed at restoring major organ perfusion, including the kidney, in patients with sepsis are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=see_link\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Marked hypovolemia &mdash; Rapid volume repletion is indicated in patients with severe hypovolemia or hypovolemic shock. Delayed therapy can lead to ischemic injury and possibly to irreversible shock and multiorgan system failure. Issues that generally need to be considered in this setting include the rate of fluid replacement and the type of fluid infused. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"       \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe pancreatitis &mdash; Fluid resuscitation is particularly important in severe pancreatitis because patients may accumulate vast amounts of fluid in the injured pancreatic bed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of acute pancreatitis\", section on 'Supportive care'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence suggests that diuretics should NOT be administered as prophylaxis for post-ischemic ATN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/153-155\">",
"     153-155",
"    </a>",
"    ]. Evidence showing that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    was ineffective and possibly harmful was shown in a study in which 126 patients with normal renal function were randomly assigned to a continuous infusion of furosemide, low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    , or isotonic saline, all initiated at the beginning of elective cardiac surgery and continued for 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/153\">",
"     153",
"    </a>",
"    ]. Although the renal outcomes among those given dopamine and isotonic saline were equivalent, furosemide resulted in a significant increase in both the plasma creatinine concentration (an average maximal change of 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    versus 0.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [27 versus 9",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    for both dopamine and saline) and the incidence of AKI (15 versus 2 and 0 percent); the latter was defined as an increase in the plasma creatinine of more than 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Some",
"    uncontrolled studies of patients with the recent onset of oliguria and renal insufficiency (who might not yet have established AKI) have shown that patients who respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    or with an increase in urine output have a better outcome than nonresponders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/156-158\">",
"     156-158",
"    </a>",
"    ]. However, the responders may simply have had less severe disease as evidenced by a shorter duration of oliguria (less than 24 hours), a higher urine output, and a higher urine osmolality (suggesting better preservation of tubular function).",
"   </p>",
"   <p>",
"    We agree with the 2012 KDIGO guidelines that diuretics not be given to",
"    <strong>",
"     prevent",
"    </strong>",
"    AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Dopamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;When infused in low doses (0.5 to 3",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    dilates the interlobular arteries and both the afferent (preglomerular) and efferent (postglomerular) arterioles, leading to a relatively large increase in renal blood flow with a lesser or no elevation in glomerular filtration rate (GFR). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/25/44435?source=see_link\">",
"     \"Renal actions of dopamine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This effect led to its use in studies to prevent or ameliorate AKI. However, numerous-placebo controlled studies and meta analyses have found that low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    is ineffective in preventing ATN. In addition, there is some evidence that such therapy may cause harm.",
"   </p>",
"   <p>",
"    Thus, we agree with the 2012 KDIGO guidelines that recommend that \"low dose\"",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    NOT be used to protect patients considered to be at risk for AKI or in those with early",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    established AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Overview of studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overall lack of efficacy of low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    among patients with or at risk for ATN was noted in a 2005 meta-analysis of 61 trials that enrolled 3359 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/159\">",
"     159",
"    </a>",
"    ]. There were no benefits in terms of mortality, requirement for renal replacement therapy, or adverse effects, although there was an increase in urine output on day one of therapy.",
"   </p>",
"   <p>",
"    The following studies also illustrate that low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    in early ATN does NOT provide protection from worsening renal dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/160,161\">",
"     160,161",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind prospective study of early AKI, 328 patients with either oliguria or an increase in serum creatinine concentration and at least two criteria for the systemic inflammatory response syndrome were randomly administered either low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/161\">",
"       161",
"      </a>",
"      ]. Both groups had similar peak serum creatinine concentrations and number of individuals who progressed to requiring dialysis.",
"     </li>",
"     <li>",
"      In the NORASEPT II study of nearly 400 patients with oliguria and shock due to sepsis, 174 patients nonrandomly received low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      (44 percent), high-dose dopamine (32 percent), or no dopamine (24 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/160\">",
"       160",
"      </a>",
"      ]. The incidence of AKI and the requirement for dialysis was similar among the three patient groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A possible contributor to the lack of benefit is that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    may actually reduce renal blood flow in patients with early post-ischemic ATN in contrast to the typical increase seen in normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/162\">",
"     162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A related issue is whether prophylactic administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    to patients during or after major surgery might be of benefit. The following examples illustrate the lack of superior efficacy of dopamine, compared with adequate volume expansion, in individuals at risk for ATN in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/153,163\">",
"     153,163",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One controlled trial performed in patients after elective major abdominal vascular surgery compared the effects of fluid repletion with saline alone to saline plus low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/163\">",
"       163",
"      </a>",
"      ]. No difference in renal function was noted between the two groups. However, AKI was an infrequent occurrence in these well hydrated patients; as a result, improvement with dopamine would have been difficult to demonstrate.",
"     </li>",
"     <li>",
"      In a second study, 126 patients with normal renal function were randomly assigned to a continuous infusion of low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      , or isotonic saline, all initiated at the beginning of elective cardiac surgery and continued for 48 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/153\">",
"       153",
"      </a>",
"      ]. The renal outcomes among those given dopamine and isotonic saline were equivalent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are potential risks associated with even low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    , including tachycardia, arrhythmias (particularly among cardiac surgery patients), myocardial ischemia, and intestinal ischemia (due to precapillary vasoconstriction), which might promote bacterial translocation from the intestinal lumen into the systemic circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/157,164,165\">",
"     157,164,165",
"    </a>",
"    ]. In one study in cardiac surgery patients, for example, low dose dopamine was independently associated with an increased risk of post-operative atrial fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/164\">",
"     164",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fenoldopam",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    receptor -1 agonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35284?source=see_link\">",
"     fenoldopam",
"    </a>",
"    has been studied for the prevention of AKI following cardiac surgery and in other patients, including those with sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/166-171\">",
"     166-171",
"    </a>",
"    ]. Some studies have shown benefit, while others have not confirmed a clinically relevant benefit. These trials have been limited in part due to small sample size and design.",
"   </p>",
"   <p>",
"    To better assess the possible prophylactic benefits with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35284?source=see_link\">",
"     fenoldopam",
"    </a>",
"    , a 2007 meta-analysis was performed of 16 randomized studies with a total of 622 patients administered fenoldopam (at varying doses) and 668 given placebo or other therapy (principally low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    ) for the prevention or treatment of AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/170\">",
"     170",
"    </a>",
"    ]. Fenoldopam significantly reduced the risk for the following adverse outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AKI (OR 0.43, 95% CI 0.32-0.59)",
"     </li>",
"     <li>",
"      Need for renal replacement therapy (OR 0.54, 95% CI 0.34-0.84)",
"     </li>",
"     <li>",
"      In hospital death (OR 0.65, 95% CI 0.45-0.91)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limitations with this analysis included the lack of consistent criteria for initiating renal replacement therapy, heterogeneity of enrolled patients, and inability to independently verify the change in glomerular filtration with infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35284?source=see_link\">",
"     fenoldopam",
"    </a>",
"    . Thus, confirmation of these benefits is required in a large multicenter randomized controlled trial. We agree with the 2012 KDIGO guidelines that suggest NOT giving fenoldopam for the prevention of post-ischemic ATN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Atrial natriuretic peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natriuretic peptides are a family of peptides that block tubular reabsorption of sodium, vasodilate afferent arterioles, and inhibit the renin-angiotensin system. Its renoprotective effects have been evaluated in multiple trials of patients undergoing surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/172-174\">",
"     172-174",
"    </a>",
"    ]. Among the best data are a meta-analysis that included 13 randomized controlled trials and examined the effects of natriuretic peptides among 934 adult patients with cardiovascular surgery-associated renal dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/172\">",
"     172",
"    </a>",
"    ]. A subgroup analysis showed a reduction in AKI requiring dialysis in those receiving natriuretic peptide compared to controls (OR 0.32, 95% CI 0.15-0.66). Interpretation of this meta-analysis is limited by the small size and variable quality of the included trials.",
"   </p>",
"   <p>",
"    A randomized controlled trial that was published after the meta-analysis examined the effect of human ANP on post-operative changes in the serum creatinine and estimated GFR, and the need for dialysis one year following surgery among 285 patients with chronic kidney disease not yet on dialysis who were undergoing on-pump coronary artery bypass grafting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/175\">",
"     175",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who received ANP had a significantly smaller post-operative rise in serum creatinine compared with control (1.27 versus",
"    <span class=\"nowrap\">",
"     1.46mg/dL).",
"    </span>",
"    In the early post-operative period, fewer patients in the ANP group required dialysis compared with control (1 versus 8). At one year, only one patient from the ANP group was on dialysis versus five in the placebo group. At the time of publication, the study drug, carperitide was only available in Japan, although the authors suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    may be equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/175\">",
"     175",
"    </a>",
"    ]. Pending further randomized controlled trial data, we do not recommend routine use of ANP for prophylaxis against ATN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several systematic reviews and meta-analysis have examined the efficacy of N-acetylcysteine in the prevention of AKI following surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/176-178\">",
"     176-178",
"    </a>",
"    ]. A 2009 meta-analysis that included 10 studies involving 1193 patients undergoing surgery found that N-acetylcysteine, compared with placebo, did not provide any beneficial effect in preventing AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/178\">",
"     178",
"    </a>",
"    ]. This includes the prevention of AKI requiring dialysis (OR 1.04, 95% CI 0.45-2.37) and incremental increase in serum creatinine concentration (OR 0.84, 95% CI 0.64-1.11) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/178\">",
"     178",
"    </a>",
"    ]. We agree with the 2012 KDIGO guidelines that recommend NOT administering N-acetylcysteine to patients at risk for or with early onset post-ischemic ATN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Intensive insulin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperglycemia among critically ill patients appears to be associated with increased mortality, and there is some evidence that stringent glucose control with intensive insulin therapy may be associated with improved outcomes, particularly increased survival. This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of studies have also evaluated the efficacy of intensive insulin therapy to prevent the development of ATN among critically ill patients. While some studies suggest a renoprotective effect, renal injury was always a secondary outcome in these trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/179-183\">",
"     179-183",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest trial to examine the effects of intensive insulin therapy was the multicenter Normoglycemia in Intensive Care Evaluation Survival Using Glucose Algorithm Regulation (NICE-SUGAR) trial, which randomly assigned 6104 medical and surgical patients to either intensive therapy (target blood glucose level of 81 to 108",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.5 to 6",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    or conventional glucose control (target blood glucose of &lt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&lt;10",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/183\">",
"     183",
"    </a>",
"    ]. There was no difference in the percentage and duration of those requiring renal replacement therapy. Other outcomes of this trial are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2007 meta-analysis was performed on five studies that evaluated the effect of insulin therapy on outcomes including AKI among critically ill patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/184\">",
"     184",
"    </a>",
"    ]. This meta-analysis did not include the NICE-SUGAR trial and only three of the included trials were randomized controlled trials; the other two were non-concurrent prospective cohort studies. Although not statistically significant, intensive insulin therapy (target glucose of 80 to 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [4.4 to 5.6",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    lowered the risk for required dialysis compared with conventional insulin therapy (target glucose of 180 to 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [10 to 11",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    (RR 0.65, 95% CI 0.40-1.05).",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend administering insulin to prevent ATN among critically ill patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24236462\">",
"    <span class=\"h2\">",
"     Remote ischemic preconditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remote ischemic preconditioning (RIPC) is a method by which the deliberate induction of transient nonlethal ischemia of an organ protects against subsequent ischemic injury of another organ. Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/185-187\">",
"     185-187",
"    </a>",
"    ], but not all studies have suggested that RIPC protects against AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/188\">",
"     188",
"    </a>",
"    ]. The best data are from a single-blind randomized trial in which RIPC was induced by three five-minute cycles of thigh ischemia in 120 patients prior to elective cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/186\">",
"     186",
"    </a>",
"    ]. Post-operative AKI (defined as an elevation of serum creatinine &ge;0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or &ge;50 percent within 48 hours of surgery) was reduced among patients randomized to RIPC compared with controls (20 versus 47 percent, respectively). Post hoc analysis showed that kidney injury that was sustained for at least two days was also reduced in the RIPC group (17 versus 36 percent). By contrast, in a second randomized study involving 76 patients undergoing &lsquo;complex&rsquo; valvular heart surgery, there was no difference in the incidence of AKI, nor of biomarkers of renal injury, between those receiving RIPC and controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/188\">",
"     188",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of RIPC on renal outcomes, morbidity and mortality needs to be studied in larger multicenter trials before it is used clinically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/189\">",
"     189",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1884600\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A population-based retrospective study suggested that the use of statins may reduce the risk of AKI following elective surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/190\">",
"     190",
"    </a>",
"    ]. This study identified 213,347 patients over the age of 66 years who underwent surgery in the province of Ontario. Of these, 32 percent were taking a statin prior to surgery and postoperative AKI developed in 4020 patients (1.9 percent). After adjusting for multiple patient and surgical characteristics, the use of statins was associated with a decreased risk of AKI (odds ratio (OR) 0.84, 95% CI 0.78-0.90), less acute dialysis (OR 0.83, 95% CI 0.72-0.95), and a decreased 30-day mortality (OR 0.79, 95% CI 0.74-0.85).There was no difference between groups in dialysis requirement 90 to 120 days after surgery. This retrospective analysis is limited by its observational design and the findings may reflect residual confounding. These data need to be corroborated by a randomized trial or follow-up observational studies before being used to guide clinical care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/191\">",
"     191",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Procedure-related measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, the major surgeries most commonly associated with ATN are cardiac surgery, abdominal aortic aneurysm surgery, and surgery to correct obstructive jaundice. Aspects of these procedures may affect the risk of post-ischemic ATN.",
"   </p>",
"   <p>",
"    As an example, patients who undergo cardiopulmonary bypass surgery rely upon a heart-lung pump to maintain tissue perfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/140\">",
"     140",
"    </a>",
"    ]. General measures that are used",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have been evaluated to ameliorate tissue ischemia include cardioplegia, temperature manipulation, administration of agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    use of specific materials to dampen inflammation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulsatile perfusion via an intraabdominal balloon pump.",
"   </p>",
"   <p>",
"    It is unclear if pulsatile perfusion via an intraabdominal balloon pump protects renal function. Previously, a limitation with this technique was that the pump had to be stopped during cardioplegic arrest. By using the automatic mode, however, the pump can continue to function throughout arrest. The ability of the automatic mode approach to preserve renal function is unclear since studies evaluating its effect are limited, due in part to inaccurate estimates of kidney function.",
"   </p>",
"   <p>",
"    To evaluate the effectiveness of pulsatile perfusion using the automatic mode versus nonpulsatile perfusion, 100 patients with CKD (grades 1 to 3) were randomly assigned to nonpulsatile perfusion during cardiopulmonary bypass or automatic intra-aortic balloon pump-induced pulsatile perfusion during bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/142\">",
"     142",
"    </a>",
"    ]. Significantly better kidney function was observed with pulsatile perfusion (74 versus 58",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) with a greater difference observed in those with stage 3 CKD. Further studies in a larger number of patients with kidney dysfunction are required before pulsatile intra-aortic balloon pumps can be recommended.",
"   </p>",
"   <p>",
"    In comparison to on-pump coronary bypass surgery, some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/192,193\">",
"     192,193",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/194-196\">",
"     194-196",
"    </a>",
"    ] studies have suggested that off-pump surgery reduces the risk of AKI. A 2005 meta-analysis evaluating 37 randomized controlled trials and 22 risk-adjusted observational studies demonstrated that off-pump CABG was associated with a nonsignificant reduction in AKI in randomized trials (OR 0.61, 95% CI 0.25-1.47) but a significant reduction in observational studies (OR 0.54, 95% CI 0.39-0.77) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/197\">",
"     197",
"    </a>",
"    ]. A more recent meta-analysis published in 2010, which included only randomized trials (n = 22, 4819 patients) found that off-pump CABG was associated with a statistically significant 40 percent lower odds of postoperative AKI (variable definitions), and a non-statistically significant 33 percent lower odds of dialysis requirement, with no discernible mortality benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/198\">",
"     198",
"    </a>",
"    ]. No difference in effect was seen based on preoperative serum creatinine, which had been suggested by an observational study in which off-pump CABG was protective in patients with a baseline serum creatinine less than 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    but not in those with higher values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/199\">",
"     199",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a nonrandomized cohort study that was published after the 2010 meta-analysis and included 742,909 nonemergent CABG cases, off-pump surgery compared with on-pump surgery was associated with a reduction in a composite outcome of in-hospital death or renal replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/193\">",
"     193",
"    </a>",
"    ]. The greatest reduction in risk was observed among patients with estimated GFR 15 to 29",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 (with an on-pump minus off-pump risk difference of 3.66 per 100 patients [95% CI 2.14-5.18]) and was almost entirely driven by a reduction in the risk of renal replacement therapy not death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37031?source=see_link\">",
"     \"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Established post-ischemic ATN in humans represents a more severe reduction of glomerular filtration rate and may represent an extension of severe early post-ischemic ATN (prerenal azotemia). In some patients, ATN may not be preceded by early ATN (eg, sepsis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, early management of patients with established postischemic ATN should include an assessment of the etiology and volume",
"    <span class=\"nowrap\">",
"     status/systemic",
"    </span>",
"    hemodynamics, and the institution of appropriate therapeutic measures designed to prevent or reduce worsening kidney function. Thus, non-pharmacologic interventions should include maintenance of adequate hemodynamic status, as discussed in the previous section, to ensure renal perfusion and avoidance of further injury by removing or decreasing the effect of any nephrotoxins.",
"   </p>",
"   <p>",
"    There have been conflicting results concerning the efficacy of other pharmacologic agents in patients with postischemic AKI. Their overall efficacy has yet to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics, particularly high doses of loop diuretics, are frequently administered to patients with AKI. This is done in part in an attempt to convert oliguric to nonoliguric AKI.",
"   </p>",
"   <p>",
"    Among patients with established renal failure, a variety of studies, including two randomized trials, have found that diuretics augment urine output but do not have an effect upon renal and patient survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/65,200-203\">",
"     65,200-203",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best designed and largest study found that high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    maintained urine output but had no effect upon renal and patient survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/200\">",
"     200",
"    </a>",
"    ]. In this trial, 388 patients with established AKI requiring dialysis were randomly assigned to furosemide or placebo. Furosemide was administered at a dose of 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously (maximum of 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    given over four to six hours) or 35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally (maximum of 2.5",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    The use of furosemide was significantly associated with a decreased time to a two liter per day diuresis (5.7 versus 7.8 days) as well as an increased likelihood of obtaining such a diuresis (57 versus 33 percent). Despite the increase in urine output, there were no differences between the two groups in terms of patient survival, renal recovery rates, number of dialysis sessions required, and time on dialysis.",
"   </p>",
"   <p>",
"    A similar lack of benefit on these hard end points with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    in established ATN was noted in an earlier trial in which high-dose diuretic therapy (3",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    led, in a few patients, to hearing loss that can be permanent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/201\">",
"     201",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dissociation between increasing the urine output and not affecting the course of ATN with diuretic therapy in these trials probably reflects the ability of the diuretic to enhance the urine output in those few nephrons that are still functioning. However, since there is little recruitment of previously nonfunctioning nephrons, there is no effect on the course of the renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2012 KDIGO guidelines that suggest that diuretics NOT be used to treat AKI except in the management of volume overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/134\">",
"     134",
"    </a>",
"    ]. They can be given for a short length of time for volume control, but such use should not postpone the initiation of dialysis (if required) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/204\">",
"     204",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\", section on 'Supportive management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link&amp;anchor=H2#H2\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\", section on 'Indications for and timing of initiation of dialysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dosing related to loop diuretics is available in a separate topic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40710?source=see_link\">",
"     \"Loop diuretics: Maximum effective dose and major side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Dopamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite an increase in natriuresis, low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    is ineffective in the treatment of established AKI. We therefore do NOT administer low-dose dopamine in this setting.",
"   </p>",
"   <p>",
"    Well-designed clinical studies have found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    alone is not effective for the treatment of AKI. This was best shown in a meta-analysis of 61 trials that randomly assigned 3359 patients with or at risk for AKI to low-dose dopamine (&le;5",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    per minute) or either placebo or no therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/159\">",
"     159",
"    </a>",
"    ]. There was no significant effect of low-dose dopamine on mortality, need for renal replacement therapy, or adverse effects, although urine output increased by 24 percent.",
"   </p>",
"   <p>",
"    As previously mentioned, a possible explanation for this finding is the observation that low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    per minute) may actually increase renovascular resistance and reduce renal blood flow among patients with AKI, in contrast to the typical increase in renal blood flow seen in normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/162\">",
"     162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, there are potential risks associated with even low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    . These include tachycardia, arrhythmias (particularly among cardiac surgery patients), myocardial ischemia, and intestinal ischemia. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other agents have been tried to reduce the duration or severity of ATN, including thyroid hormone and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35284?source=see_link\">",
"     fenoldopam",
"    </a>",
"    . To date, however, there has not been convincing evidence for the beneficial effect of either agent in the treatment of established ATN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Thyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of thyroid hormone does not appear to provide benefit in patients with AKI, as shown in a prospective, randomized, placebo-controlled trial of 59 patients with AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/205\">",
"     205",
"    </a>",
"    ]; in addition, active therapy, which suppressed TSH levels, was associated with higher mortality rates (43 versus 13 percent for placebo).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Fenoldopam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inconclusive results with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35284?source=see_link\">",
"     fenoldopam",
"    </a>",
"    were obtained from a trial of 155 patients with established ATN randomly assigned to fenoldopam (given for 72 hours) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/206\">",
"     206",
"    </a>",
"    ]. Although not statistically significant, dialysis was required by fewer patients administered fenoldopam (16 versus 25 percent). Mortality was similar in both groups. Further studies in larger numbers of patients would be necessary to determine whether this agent is effective in reducing the severity of ATN. We agree with the 2012 KDIGO guidelines that fenoldopam not be used to prevent or treat AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Atrial natriuretic peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential efficacy of ANP alone in established ATN in humans has been evaluated in several major trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/207-209\">",
"     207-209",
"    </a>",
"    ]. In a large, multicenter study, 504 critically ill patients with ATN were randomly assigned to a 24 hour infusion of placebo or anaritide (a synthetic form of ANP at a dose of 200",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    per min) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/208\">",
"     208",
"    </a>",
"    ]. The major end-point was dialysis-free survival; the following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no overall difference between the two groups (43 versus 47 percent dialysis-free survival with placebo).",
"     </li>",
"     <li>",
"      Patients who were nonoliguric appeared to do worse with anaritide (48 versus 59 percent dialysis-free survival with placebo, p = 0.03) while those with oliguric ATN (urine output less than 400",
"      <span class=\"nowrap\">",
"       mL/day)",
"      </span>",
"      did better (27 versus 8 percent dialysis-free survival with placebo, p = 0.008). As in other studies, the outcome was worse in patients with oliguric versus nonoliguric ATN. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2501?source=see_link\">",
"       \"Nonoliguric versus oliguric acute tubular necrosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the last finding that oliguric patients may have had a better outcome than nonoliguric individuals when administered anaritide, a randomized prospective trial was performed that evaluated the efficacy of this agent in oliguric AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/209\">",
"     209",
"    </a>",
"    ]. Among 222 such patients, a 24 hour infusion of anaritide (200",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    per min) provided",
"    <strong>",
"     no",
"    </strong>",
"    benefit compared with placebo.",
"   </p>",
"   <p>",
"    The administration of too high doses of anaritide for only 24 hours may be one reason for the lack of benefit observed in these two trials. This was evaluated in a smaller study of 61 patients with postoperative ATN (defined as a serum creatinine concentration 50 percent above baseline values) who were randomly assigned to human ANP (50",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    per min) or placebo, which was continued until dialysis was required or the serum creatinine concentration had decreased below the study inclusion value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/210\">",
"     210",
"    </a>",
"    ]. Prior to or at day 21, active therapy resulted in a significantly decreased frequency of required dialysis (6 versus 14 patients, hazard ratio (HR) 0.28, 95% CI 0.10-0.73).",
"   </p>",
"   <p>",
"    Despite these positive results with low dose ANP, the study was small and underpowered and a larger randomized prospective study is required to confirm these results and better characterize the role for this agent.",
"   </p>",
"   <p>",
"    The meta-analysis cited previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/172\">",
"     172",
"    </a>",
"    ] that examined the effect of natriuretic peptide use in cardiovascular surgery-associated renal dysfunction included only three trials that assessed the effects of natriuretic peptides in patients with impaired renal function. Of these, only one (cited above) initiated natriuretic peptide after the establishment of AKI. A second meta-analysis and Cochrane Review from the same authors included patients from eight trials who had established ATN following surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/173,174\">",
"     173,174",
"    </a>",
"    ]. Sub-group analysis suggested that low dose ANP may reduce dialysis requirements, though study heterogeneity, design weaknesses, and small numbers, limit any conclusions that can be drawn regarding the use of natriuretic peptide as a treatment of ATN. KDIGO 2012 guidelines suggest not using ANP to prevent or treat AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263676464\">",
"    <span class=\"h2\">",
"     Erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A double-blinded placebo-controlled trial examined the effect of erythropoietin on the prevention of AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/211\">",
"     211",
"    </a>",
"    ]. The study used two biomarkers, gamma-glutamyl transpeptidase and alkaline phosphatase, to identify patients at risk for AKI. One hundred sixty-two patients with increased biomarkers were assigned to receive either erythropoietin or placebo. There was no difference between groups in the change in the plasma creatinine over four to seven days. However, although this study was negative, we do not believe that erythropoietin should be eliminated as a potential therapeutic option. Potential reasons for failure to show a benefit of erythropoietin included the choice of biomarkers and delayed randomization after entry to the intensive care unit to the first dose of erythropoietin (6.3 hours).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Insulin growth factor-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin growth factor-1 (IGF-1) has failed to reduce AKI in clinical trials. One report of a randomized, placebo controlled, double-blind trial of 72 patients with AKI of less than seven days duration found no benefit in patients treated with IGF-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/212\">",
"     212",
"    </a>",
"    ]. It is possible that delayed therapy, hypotension with IGF-1,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the heterogeneity of causes of AKI contributed to the negative results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10493575\">",
"    <span class=\"h3\">",
"     Alkaline phosphatase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkaline phosphatase is inactivated by reactive oxygen species and peroxynitrite in experimental studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/84\">",
"     84",
"    </a>",
"    ] and reduces inflammation and mortality in sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/83-87\">",
"     83-87",
"    </a>",
"    ]. A multicenter randomized placebo controlled trial examined the effect of an alkaline phosphatase infusion of alkaline phosphatase in 36 critically ill patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/213\">",
"     213",
"    </a>",
"    ]. At nearly 24 hours, alkaline phosphatase infusion was associated with reduced excretion of a proximal tubule biomarker, glutathione S-transferase, A1-1, reduced NO synthase expression and a decrease in the median plasma creatinine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/213\">",
"     213",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Renal tubule cell therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renal assist device (RAD) is a conventional hemofilter that is lined with monolayers of renal cells. It is designed to perform the absorptive, metabolic, endocrine and immunologic functions that are normally performed by a healthy kidney but are not provided by dialysis. A phase II, multicenter, randomized, controlled, open-label trial compared mortality and recovery of renal function among 58 patients with established AKI who received either continuous venovenous hemofiltration (CRRT) with the addition of an RAD or traditional CRRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/10/42154/abstract/214\">",
"     214",
"    </a>",
"    ]. There was a nonsignificant trend toward decreased all-cause mortality among patients who were treated with the RAD compared to control patients at 28 days. There was a decrease in mortality at 180 days in the RAD-treated group compared to the control group (HR 0.48, 95% CI 0.23-0.99). At day 28, 53 percent in the RAD group had recovered renal function compared to 28 percent of control patients. Serious adverse effects attributed to the RAD were uncommon and included hypoglycemia and thrombocytopenia. A randomized phase II trial is necessary to evaluate this therapy further.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vast majority of animal studies have yet to conclusively demonstrate the benefit of pharmacological therapy in the prevention or treatment of acute tubular necrosis (ATN). A large number of compounds have been evaluated. Attempts have been made to preserve renal function via the following general mechanisms: preserving cell viability; attenuating inflammation, preserving renal blood flow; and preventing or reversing intratubular obstruction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Experimental studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several barriers exist for the successful completion of clinical trials in postischemic ATN. These include heterogeneous and complex patient factors, lack of a standardized definition of acute kidney injury (AKI) and diagnostic criteria, and the lack of clear and specific endpoints for clinical trials. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Barriers to clinical trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are widely varying definitions of AKI. The Acute Dialysis Quality Initiative (ADQI) has used a set of criteria called the RIFLE (Risk, Injury, Failure, Loss, and End stage) criteria. High-risk patients include those with risk factors for AKI but a normal baseline glomerular filtration rate. This may include patients who have diabetes and hypertension or are taking medications such as nonsteroidal anti-inflammatory drugs. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Definition of AKI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first step in preventing postischemic ATN is to identify the patient at increased risk. In patients at risk for postischemic ATN or early in the ischemic phase, we optimize volume status with intravenous fluids (if necessary) with the goal of optimizing cardiac preload, cardiac output, and ultimately renal blood flow. The exact approach may vary based upon patient characteristics and the particular settings in which post-ischemic ATN is most likely to occur. Additional measures should include the avoidance of nephrotoxins and hypotension, a surrogate for reduced renal blood flow (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevention'",
"      </a>",
"      above). Inotropes may be considered in clinically significant hypotension refractory to volume optimization.",
"     </li>",
"     <li>",
"      A number of pharmacologic agents have been evaluated for the prevention of postischemic ATN. None has been proven effective and some have proven harmful. We therefore do NOT administer any pharmacologic agents for the prevention of postischemic ATN. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with established postischemic ATN, management should include an assessment of the etiology and volume status, and the institution of appropriate therapeutic measures designed to prevent or reduce worsening kidney function. These include maintenance of adequate hemodynamic status to ensure renal perfusion and avoidance of further kidney injury.",
"     </li>",
"     <li>",
"      If necessary for volume control, diuretics can be given for a short length of time among patients with established postischemic ATN. We recommend that diuretics NOT be used as prolonged therapy for volume control for established ATN (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend NOT administering low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      among patients with established postischemic ATN (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/1\">",
"      Myers BD, Moran SM. Hemodynamically mediated acute renal failure. N Engl J Med 1986; 314:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/2\">",
"      Duffield JS, Park KM, Hsiao LL, et al. Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J Clin Invest 2005; 115:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/3\">",
"      Lin F, Moran A, Igarashi P. Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. J Clin Invest 2005; 115:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/4\">",
"      Gupta S, Verfaillie C, Chmielewski D, et al. Isolation and characterization of kidney-derived stem cells. J Am Soc Nephrol 2006; 17:3028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/5\">",
"      Hanley MJ, Davidson K. Prior mannitol and furosemide infusion in a model of ischemic acute renal failure. Am J Physiol 1981; 241:F556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/6\">",
"      Schrier RW, Arnold PE, Gordon JA, Burke TJ. Protection of mitochondrial function by mannitol in ischemic acute renal failure. Am J Physiol 1984; 247:F365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/7\">",
"      Escalante B, Erlij D, Falck JR, McGiff JC. Effect of cytochrome P450 arachidonate metabolites on ion transport in rabbit kidney loop of Henle. Science 1991; 251:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/8\">",
"      Heyman SN, Rosen S, Epstein FH, et al. Loop diuretics reduce hypoxic damage to proximal tubules of the isolated perfused rat kidney. Kidney Int 1994; 45:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/9\">",
"      Beach RE, Good DW. Effects of adenosine on ion transport in rat medullary thick ascending limb. Am J Physiol 1992; 263:F482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/10\">",
"      Ambrosio G, Flaherty JT. Effects of the superoxide radical scavenger superoxide dismutase, and of the hydroxyl radical scavenger mannitol, on reperfusion injury in isolated rabbit hearts. Cardiovasc Drugs Ther 1992; 6:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/11\">",
"      Conger JD, Falk SA, Yuan BH, Schrier RW. Atrial natriuretic peptide and dopamine in a rat model of ischemic acute renal failure. Kidney Int 1989; 35:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/12\">",
"      Shaw S, Weidmann P, Zimmermann A. Urodilatin, not nitroprusside, combined with dopamine reverses ischemic acute renal failure. Kidney Int 1992; 42:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/13\">",
"      Heyman SN, Kaminski N, Brezis M. Dopamine increases renal medullary blood flow without improving regional hypoxia. Exp Nephrol 1995; 3:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/14\">",
"      Fish EM, Molitoris BA. Alterations in epithelial polarity and the pathogenesis of disease states. N Engl J Med 1994; 330:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/15\">",
"      Alejandro VS, Nelson WJ, Huie P, et al. Postischemic injury, delayed function and Na+/K(+)-ATPase distribution in the transplanted kidney. Kidney Int 1995; 48:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/16\">",
"      Lieberthal W, Sheridan AM, Valeri CR. Protective effect of atrial natriuretic factor and mannitol following renal ischemia. Am J Physiol 1990; 258:F1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/17\">",
"      Russell JD, Churchill DN. Calcium antagonists and acute renal failure. Am J Med 1989; 87:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/18\">",
"      Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 2001; 345:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/19\">",
"      Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis 1998; 31:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/20\">",
"      Aravindan N, Samuels J, Riedel B, Shaw A. Fenoldopam improves corticomedullary oxygen delivery and attenuates angiogenesis gene expression in acute ischemic renal injury. Kidney Blood Press Res 2006; 29:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/21\">",
"      Halpenny M, Markos F, Snow HM, et al. Effects of prophylactic fenoldopam infusion on renal blood flow and renal tubular function during acute hypovolemia in anesthetized dogs. Crit Care Med 2001; 29:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/22\">",
"      Halpenny M, Markos F, Snow HM, et al. The effects of fenoldopam on renal blood flow and tubular function during aortic cross-clamping in anaesthetized dogs. Eur J Anaesthesiol 2000; 17:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/23\">",
"      Pollock DM, Arendshorst WJ. Tubuloglomerular feedback and blood flow autoregulation during DA1-induced renal vasodilation. Am J Physiol 1990; 258:F627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/24\">",
"      Weinberg JM, Davis JA, Roeser NF, Venkatachalam MA. Role of increased cytosolic free calcium in the pathogenesis of rabbit proximal tubule cell injury and protection by glycine or acidosis. J Clin Invest 1991; 87:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/25\">",
"      Wetzels JF, Yu L, Shanley PF, et al. Infusion of glycine does not attenuate in vivo ischemic acute renal failure in the rat. J Lab Clin Med 1993; 121:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/26\">",
"      Daemen MA, van 't Veer C, Denecker G, et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 1999; 104:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/27\">",
"      Tiwari MM, Brock RW, Megyesi JK, et al. Disruption of renal peritubular blood flow in lipopolysaccharide-induced renal failure: role of nitric oxide and caspases. Am J Physiol Renal Physiol 2005; 289:F1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/28\">",
"      Melnikov VY, Faubel S, Siegmund B, et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest 2002; 110:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/29\">",
"      Sutton TA, Kelly KJ, Mang HE, et al. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 2005; 288:F91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/30\">",
"      Kunugi S, Shimizu A, Kuwahara N, et al. Inhibition of matrix metalloproteinases reduces ischemia-reperfusion acute kidney injury. Lab Invest 2011; 91:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/31\">",
"      Kelly KJ, Plotkin Z, Dagher PC. Guanosine supplementation reduces apoptosis and protects renal function in the setting of ischemic injury. J Clin Invest 2001; 108:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/32\">",
"      Kelly KJ, Plotkin Z, Vulgamott SL, Dagher PC. P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor. J Am Soc Nephrol 2003; 14:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/33\">",
"      Molitoris BA, Dagher PC, Sandoval RM, et al. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 2009; 20:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/34\">",
"      Chatterjee PK, Chatterjee BE, Pedersen H, et al. 5-Aminoisoquinolinone reduces renal injury and dysfunction caused by experimental ischemia/reperfusion. Kidney Int 2004; 65:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/35\">",
"      Walker PD, Shah SV. Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J Clin Invest 1988; 81:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/36\">",
"      Walker PD, Shah SV. Reactive oxygen metabolites in endotoxin-induced acute renal failure in rats. Kidney Int 1990; 38:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/37\">",
"      Baliga R, Zhang Z, Baliga M, et al. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 1998; 53:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/38\">",
"      Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 1999; 31:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/39\">",
"      Szeto HH, Liu S, Soong Y, et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol 2011; 22:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/40\">",
"      Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/41\">",
"      Spandou E, Tsouchnikas I, Karkavelas G, et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant 2006; 21:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/42\">",
"      Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/43\">",
"      Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 1994; 266:F360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/44\">",
"      Patschan D, Krupincza K, Patschan S, et al. Dynamics of mobilization and homing of endothelial progenitor cells after acute renal ischemia: modulation by ischemic preconditioning. Am J Physiol Renal Physiol 2006; 291:F176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/45\">",
"      Bahlmann FH, DeGroot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003; 64:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/46\">",
"      Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/47\">",
"      Gohda E, Tsubouchi H, Nakayama H, et al. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest 1988; 81:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/48\">",
"      Vijayan A, Martin DR, Sadow JL, et al. Hepatocyte growth factor inhibits apoptosis after ischemic renal injury in rats. Am J Kidney Dis 2001; 38:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/49\">",
"      Miller SB, Martin DR, Kissane J, Hammerman MR. Insulin-like growth factor I accelerates recovery from ischemic acute tubular necrosis in the rat. Proc Natl Acad Sci U S A 1992; 89:11876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/50\">",
"      Birck R, Knoll T, Braun C, et al. Improvement of postischemic acute renal failure with the novel orally active endothelin-A receptor antagonist LU 135252 in the rat. J Cardiovasc Pharmacol 1998; 32:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/51\">",
"      Heyman SN, Clark BA, Kaiser N, et al. Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol 1992; 3:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/52\">",
"      Wilhelm SM, Stowe NT, Robinson AV, Schulak JA. The use of the endothelin receptor antagonist, tezosentan, before or after renal ischemia protects renal function. Transplantation 2001; 71:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/53\">",
"      Sikorski EM, Hock T, Hill-Kapturczak N, Agarwal A. The story so far: Molecular regulation of the heme oxygenase-1 gene in renal injury. Am J Physiol Renal Physiol 2004; 286:F425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/54\">",
"      Nath KA, Balla G, Vercellotti GM, et al. Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 1992; 90:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/55\">",
"      Naik JS, Walker BR. Heme oxygenase-mediated vasodilation involves vascular smooth muscle cell hyperpolarization. Am J Physiol Heart Circ Physiol 2003; 285:H220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/56\">",
"      Wu L, Wang R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev 2005; 57:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/57\">",
"      Vera T, Henegar JR, Drummond HA, et al. Protective effect of carbon monoxide-releasing compounds in ischemia-induced acute renal failure. J Am Soc Nephrol 2005; 16:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/58\">",
"      Adin CA, Croker BP, Agarwal A. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 2005; 288:F778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/59\">",
"      Nishiki T, Kitada H, Okabe Y, et al. Effect of milrinone on ischemia-reperfusion injury in the rat kidney. Transplant Proc 2011; 43:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/60\">",
"      Li L, Okusa MD. Blocking the immune response in ischemic acute kidney injury: the role of adenosine 2A agonists. Nat Clin Pract Nephrol 2006; 2:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/61\">",
"      Burne MJ, Daniels F, El Ghandour A, et al. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 2001; 108:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/62\">",
"      Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004; 66:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/63\">",
"      Noiri E, Gailit J, Sheth D, et al. Cyclic RGD peptides ameliorate ischemic acute renal failure in rats. Kidney Int 1994; 46:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/64\">",
"      Noiri E, Romanov V, Forest T, et al. Pathophysiology of renal tubular obstruction: therapeutic role of synthetic RGD peptides in acute renal failure. Kidney Int 1995; 48:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/65\">",
"      Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/66\">",
"      Chiao H, Kohda Y, McLeroy P, et al. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest 1997; 99:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/67\">",
"      Doi K, Hu X, Yuen PS, et al. AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality. Kidney Int 2008; 73:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/68\">",
"      Noiri E, Peresleni T, Miller F, Goligorsky MS. In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest 1996; 97:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/69\">",
"      Day YJ, Huang L, McDuffie MJ, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 2003; 112:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/70\">",
"      Okusa MD, Linden J, Macdonald T, Huang L. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol 1999; 277:F404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/71\">",
"      Okusa MD, Linden J, Huang L, et al. Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney Int 2001; 59:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/72\">",
"      Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277:21453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/73\">",
"      Awad AS, Ye H, Huang L, et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol 2006; 290:F1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/74\">",
"      Lien YH, Yong KC, Cho C, et al. S1P(1)-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int 2006; 69:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/75\">",
"      Bajwa A, Jo SK, Ye H, et al. Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J Am Soc Nephrol 2010; 21:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/76\">",
"      Li S, Gokden N, Okusa MD, et al. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005; 289:F469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/77\">",
"      Wu QQ, Wang Y, Senitko M, et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPAR&gamma;, and HO-1. Am J Physiol Renal Physiol 2011; 300:F1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/78\">",
"      Yasuda H, Yuen PS, Hu X, et al. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int 2006; 69:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/79\">",
"      Sharfuddin AA, Sandoval RM, Berg DT, et al. Soluble thrombomodulin protects ischemic kidneys. J Am Soc Nephrol 2009; 20:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/80\">",
"      Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/81\">",
"      Harris H. The human alkaline phosphatases: what we know and what we don't know. Clin Chim Acta 1990; 186:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/82\">",
"      Poelstra K, Bakker WW, Klok PA, et al. A physiologic function for alkaline phosphatase: endotoxin detoxification. Lab Invest 1997; 76:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/83\">",
"      Bentala H, Verweij WR, Huizinga-Van der Vlag A, et al. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 2002; 18:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/84\">",
"      Beumer C, Wulferink M, Raaben W, et al. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J Pharmacol Exp Ther 2003; 307:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/85\">",
"      Koyama I, Matsunaga T, Harada T, et al. Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation. Clin Biochem 2002; 35:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/86\">",
"      van Veen SQ, van Vliet AK, Wulferink M, et al. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice. Infect Immun 2005; 73:4309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/87\">",
"      Su F, Brands R, Wang Z, et al. Beneficial effects of alkaline phosphatase in septic shock. Crit Care Med 2006; 34:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/88\">",
"      Kale S, Karihaloo A, Clark PR, et al. Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J Clin Invest 2003; 112:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/89\">",
"      Broekema M, Harmsen MC, Koerts JA, et al. Determinants of tubular bone marrow-derived cell engraftment after renal ischemia/reperfusion in rats. Kidney Int 2005; 68:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/90\">",
"      Lange C, T&ouml;gel F, Ittrich H, et al. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int 2005; 68:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/91\">",
"      Cantley LG. Adult stem cells in the repair of the injured renal tubule. Nat Clin Pract Nephrol 2005; 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/92\">",
"      Humphreys BD, Valerius MT, Kobayashi A, et al. Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell 2008; 2:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/93\">",
"      T&ouml;gel F, Weiss K, Yang Y, et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007; 292:F1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/94\">",
"      T&ouml;gel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289:F31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/95\">",
"      Patel J, Pancholi N, Gudehithlu KP, et al. Stem cells from foreign body granulation tissue accelerate recovery from acute kidney injury. Nephrol Dial Transplant 2012; 27:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/96\">",
"      Bruno S, Grange C, Deregibus MC, et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009; 20:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/97\">",
"      Feng Z, Ting J, Alfonso Z, et al. Fresh and cryopreserved, uncultured adipose tissue-derived stem and regenerative cells ameliorate ischemia-reperfusion-induced acute kidney injury. Nephrol Dial Transplant 2010; 25:3874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/98\">",
"      Zager RA, Fuerstenberg SM, Baehr PH, et al. An evaluation of antioxidant effects on recovery from postischemic acute renal failure. J Am Soc Nephrol 1994; 4:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/99\">",
"      Kumar S, Allen DA, Kieswich JE, et al. Dexamethasone ameliorates renal ischemia-reperfusion injury. J Am Soc Nephrol 2009; 20:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/100\">",
"      Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004; 15:3073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/101\">",
"      Riedemann NC, Neff TA, Guo RF, et al. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 2003; 170:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/102\">",
"      Deng J, Kohda Y, Chiao H, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 2001; 60:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/103\">",
"      Takeda R, Nishimatsu H, Suzuki E, et al. Ghrelin improves renal function in mice with ischemic acute renal failure. J Am Soc Nephrol 2006; 17:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/104\">",
"      Jia RP, Xie JJ, Luo FY, Zhu JG. Ischemic preconditioning improves rat kidney allograft function after ischemia/reperfusion injury: the role of tumor necrosis factor-alpha. Transplant Proc 2008; 40:3316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/105\">",
"      Jia RP, Zhu JG, Wu JP, et al. Experimental study on early protective effect of ischemic preconditioning on rat kidney graft. Transplant Proc 2009; 41:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/106\">",
"      Hotta K, Sho M, Yamato I, et al. Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int 2011; 79:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/107\">",
"      Wu H, Ma J, Wang P, et al. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 2010; 21:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/108\">",
"      Liu M, Gu M, Xu D, et al. Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury. Transplant Proc 2010; 42:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/109\">",
"      Wan X, Fan L, Hu B, et al. Small interfering RNA targeting IKK&beta; prevents renal ischemia-reperfusion injury in rats. Am J Physiol Renal Physiol 2011; 300:F857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/110\">",
"      Safirstein R. Gene expression in nephrotoxic and ischemic acute renal failure. J Am Soc Nephrol 1994; 4:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/111\">",
"      Ouellette AJ, Malt RA, Sukhatme VP, Bonventre JV. Expression of two \"immediate early\" genes, Egr-1 and c-fos, in response to renal ischemia and during compensatory renal hypertrophy in mice. J Clin Invest 1990; 85:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/112\">",
"      Humes HD, Liu S. Cellular and molecular basis of renal repair in acute renal failure. J Lab Clin Med 1994; 124:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/113\">",
"      Hammerman MR. The growth hormone-insulin-like growth factor axis in kidney re-revisited. Nephrol Dial Transplant 1999; 14:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/114\">",
"      Verstrepen WA, Nouwen EJ, Yue XS, De Broe ME. Altered growth factor expression during toxic proximal tubular necrosis and regeneration. Kidney Int 1993; 43:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/115\">",
"      Humes HD, Cieslinski DA, Coimbra TM, et al. Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure. J Clin Invest 1989; 84:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/116\">",
"      Coimbra TM, Cieslinski DA, Humes HD. Epidermal growth factor accelerates renal repair in mercuric chloride nephrotoxicity. Am J Physiol 1990; 259:F438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/117\">",
"      Ding H, Kopple JD, Cohen A, Hirschberg R. Recombinant human insulin-like growth factor-I accelerates recovery and reduces catabolism in rats with ischemic acute renal failure. J Clin Invest 1993; 91:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/118\">",
"      Miller SB, Martin DR, Kissane J, Hammerman MR. Rat models for clinical use of insulin-like growth factor I in acute renal failure. Am J Physiol 1994; 266:F949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/119\">",
"      Cronin RE, Newman JA. Protective effect of thyroxine but not parathyroidectomy on gentamicin nephrotoxicity. Am J Physiol 1985; 248:F332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/120\">",
"      Cronin RE, Brown DM, Simonsen R. Protection by thyroxine in nephrotoxic acute renal failure. Am J Physiol 1986; 251:F408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/121\">",
"      Conger JD, Falk SA, Hammond WS. Atrial natriuretic peptide and dopamine in established acute renal failure in the rat. Kidney Int 1991; 40:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/122\">",
"      Conger JD. Interventions in clinical acute renal failure: what are the data? Am J Kidney Dis 1995; 26:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/123\">",
"      Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon. Clin J Am Soc Nephrol 2007; 2:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/124\">",
"      Waikar SS, Curhan GC, Wald R, et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006; 17:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/125\">",
"      Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int 2004; 66:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/126\">",
"      Kelly KJ, Molitoris BA. Acute renal failure in the new millennium: time to consider combination therapy. Semin Nephrol 2000; 20:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/127\">",
"      Lien J, Chan V. Risk factors influencing survival in acute renal failure treated by hemodialysis. Arch Intern Med 1985; 145:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/128\">",
"      Groeneveld AB, Tran DD, van der Meulen J, et al. Acute renal failure in the medical intensive care unit: predisposing, complicating factors and outcome. Nephron 1991; 59:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/129\">",
"      Rabb H, Chamoun F, Hotchkiss J. Molecular mechanisms underlying combined kidney-lung dysfunction during acute renal failure. Contrib Nephrol 2001; :41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/130\">",
"      Star R. Design issues for clinical trials in acute renal failure. Blood Purif 2001; 19:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/131\">",
"      Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/132\">",
"      Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/133\">",
"      Levin A, Warnock DG, Mehta RL, et al. Improving outcomes from acute kidney injury: report of an initiative. Am J Kidney Dis 2007; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/134\">",
"      Kidney Int Suppl 2012; 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/135\">",
"      Star RA. Treatment of acute renal failure. Kidney Int 1998; 54:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/136\">",
"      Han WK, Bonventre JV. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care 2004; 10:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/137\">",
"      Ichimura T, Hung CC, Yang SA, et al. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 2004; 286:F552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/138\">",
"      Mishra J, Mori K, Ma Q, et al. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004; 24:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/139\">",
"      Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006; 70:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/140\">",
"      Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006; 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/141\">",
"      Billings FT 4th, Pretorius M, Schildcrout JS, et al. Obesity and oxidative stress predict AKI after cardiac surgery. J Am Soc Nephrol 2012; 23:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/142\">",
"      Onorati F, Presta P, Fuiano G, et al. A randomized trial of pulsatile perfusion using an intra-aortic balloon pump versus nonpulsatile perfusion on short-term changes in kidney function during cardiopulmonary bypass during myocardial reperfusion. Am J Kidney Dis 2007; 50:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/143\">",
"      Thakar CV, Arrigain S, Worley S, et al. A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol 2005; 16:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/144\">",
"      Candela-Toha A, El&iacute;as-Mart&iacute;n E, Abraira V, et al. Predicting acute renal failure after cardiac surgery: external validation of two new clinical scores. Clin J Am Soc Nephrol 2008; 3:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/145\">",
"      Brienza N, Giglio MT, Marucci M, Fiore T. Does perioperative hemodynamic optimization protect renal function in surgical patients? A meta-analytic study. Crit Care Med 2009; 37:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/146\">",
"      Mahmood A, Gosling P, Vohra RK. Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatine during aortic aneurysm surgery. Br J Surg 2007; 94:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/147\">",
"      Ragaller MJ, Theilen H, Koch T. Volume replacement in critically ill patients with acute renal failure. J Am Soc Nephrol 2001; 12 Suppl 17:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/148\">",
"      Boldt J, Brenner T, Lehmann A, et al. Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin. Intensive Care Med 2003; 29:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/149\">",
"      Haase M, Haase-Fielitz A, Bellomo R, et al. Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. Crit Care Med 2009; 37:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/150\">",
"      Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/151\">",
"      Rioux JP, Lessard M, De Bortoli B, et al. Pentastarch 10% (250 kDa/0.45) is an independent risk factor of acute kidney injury following cardiac surgery. Crit Care Med 2009; 37:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/152\">",
"      Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg 2004; 139:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/153\">",
"      Lassnigg A, Donner E, Grubhofer G, et al. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 2000; 11:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/154\">",
"      Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006; 333:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/155\">",
"      Mahesh B, Yim B, Robson D, et al. Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial. Eur J Cardiothorac Surg 2008; 33:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/156\">",
"      Luke RG, Briggs JD, Allison ME, Kennedy AC. Factors determining response to mannitol in acute renal failure. Am J Med Sci 1970; 259:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/157\">",
"      Graziani G, Cantaluppi A, Casati S, et al. Dopamine and frusemide in oliguric acute renal failure. Nephron 1984; 37:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/158\">",
"      Szerlip HM. Renal-dose dopamine: fact and fiction. Ann Intern Med 1991; 115:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/159\">",
"      Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/160\">",
"      Marik PE, Iglesias J. Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria. NORASEPT II Study Investigators. Am J Med 1999; 107:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/161\">",
"      Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/162\">",
"      Lauschke A, Teichgr&auml;ber UK, Frei U, Eckardt KU. 'Low-dose' dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 2006; 69:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/163\">",
"      Baldwin L, Henderson A, Hickman P. Effect of postoperative low-dose dopamine on renal function after elective major vascular surgery. Ann Intern Med 1994; 120:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/164\">",
"      Argalious M, Motta P, Khandwala F, et al. \"Renal dose\" dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. Crit Care Med 2005; 33:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/165\">",
"      Hoffman TM, Bush DM, Wernovsky G, et al. Postoperative junctional ectopic tachycardia in children: incidence, risk factors, and treatment. Ann Thorac Surg 2002; 74:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/166\">",
"      Ranucci M, Soro G, Barzaghi N, et al. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann Thorac Surg 2004; 78:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/167\">",
"      Bove T, Landoni G, Calabr&ograve; MG, et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation 2005; 111:3230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/168\">",
"      Brienza N, Malcangi V, Dalfino L, et al. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Crit Care Med 2006; 34:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/169\">",
"      Morelli A, Ricci Z, Bellomo R, et al. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. Crit Care Med 2005; 33:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/170\">",
"      Landoni G, Biondi-Zoccai GG, Tumlin JA, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007; 49:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/171\">",
"      Roasio A, Lobreglio R, Santin A, et al. Fenoldopam reduces the incidence of renal replacement therapy after cardiac surgery. J Cardiothorac Vasc Anesth 2008; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/172\">",
"      Nigwekar SU, Hix JK. The role of natriuretic peptide administration in cardiovascular surgery-associated renal dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2009; 23:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/173\">",
"      Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for preventing and treating acute kidney injury. Cochrane Database Syst Rev 2009; :CD006028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/174\">",
"      Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/175\">",
"      Sezai A, Hata M, Niino T, et al. Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD. J Am Coll Cardiol 2011; 58:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/176\">",
"      Adabag AS, Ishani A, Bloomfield HE, et al. Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials. Eur Heart J 2009; 30:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/177\">",
"      Baker WL, Anglade MW, Baker EL, et al. Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis. Eur J Cardiothorac Surg 2009; 35:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/178\">",
"      Ho KM, Morgan DJ. Meta-analysis of N-acetylcysteine to prevent acute renal failure after major surgery. Am J Kidney Dis 2009; 53:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/179\">",
"      van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/180\">",
"      Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/181\">",
"      Wang LC, Lei S, Wu YC, et al. [Intensive insulin therapy in critically ill patients]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2006; 18:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/182\">",
"      Schetz M, Vanhorebeek I, Wouters PJ, et al. Tight blood glucose control is renoprotective in critically ill patients. J Am Soc Nephrol 2008; 19:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/183\">",
"      NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/184\">",
"      Thomas G, Rojas MC, Epstein SK, et al. Insulin therapy and acute kidney injury in critically ill patients a systematic review. Nephrol Dial Transplant 2007; 22:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/185\">",
"      Venugopal V, Laing CM, Ludman A, et al. Effect of remote ischemic preconditioning on acute kidney injury in nondiabetic patients undergoing coronary artery bypass graft surgery: a secondary analysis of 2 small randomized trials. Am J Kidney Dis 2010; 56:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/186\">",
"      Zimmerman RF, Ezeanuna PU, Kane JC, et al. Ischemic preconditioning at a remote site prevents acute kidney injury in patients following cardiac surgery. Kidney Int 2011; 80:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/187\">",
"      Ali ZA, Callaghan CJ, Lim E, et al. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation 2007; 116:I98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/188\">",
"      Choi YS, Shim JK, Kim JC, et al. Effect of remote ischemic preconditioning on renal dysfunction after complex valvular heart surgery: a randomized controlled trial. J Thorac Cardiovasc Surg 2011; 142:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/189\">",
"      Endre ZH. Renal ischemic preconditioning: finally some good news for prevention of acute kidney injury. Kidney Int 2011; 80:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/190\">",
"      Molnar AO, Coca SG, Devereaux PJ, et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol 2011; 22:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/191\">",
"      Waikar SS, Brunelli SM. Peri-surgical statins lessen acute kidney injury. J Am Soc Nephrol 2011; 22:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/192\">",
"      Stallwood MI, Grayson AD, Mills K, Scawn ND. Acute renal failure in coronary artery bypass surgery: independent effect of cardiopulmonary bypass. Ann Thorac Surg 2004; 77:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/193\">",
"      Chawla LS, Zhao Y, Lough FC, et al. Off-pump versus on-pump coronary artery bypass grafting outcomes stratified by preoperative renal function. J Am Soc Nephrol 2012; 23:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/194\">",
"      Straka Z, Widimsky P, Jirasek K, et al. Off-pump versus on-pump coronary surgery: final results from a prospective randomized study PRAGUE-4. Ann Thorac Surg 2004; 77:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/195\">",
"      Tang AT, Knott J, Nanson J, et al. A prospective randomized study to evaluate the renoprotective action of beating heart coronary surgery in low risk patients. Eur J Cardiothorac Surg 2002; 22:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/196\">",
"      Chukwuemeka A, Weisel A, Maganti M, et al. Renal dysfunction in high-risk patients after on-pump and off-pump coronary artery bypass surgery: a propensity score analysis. Ann Thorac Surg 2005; 80:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/197\">",
"      Wijeysundera DN, Beattie WS, Djaiani G, et al. Off-pump coronary artery surgery for reducing mortality and morbidity: meta-analysis of randomized and observational studies. J Am Coll Cardiol 2005; 46:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/198\">",
"      Seabra VF, Alobaidi S, Balk EM, et al. Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol 2010; 5:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/199\">",
"      Di Mauro M, Gagliardi M, Iac&ograve; AL, et al. Does off-pump coronary surgery reduce postoperative acute renal failure? The importance of preoperative renal function. Ann Thorac Surg 2007; 84:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/200\">",
"      Cantarovich F, Rangoonwala B, Lorenz H, et al. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis 2004; 44:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/201\">",
"      Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure: a controlled trial. Clin Nephrol 1981; 15:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/202\">",
"      van der Voort PH, Boerma EC, Koopmans M, et al. Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial. Crit Care Med 2009; 37:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/203\">",
"      Uchino S, Doig GS, Bellomo R, et al. Diuretics and mortality in acute renal failure. Crit Care Med 2004; 32:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/204\">",
"      Lameire N, Vanholder R, Van Biesen W. Loop diuretics for patients with acute renal failure: helpful or harmful? JAMA 2002; 288:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/205\">",
"      Acker CG, Singh AR, Flick RP, et al. A trial of thyroxine in acute renal failure. Kidney Int 2000; 57:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/206\">",
"      Tumlin JA, Finkel KW, Murray PT, et al. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis 2005; 46:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/207\">",
"      Rahman SN, Kim GE, Mathew AS, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int 1994; 45:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/208\">",
"      Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997; 336:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/209\">",
"      Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000; 36:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/210\">",
"      Sw&auml;rd K, Valsson F, Odencrants P, et al. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med 2004; 32:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/211\">",
"      Endre ZH, Walker RJ, Pickering JW, et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010; 77:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/212\">",
"      Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 1999; 55:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/213\">",
"      Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med 2009; 37:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/10/42154/abstract/214\">",
"      Tumlin J, Wali R, Williams W, et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 2008; 19:1034.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7224 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42154=[""].join("\n");
var outline_f41_10_42154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXPERIMENTAL STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BARRIERS TO CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Definition of AKI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Optimizing volume status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Dopamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Overview of studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fenoldopam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Atrial natriuretic peptide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Intensive insulin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24236462\">",
"      Remote ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1884600\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Procedure-related measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Dopamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Fenoldopam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Atrial natriuretic peptide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H263676464\">",
"      Erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Insulin growth factor-1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10493575\">",
"      - Alkaline phosphatase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Renal tubule cell therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7224\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7224|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/53/27487\" title=\"figure 1\">",
"      Clinical phases for AKI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42773?source=related_link\">",
"      Definition of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16758?source=related_link\">",
"      Ghrelin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40710?source=related_link\">",
"      Loop diuretics: Maximum effective dose and major side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/28/2501?source=related_link\">",
"      Nonoliguric versus oliguric acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37031?source=related_link\">",
"      Off-pump and minimally invasive direct coronary artery bypass graft surgery: Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/25/44435?source=related_link\">",
"      Renal actions of dopamine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4553?source=related_link\">",
"      Renal and patient outcomes after acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_10_42155="Tissue process soft tissue mass";
var content_f41_10_42155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Procedure for optimal tissue processing for a soft tissue mass",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tissue prep",
"       </td>",
"       <td class=\"subtitle1\">",
"        Studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Intraoperative samples",
"       </td>",
"       <td>",
"        Frozen tissue with cryopreservative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytological, scrape and squash imprints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Formalin-fixed tissue",
"       </td>",
"       <td>",
"        Routine histopathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunohistochemical staining",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reverse transcriptase polymerase chain reaction (RT-PCR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluorescent in situ hybridization for cytogenetics (tissue sections)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glutaraldehyde-fixed tissue",
"       </td>",
"       <td>",
"        Electron microscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Fresh tissue (tissue culture media)",
"       </td>",
"       <td>",
"        Cytogenetics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Molecular studies (translocations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tissue culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fresh tissue",
"       </td>",
"       <td>",
"        Flow cytometry (DNA ploidy, cell surface markers)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frozen tissue (no cryopreservative)",
"       </td>",
"       <td>",
"        Molecular studies, gene rearrangement, immunocytochemistry, microarray gene analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Alcohol-fixed tissue",
"       </td>",
"       <td>",
"        Immunocytochemistry (if required improved cytoplasmic preservation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microarray gene analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytologic imprinting for FISH studies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    FISH: fluorescence in situ hybridization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42155=[""].join("\n");
var outline_f41_10_42155=null;
var title_f41_10_42156="Thromboelastography definitions";
var content_f41_10_42156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Thromboelastography definitions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"7\" width=\"14%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clot phase",
"       </td>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Measurement",
"       </td>",
"       <td class=\"subtitle1\">",
"        TEG",
"        <sup>",
"         &reg;",
"        </sup>",
"        abbreviation",
"       </td>",
"       <td class=\"subtitle1\">",
"        ROTEM",
"        <sup>",
"         &reg;",
"        </sup>",
"        abbreviation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Enzymatic stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Clot initiation",
"        </strong>",
"       </td>",
"       <td>",
"        Clotting time",
"       </td>",
"       <td>",
"        Time from start of sample to 2 mm clot amplitude",
"       </td>",
"       <td>",
"        Reaction time (R)",
"       </td>",
"       <td>",
"        Clot time (CT)",
"       </td>",
"       <td>",
"        Early activation of clotting cascade resulting in initial thrombin burst",
"       </td>",
"       <td>",
"        Prolonged by clotting factor deficiencies, anticoagulants, and hypofibrinogenemia. Shortened in hypercoagulable states.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Clot kinetics",
"        </strong>",
"       </td>",
"       <td>",
"        Clot formation time",
"       </td>",
"       <td>",
"        Time from 2 mm to 20 mm clot amplitude",
"       </td>",
"       <td>",
"        Clot formation time (K)",
"       </td>",
"       <td>",
"        Clot formation time (CFT)",
"       </td>",
"       <td rowspan=\"2\">",
"        Clot potentiation by activation of platelets and thrombin-mediated cleavage of soluble fibrinogen",
"       </td>",
"       <td>",
"        Prolonged by clotting factor deficiencies, hypofibrinogenemia, thrombocytopenia, and platelet dysfunction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angle",
"       </td>",
"       <td>",
"        Angle of tangent line from 2 mm to 20 mm clot formation",
"       </td>",
"       <td>",
"        Alpha angle",
"       </td>",
"       <td>",
"        Alpha angle",
"       </td>",
"       <td>",
"        Abnormally low in clotting factor deficiencies, hypofibrinogenemia, thrombocytopenia, and platelet dysfunction.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Clot strength",
"        </strong>",
"       </td>",
"       <td>",
"        Maximal clot strength",
"       </td>",
"       <td>",
"        Amplitude measured at peak clot strength",
"       </td>",
"       <td>",
"        Maximal amplitude (MA)",
"       </td>",
"       <td>",
"        Maximal clot firmness (MCF)",
"       </td>",
"       <td rowspan=\"2\">",
"        Maximal clot strength achieved via GP IIb/IIIa-mediated platelet-fibrin interactions",
"       </td>",
"       <td>",
"        Abnormally low in hypofibrinogenemia, thromboyctopenia, or platelet dysfunction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clot viscoelasticity",
"       </td>",
"       <td>",
"        Calculated from maximal amplitude",
"       </td>",
"       <td>",
"        G",
"       </td>",
"       <td>",
"        Maximal clot elasticity (MCE)",
"       </td>",
"       <td>",
"        Abnormally high in platelet hypercoagulability.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Clot lysis",
"        </strong>",
"       </td>",
"       <td>",
"        Clot lysis",
"       </td>",
"       <td>",
"        Percentage of loss of amplitude at fixed time after maximal amplitude",
"       </td>",
"       <td>",
"        Lysis at 30 min (LY30), estimated percentage of lysis (EPL)",
"       </td>",
"       <td>",
"        Lysis index at 30 min (LI30), maximal lysis (ML)",
"       </td>",
"       <td>",
"        Activation of fibrinolytic system",
"       </td>",
"       <td>",
"        Abnormally high in enzymatic or mechanical hyperfibrinolysis.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42156=[""].join("\n");
var outline_f41_10_42156=null;
var title_f41_10_42157="Cardiopul exercise outc HF";
var content_f41_10_42157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peak VO2 and systolic pressure predict outcome in HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 186px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a series 500 patients with chronic heart failure (HF), the three year survival rate was excellent in patients with a peak VO2 above 14 mL/min/kg (top curve). Among patients with a lower peak VO2, three year survival was higher in those able to achieve a peak systolic blood pressure above 120 mmHg with exercise (p = 0.02).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Osada, N, Chaitman, BR, Miller, LW, et al, J Am Coll Cardiol 1998; 31:577.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42157=[""].join("\n");
var outline_f41_10_42157=null;
var title_f41_10_42158="LAR of all cancer from a 64-slice CCTA";
var content_f41_10_42158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    LAR of all cancer from a 64-slice CCTA",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Radiation exposure dose",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Age at exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\" rowspan=\"2\">",
"        Quantiles",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        DLP",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        E",
"       </td>",
"       <td class=\"subtitle3\" rowspan=\"2\">",
"        20",
"       </td>",
"       <td class=\"subtitle3\" rowspan=\"2\">",
"        30",
"       </td>",
"       <td class=\"subtitle3\" rowspan=\"2\">",
"        40",
"       </td>",
"       <td class=\"subtitle3\" rowspan=\"2\">",
"        50",
"       </td>",
"       <td class=\"subtitle3\" rowspan=\"2\">",
"        60",
"       </td>",
"       <td class=\"subtitle3\" rowspan=\"2\">",
"        70",
"       </td>",
"       <td class=\"subtitle3\" rowspan=\"2\">",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        mGy &bull; cm",
"       </td>",
"       <td class=\"subtitle3\">",
"        Class midpoint",
"       </td>",
"       <td class=\"subtitle3\">",
"        mSv",
"       </td>",
"       <td class=\"subtitle3\">",
"        Class midpoint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"12\">",
"        In male patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        95 to 272",
"       </td>",
"       <td>",
"        228",
"       </td>",
"       <td>",
"        1.33 to 3.81",
"       </td>",
"       <td>",
"        3.20",
"       </td>",
"       <td>",
"        1 in 2192",
"       </td>",
"       <td>",
"        1 in 3125",
"       </td>",
"       <td>",
"        1 in 3300",
"       </td>",
"       <td>",
"        1 in 3571",
"       </td>",
"       <td>",
"        1 in 4329",
"       </td>",
"       <td>",
"        1 in 6172",
"       </td>",
"       <td>",
"        1 in 12,195",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        273 to 337",
"       </td>",
"       <td>",
"        297",
"       </td>",
"       <td>",
"        3.82 to 4.71",
"       </td>",
"       <td>",
"        4.49",
"       </td>",
"       <td>",
"        1 in 1508",
"       </td>",
"       <td>",
"        1 in 2150",
"       </td>",
"       <td>",
"        1 in 2277",
"       </td>",
"       <td>",
"        1 in 3311",
"       </td>",
"       <td>",
"        1 in 4000",
"       </td>",
"       <td>",
"        1 in 5714",
"       </td>",
"       <td>",
"        1 in 11,235",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        338 to 412",
"       </td>",
"       <td>",
"        379",
"       </td>",
"       <td>",
"        4.72 to 5.77",
"       </td>",
"       <td>",
"        5.39",
"       </td>",
"       <td>",
"        1 in 1434",
"       </td>",
"       <td>",
"        1 in 2040",
"       </td>",
"       <td>",
"        1 in 2164",
"       </td>",
"       <td>",
"        1 in 2577",
"       </td>",
"       <td>",
"        1 in 3115",
"       </td>",
"       <td>",
"        1 in 4444",
"       </td>",
"       <td>",
"        1 in 8771",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        413 to 571",
"       </td>",
"       <td>",
"        537",
"       </td>",
"       <td>",
"        5.78 to 8.00",
"       </td>",
"       <td>",
"        7.45",
"       </td>",
"       <td>",
"        1 in 1117",
"       </td>",
"       <td>",
"        1 in 1589",
"       </td>",
"       <td>",
"        1 in 1683",
"       </td>",
"       <td>",
"        1 in 1798",
"       </td>",
"       <td>",
"        1 in 2173",
"       </td>",
"       <td>",
"        1 in 3095",
"       </td>",
"       <td>",
"        1 in 6097",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        572 to 738",
"       </td>",
"       <td>",
"        738",
"       </td>",
"       <td>",
"        8.01 to 10.33",
"       </td>",
"       <td>",
"        10.33",
"       </td>",
"       <td>",
"        1 in 919",
"       </td>",
"       <td>",
"        1 in 1308",
"       </td>",
"       <td>",
"        1 in 1386",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"       <td>",
"        739 to 1387",
"       </td>",
"       <td>",
"        1268",
"       </td>",
"       <td>",
"        10.34 to 18.97",
"       </td>",
"       <td>",
"        17.80",
"       </td>",
"       <td>",
"        1 in 350",
"       </td>",
"       <td>",
"        1 in 499",
"       </td>",
"       <td>",
"        1 in 528",
"       </td>",
"       <td>",
"        1 in 1106",
"       </td>",
"       <td>",
"        1 in 1336",
"       </td>",
"       <td>",
"        1 in 1908",
"       </td>",
"       <td>",
"        1 in 3759",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7",
"       </td>",
"       <td>",
"        1388 to 1528",
"       </td>",
"       <td>",
"        1453",
"       </td>",
"       <td>",
"        18.98 to 21.38",
"       </td>",
"       <td>",
"        20.22",
"       </td>",
"       <td>",
"        1 in 315",
"       </td>",
"       <td>",
"        1 in 449",
"       </td>",
"       <td>",
"        1 in 476",
"       </td>",
"       <td>",
"        1 in 520",
"       </td>",
"       <td>",
"        1 in 628",
"       </td>",
"       <td>",
"        1 in 896",
"       </td>",
"       <td>",
"        1 in 1766",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8",
"       </td>",
"       <td>",
"        1529 to 1781",
"       </td>",
"       <td>",
"        1582",
"       </td>",
"       <td>",
"        21.39 to 24.93",
"       </td>",
"       <td>",
"        22.15",
"       </td>",
"       <td>",
"        1 in 288",
"       </td>",
"       <td>",
"        1 in 410",
"       </td>",
"       <td>",
"        1 in 434",
"       </td>",
"       <td>",
"        1 in 541",
"       </td>",
"       <td>",
"        1 in 654",
"       </td>",
"       <td>",
"        1 in 932",
"       </td>",
"       <td>",
"        1 in 1838",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9",
"       </td>",
"       <td>",
"        1782 to 1999",
"       </td>",
"       <td>",
"        1894",
"       </td>",
"       <td>",
"        24.94 to 26.58",
"       </td>",
"       <td>",
"        24.94",
"       </td>",
"       <td>",
"        1 in 327",
"       </td>",
"       <td>",
"        1 in 465",
"       </td>",
"       <td>",
"        1 in 493",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10",
"       </td>",
"       <td>",
"        2000 to 2492",
"       </td>",
"       <td>",
"        2105",
"       </td>",
"       <td>",
"        26.59 to 34.98",
"       </td>",
"       <td>",
"        28.23",
"       </td>",
"       <td>",
"        1 in 314",
"       </td>",
"       <td>",
"        1 in 447",
"       </td>",
"       <td>",
"        1 in 474",
"       </td>",
"       <td>",
"        1 in 425",
"       </td>",
"       <td>",
"        1 in 514",
"       </td>",
"       <td>",
"        1 in 733",
"       </td>",
"       <td>",
"        1 in 1445",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"12\">",
"        In female patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        95 to 272",
"       </td>",
"       <td>",
"        228",
"       </td>",
"       <td>",
"        1.33 to 3.81",
"       </td>",
"       <td>",
"        3.20",
"       </td>",
"       <td>",
"        1 in 1283",
"       </td>",
"       <td>",
"        1 in 198",
"       </td>",
"       <td>",
"        1 in 2380",
"       </td>",
"       <td>",
"        1 in 3676",
"       </td>",
"       <td>",
"        1 in 4629",
"       </td>",
"       <td>",
"        1 in 6622",
"       </td>",
"       <td>",
"        1 in 12,658",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        273 to 337",
"       </td>",
"       <td>",
"        297",
"       </td>",
"       <td>",
"        3.82 to 4.71",
"       </td>",
"       <td>",
"        4.49",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        1 in 2754",
"       </td>",
"       <td>",
"        1 in 3484",
"       </td>",
"       <td>",
"        1 in 4975",
"       </td>",
"       <td>",
"        1 in 9523",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        338 to 412",
"       </td>",
"       <td>",
"        379",
"       </td>",
"       <td>",
"        4.72 to 5.77",
"       </td>",
"       <td>",
"        5.39",
"       </td>",
"       <td>",
"        1 in 831",
"       </td>",
"       <td>",
"        1 in 1285",
"       </td>",
"       <td>",
"        1 in 1545",
"       </td>",
"       <td>",
"        1 in 1841",
"       </td>",
"       <td>",
"        1 in 2325",
"       </td>",
"       <td>",
"        1 in 3333",
"       </td>",
"       <td>",
"        1 in 6369",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        413 to 571",
"       </td>",
"       <td>",
"        537",
"       </td>",
"       <td>",
"        5.78 to 8.00",
"       </td>",
"       <td>",
"        7.45",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        1 in 1506",
"       </td>",
"       <td>",
"        1 in 1904",
"       </td>",
"       <td>",
"        1 in 2724",
"       </td>",
"       <td>",
"        1 in 5208",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        572 to 738",
"       </td>",
"       <td>",
"        738",
"       </td>",
"       <td>",
"        8.01 to 10.33",
"       </td>",
"       <td>",
"        10.33",
"       </td>",
"       <td>",
"        1 in 560",
"       </td>",
"       <td>",
"        1 in 867",
"       </td>",
"       <td>",
"        1 in 1041",
"       </td>",
"       <td>",
"        1 in 1447",
"       </td>",
"       <td>",
"        1 in 1824",
"       </td>",
"       <td>",
"        1 in 2617",
"       </td>",
"       <td>",
"        1 in 5000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"       <td>",
"        739 to 1387",
"       </td>",
"       <td>",
"        1268",
"       </td>",
"       <td>",
"        10.34 to 18.97",
"       </td>",
"       <td>",
"        17.80",
"       </td>",
"       <td>",
"        1 in 319",
"       </td>",
"       <td>",
"        1 in 493",
"       </td>",
"       <td>",
"        1 in 593",
"       </td>",
"       <td>",
"        1 in 486",
"       </td>",
"       <td>",
"        1 in 614",
"       </td>",
"       <td>",
"        1 in 880",
"       </td>",
"       <td>",
"        1 in 1680",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7",
"       </td>",
"       <td>",
"        1388 to 1528",
"       </td>",
"       <td>",
"        1453",
"       </td>",
"       <td>",
"        18.98 to 21.38",
"       </td>",
"       <td>",
"        20.22",
"       </td>",
"       <td>",
"        1 in 183",
"       </td>",
"       <td>",
"        1 in 283",
"       </td>",
"       <td>",
"        1 in 340",
"       </td>",
"       <td>",
"        1 in 398",
"       </td>",
"       <td>",
"        1 in 502",
"       </td>",
"       <td>",
"        1 in 720",
"       </td>",
"       <td>",
"        1 in 1377",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8",
"       </td>",
"       <td>",
"        1529 to 1781",
"       </td>",
"       <td>",
"        1582",
"       </td>",
"       <td>",
"        21.39 to 24.93",
"       </td>",
"       <td>",
"        22.15",
"       </td>",
"       <td>",
"        1 in 169",
"       </td>",
"       <td>",
"        1 in 261",
"       </td>",
"       <td>",
"        1 in 314",
"       </td>",
"       <td>",
"        1 in 368",
"       </td>",
"       <td>",
"        1 in 464",
"       </td>",
"       <td>",
"        1 in 665",
"       </td>",
"       <td>",
"        1 in 1272",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9",
"       </td>",
"       <td>",
"        1782 to 1999",
"       </td>",
"       <td>",
"        1894",
"       </td>",
"       <td>",
"        24.94 to 26.58",
"       </td>",
"       <td>",
"        24.94",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        1 in 418",
"       </td>",
"       <td>",
"        1 in 528",
"       </td>",
"       <td>",
"        1 in 757",
"       </td>",
"       <td>",
"        1 in 1447",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10",
"       </td>",
"       <td>",
"        2000 to 2492",
"       </td>",
"       <td>",
"        2105",
"       </td>",
"       <td>",
"        26.59 to 34.98",
"       </td>",
"       <td>",
"        28.23",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Heart,&nbsp;Faletra FF, D'Angeli I, Klersy C, et al. Estimates of lifetime attributable risk of cancer after a single radiation exposure from 64-slice computed tomographic coronary angiography, volume 96, pages 927-32, Copyright &copy; 2010, with permission from BMJ Publishing Group Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42158=[""].join("\n");
var outline_f41_10_42158=null;
var title_f41_10_42159="Acute paronychia finger 1";
var content_f41_10_42159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute paronychia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 167px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Painful erythema and swelling with a purulent collection is present in this patient with an acute paronychia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_10_42159=[""].join("\n");
var outline_f41_10_42159=null;
